

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
7 February 2002 (07.02.2002)

PCT

(10) International Publication Number
WO 02/10409 A1

(51) International Patent Classification⁷: **C12N 15/63**,
5/08, 5/00, C12P 19/34, C12Q 1/68, C07H 21/00, 21/02,
21/04

(74) Agents: **LICATA, Jane, Massey** et al.; Licata & Tyrrell
P.C., 66 E. Main Street, Marlton, NJ 08053 (US).

(21) International Application Number: PCT/US01/22751

(22) International Filing Date: 18 July 2001 (18.07.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
09/630,706 31 July 2000 (31.07.2000) US

(71) Applicant (*for all designated States except US*): **ISIS
PHARMACEUTICALS, INC.** [US/US]; 2292 Faraday
Avenue, Carlsbad, CA 92008 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,
LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX,
MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL,
TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
TG).

Published:

— *with international search report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **BENNETT, C.,
Frank** [US/US]; 1347 Cassins Street, Carlsbad, CA 92008
(US). **COWSERT, Lex, M.** [US/US]; 1299 Parrott Drive,
San Mateo, CA 94402 (US).

(54) Title: ANTISENSE INHIBITION OF HER-3 EXPRESSION

(57) Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Her-3. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Her-3. Methods of using these compounds for modulation of Her-3 expression and for treatment of diseases associated with expression of Her-3 are provided.



WO 02/10409 A1

Antisense inhibition of HER-3 expression

FIELD OF THE INVENTION

The present invention provides compositions and methods for modulating the expression of Her-3. In particular, this invention relates to compounds, particularly oligonucleotides, specifically hybridizable with nucleic acids encoding Her-3. Such compounds have been shown to modulate the expression of Her-3.

BACKGROUND OF THE INVENTION

One of the principal mechanisms by which cellular regulation is effected is through the transduction of extracellular signals into intracellular signals that in turn modulate biochemical pathways. Examples of such extracellular signaling molecules include growth factors, cytokines, and chemokines. The cell surface receptors of these molecules and their associated signal transduction pathways are therefore one of the principal means by which cellular behavior is regulated. Because cellular phenotypes are largely influenced by the activity of these pathways, it is currently believed that a number of disease states and/or disorders are a result of either aberrant activation or functional mutations in the molecular components of signal transduction pathways. Consequently, considerable attention has been devoted to the characterization of these receptor proteins.

HER3 (also known as ErbB3), a member of the EGF family of receptor/tyrosine kinases, is a protein that has been shown to play a complex role in several signal transduction pathways by forming homo- and heterodimers with other members of the EGF family depending on their concentrations and the concentration of particular ligands. Unlike other members of the family, HER3 lacks an intrinsic kinase activity and must rely on the presence of HER2 to transduce the signal across the membrane. However, HER3 can bind ATP

and can recruit SH2-containing proteins (Carraway, *BioEssays*, **1996**, *18*, 263-266). The two groups of ligands specific to HER3 and HER4 are collectively termed neuregulins (NRGs) because of their demonstrated role in the nervous system. HER3 and HER4 function as the binding receptors; and HER2 along with EGFR are considered co-receptors and are recruited as partners to HER3 and HER4 upon ligand binding. (Burden and Yarden, *Neuron*, **1997**, *18*, 847-855).

HER3, first cloned in 1989, was found in a variety of normal epithelial tissues as well as being overexpressed in human mammary tumor cell lines (Kraus et al., *Proc. Natl. Acad. Sci. USA*, **1989**, *86*, 9193-9197). It has also been shown to act in a variety of cellular signaling cascades including those involved in neural development (Britsch et al., *Genes Dev.*, **1998**, *12*, 1825-1836), mammary morphogenesis (Alimandi et al., *Oncogene*, **1995**, *10*, 1813-1821), and phosphoinositide 3-kinase p85 binding (Hellyer et al., *Biochem. J.*, **1998**, *333*, 757-763). Disclosed in US Patent 5,183,884 and in the European Patent Application 0 444 961 A1 are the DNA encoding HER-3 as well as probes for HER-3, vectors encoding HER-3 and cell cultures expressing such vectors (Kraus and Aaronson, **1993**; Plowman et al., **1991**).

Manifestations of altered HER3 regulation appear in both injury and disease states, the most important being in the development of cancer. Cellular transformation and acquisition of the metastatic phenotype are the two main changes normal cells undergo during the progression to cancer. HER3 in cooperation with HER2 has been shown to be involved in the neoplastic transformation of cells (Alimandi et al., *Oncogene*, **1995**, *10*, 1813-1821). Recently, it has been demonstrated that HER-3 and HER-4 are expressed at high levels in gastric cancers with three out of six gastric cancers expression HER-3 and four out of six gastric cancers

overexpressing HER-4 (Kataoka et al., *Life Sci.*, **1998**, *63*, 553-564).

Currently, there are no known therapeutic agents which effectively inhibit the synthesis of HER3. Consequently,
5 there remains a long felt need for additional agents capable of effectively inhibiting HER3 function.

To date, strategies aimed at inhibiting HER3 function have involved the use of antibodies, antisense to the HER3 coreceptor, HER2, gene knockouts of HER2 and HER3 in mice
10 and modifications to the ligands that bind HER3.

Studies using antisense to reduce the expression of HER2, the coreceptor of HER3 showed that reduced HER2 attenuated the effect of HER3 signaling but did not abolish it (Yoo and Hamburger, *Mol. Cell. Endocrinol.*, **1998**, *138*,
15 163-171). Mice lacking HER3 die *in utero* due to the thinned and rudimentary development of the atrioventricular valves of the heart (Burden and Yarden, *Neuron*, **1997**, *18*, 847-855).

Therefore, it appears as though these targeting strategies are either lethal or lack specificity, thus
20 warranting further development of entities capable of safely inhibiting HER3 function. Antisense oligonucleotides provide a promising new pharmaceutical tool for the effective modification of the expression of specific genes.

SUMMARY OF THE INVENTION

25 The present invention is directed to compounds, particularly antisense oligonucleotides, which are targeted to a nucleic acid encoding Her-3, and which modulate the expression of Her-3. Pharmaceutical and other compositions comprising the compounds of the invention are also provided.
30 Further provided are methods of modulating the expression of Her-3 in cells or tissues comprising contacting said cells or tissues with one or more of the antisense compounds or compositions of the invention. Further provided are methods of treating an animal, particularly a human, suspected of
35 having or being prone to a disease or condition associated

with expression of Her-3 by administering a therapeutically or prophylactically effective amount of one or more of the antisense compounds or compositions of the invention.

DETAILED DESCRIPTION OF THE INVENTION

5 The present invention employs oligomeric compounds, particularly antisense oligonucleotides, for use in modulating the function of nucleic acid molecules encoding Her-3, ultimately modulating the amount of Her-3 produced. This is accomplished by providing antisense compounds which
10 specifically hybridize with one or more nucleic acids encoding Her-3. As used herein, the terms "target nucleic acid" and "nucleic acid encoding Her-3" encompass DNA encoding Her-3, RNA (including pre-mRNA and mRNA) transcribed from such DNA, and also cDNA derived from such
15 RNA. The specific hybridization of an oligomeric compound with its target nucleic acid interferes with the normal function of the nucleic acid. This modulation of function of a target nucleic acid by compounds which specifically hybridize to it is generally referred to as "antisense".
20 The functions of DNA to be interfered with include replication and transcription. The functions of RNA to be interfered with include all vital functions such as, for example, translocation of the RNA to the site of protein translation, translation of protein from the RNA, splicing
25 of the RNA to yield one or more mRNA species, and catalytic activity which may be engaged in or facilitated by the RNA. The overall effect of such interference with target nucleic acid function is modulation of the expression of Her-3. In the context of the present invention, "modulation" means
30 either an increase (stimulation) or a decrease (inhibition) in the expression of a gene. In the context of the present invention, inhibition is the preferred form of modulation of gene expression and mRNA is a preferred target.

It is preferred to target specific nucleic acids for
35 antisense. "Targeting" an antisense compound to a

particular nucleic acid, in the context of this invention, is a multistep process. The process usually begins with the identification of a nucleic acid sequence whose function is to be modulated. This may be, for example, a cellular gene
5 (or mRNA transcribed from the gene) whose expression is associated with a particular disorder or disease state, or a nucleic acid molecule from an infectious agent. In the present invention, the target is a nucleic acid molecule encoding Her-3. The targeting process also includes
10 determination of a site or sites within this gene for the antisense interaction to occur such that the desired effect, e.g., detection or modulation of expression of the protein, will result. Within the context of the present invention, a preferred intragenic site is the region encompassing the
15 translation initiation or termination codon of the open reading frame (ORF) of the gene. Since, as is known in the art, the translation initiation codon is typically 5'-AUG (in transcribed mRNA molecules; 5'-ATG in the corresponding DNA molecule), the translation initiation codon is also
20 referred to as the "AUG codon," the "start codon" or the "AUG start codon". A minority of genes have a translation initiation codon having the RNA sequence 5'-GUG, 5'-UUG or 5'-CUG, and 5'-AUA, 5'-ACG and 5'-CUG have been shown to function in vivo. Thus, the terms "translation initiation
25 codon" and "start codon" can encompass many codon sequences, even though the initiator amino acid in each instance is typically methionine (in eukaryotes) or formylmethionine (in prokaryotes). It is also known in the art that eukaryotic and prokaryotic genes may have two or more alternative start
30 codons, any one of which may be preferentially utilized for translation initiation in a particular cell type or tissue, or under a particular set of conditions. In the context of the invention, "start codon" and "translation initiation
35 codon" refer to the codon or codons that are used in vivo to initiate translation of an mRNA molecule transcribed from a

gene encoding Her-3, regardless of the sequence(s) of such codons.

It is also known in the art that a translation termination codon (or "stop codon") of a gene may have one of three sequences, i.e., 5'-UAA, 5'-UAG and 5'-UGA (the corresponding DNA sequences are 5'-TAA, 5'-TAG and 5'-TGA, respectively). The terms "start codon region" and "translation initiation codon region" refer to a portion of such an mRNA or gene that encompasses from about 25 to about 50 contiguous nucleotides in either direction (i.e., 5' or 3') from a translation initiation codon. Similarly, the terms "stop codon region" and "translation termination codon region" refer to a portion of such an mRNA or gene that encompasses from about 25 to about 50 contiguous nucleotides in either direction (i.e., 5' or 3') from a translation termination codon.

The open reading frame (ORF) or "coding region," which is known in the art to refer to the region between the translation initiation codon and the translation termination codon, is also a region which may be targeted effectively. Other target regions include the 5' untranslated region (5'UTR), known in the art to refer to the portion of an mRNA in the 5' direction from the translation initiation codon, and thus including nucleotides between the 5' cap site and the translation initiation codon of an mRNA or corresponding nucleotides on the gene, and the 3' untranslated region (3'UTR), known in the art to refer to the portion of an mRNA in the 3' direction from the translation termination codon, and thus including nucleotides between the translation termination codon and 3' end of an mRNA or corresponding nucleotides on the gene. The 5' cap of an mRNA comprises an N7-methylated guanosine residue joined to the 5'-most residue of the mRNA via a 5'-5' triphosphate linkage. The 5' cap region of an mRNA is considered to include the 5' cap structure itself as well as the first 50 nucleotides

-7-

adjacent to the cap. The 5' cap region may also be a preferred target region.

Although some eukaryotic mRNA transcripts are directly translated, many contain one or more regions, known as
5 "introns," which are excised from a transcript before it is translated. The remaining (and therefore translated) regions are known as "exons" and are spliced together to form a continuous mRNA sequence. mRNA splice sites, i.e., intron-exon junctions, may also be preferred target regions,
10 and are particularly useful in situations where aberrant splicing is implicated in disease, or where an overproduction of a particular mRNA splice product is implicated in disease. Aberrant fusion junctions due to rearrangements or deletions are also preferred targets. It
15 has also been found that introns can also be effective, and therefore preferred, target regions for antisense compounds targeted, for example, to DNA or pre-mRNA.

Once one or more target sites have been identified, oligonucleotides are chosen which are sufficiently
20 complementary to the target, i.e., hybridize sufficiently well and with sufficient specificity, to give the desired effect.

In the context of this invention, "hybridization" means hydrogen bonding, which may be Watson-Crick, Hoogsteen or
25 reversed Hoogsteen hydrogen bonding, between complementary nucleoside or nucleotide bases. For example, adenine and thymine are complementary nucleobases which pair through the formation of hydrogen bonds. "Complementary," as used herein, refers to the capacity for precise pairing between
30 two nucleotides. For example, if a nucleotide at a certain position of an oligonucleotide is capable of hydrogen bonding with a nucleotide at the same position of a DNA or RNA molecule, then the oligonucleotide and the DNA or RNA are considered to be complementary to each other at that
35 position. The oligonucleotide and the DNA or RNA are

-8-

complementary to each other when a sufficient number of corresponding positions in each molecule are occupied by nucleotides which can hydrogen bond with each other. Thus, "specifically hybridizable" and "complementary" are terms
5 which are used to indicate a sufficient degree of complementarity or precise pairing such that stable and specific binding occurs between the oligonucleotide and the DNA or RNA target. It is understood in the art that the sequence of an antisense compound need not be 100%
10 complementary to that of its target nucleic acid to be specifically hybridizable. An antisense compound is specifically hybridizable when binding of the compound to the target DNA or RNA molecule interferes with the normal function of the target DNA or RNA to cause a loss of
15 utility, and there is a sufficient degree of complementarity to avoid non-specific binding of the antisense compound to non-target sequences under conditions in which specific binding is desired, i.e., under physiological conditions in the case of in vivo assays or therapeutic treatment, and in
20 the case of in vitro assays, under conditions in which the assays are performed.

Antisense and other compounds of the invention which hybridize to the target and inhibit expression of the target are identified through experimentation, and the sequences of
25 these compounds are hereinbelow identified as preferred embodiments of the invention. The target sites to which these preferred sequences are complementary are hereinbelow referred to as "active sites" and are therefore preferred sites for targeting. Therefore another embodiment of the
30 invention encompasses compounds which hybridize to these active sites.

Antisense compounds are commonly used as research reagents and diagnostics. For example, antisense oligonucleotides, which are able to inhibit gene expression
35 with exquisite specificity, are often used by those of

ordinary skill to elucidate the function of particular genes. Antisense compounds are also used, for example, to distinguish between functions of various members of a biological pathway. Antisense modulation has, therefore,
5 been harnessed for research use.

The specificity and sensitivity of antisense is also harnessed by those of skill in the art for therapeutic uses. Antisense oligonucleotides have been employed as therapeutic moieties in the treatment of disease states in animals and
10 man. Antisense oligonucleotide drugs, including ribozymes, have been safely and effectively administered to humans and numerous clinical trials are presently underway. It is thus established that oligonucleotides can be useful therapeutic modalities that can be configured to be useful in treatment
15 regimes for treatment of cells, tissues and animals, especially humans.

In the context of this invention, the term "oligonucleotide" refers to an oligomer or polymer of ribonucleic acid (RNA) or deoxyribonucleic acid (DNA) or
20 mimetics thereof. This term includes oligonucleotides composed of naturally-occurring nucleobases, sugars and covalent internucleoside (backbone) linkages as well as oligonucleotides having non-naturally-occurring portions which function similarly. Such modified or substituted
25 oligonucleotides are often preferred over native forms because of desirable properties such as, for example, enhanced cellular uptake, enhanced affinity for nucleic acid target and increased stability in the presence of nucleases.

While antisense oligonucleotides are a preferred form
30 of antisense compound, the present invention comprehends other oligomeric antisense compounds, including but not limited to oligonucleotide mimetics such as are described below. The antisense compounds in accordance with this invention preferably comprise from about 8 to about 50
35 nucleobases (i.e. from about 8 to about 50 linked

-10-

nucleosides). Particularly preferred antisense compounds are antisense oligonucleotides, even more preferably those comprising from about 12 to about 30 nucleobases. Antisense compounds include ribozymes, external guide sequence (EGS) oligonucleotides (oligozymes), and other short catalytic RNAs or catalytic oligonucleotides which hybridize to the target nucleic acid and modulate its expression.

As is known in the art, a nucleoside is a base-sugar combination. The base portion of the nucleoside is normally a heterocyclic base. The two most common classes of such heterocyclic bases are the purines and the pyrimidines. Nucleotides are nucleosides that further include a phosphate group covalently linked to the sugar portion of the nucleoside. For those nucleosides that include a pentofuranosyl sugar, the phosphate group can be linked to either the 2', 3' or 5' hydroxyl moiety of the sugar. In forming oligonucleotides, the phosphate groups covalently link adjacent nucleosides to one another to form a linear polymeric compound. In turn the respective ends of this linear polymeric structure can be further joined to form a circular structure, however, open linear structures are generally preferred. Within the oligonucleotide structure, the phosphate groups are commonly referred to as forming the internucleoside backbone of the oligonucleotide. The normal linkage or backbone of RNA and DNA is a 3' to 5' phosphodiester linkage.

Specific examples of preferred antisense compounds useful in this invention include oligonucleotides containing modified backbones or non-natural internucleoside linkages. As defined in this specification, oligonucleotides having modified backbones include those that retain a phosphorus atom in the backbone and those that do not have a phosphorus atom in the backbone. For the purposes of this specification, and as sometimes referenced in the art, modified oligonucleotides that do not have a phosphorus atom

-11-

in their internucleoside backbone can also be considered to be oligonucleosides.

Preferred modified oligonucleotide backbones include, for example, phosphorothioates, chiral phosphorothioates, 5 phosphorodithioates, phosphotriesters, aminoalkylphosphotriesters, methyl and other alkyl phosphonates including 3'-alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates including 3'-amino phosphoramidate and aminoalkylphosphoramidates, thionophosphoramidates, thiono- 10 alkylphosphonates, thionoalkylphosphotriesters, and boranophosphates having normal 3'-5' linkages, 2'-5' linked analogs of these, and those having inverted polarity wherein the adjacent pairs of nucleoside units are linked 3'-5' to 5'-3' or 2'-5' to 5'-2'. Various salts, mixed salts and 15 free acid forms are also included.

Representative United States patents that teach the preparation of the above phosphorus-containing linkages include, but are not limited to, U.S.: 3,687,808; 4,469,863; 4,476,301; 5,023,243; 5,177,196; 5,188,897; 5,264,423; 20 5,276,019; 5,278,302; 5,286,717; 5,321,131; 5,399,676; 5,405,939; 5,453,496; 5,455,233; 5,466,677; 5,476,925; 5,519,126; 5,536,821; 5,541,306; 5,550,111; 5,563,253; 5,571,799; 5,587,361; and 5,625,050, certain of which are commonly owned with this application, and each of which is 25 herein incorporated by reference.

Preferred modified oligonucleotide backbones that do not include a phosphorus atom therein have backbones that are formed by short chain alkyl or cycloalkyl internucleoside linkages, mixed heteroatom and alkyl or 30 cycloalkyl internucleoside linkages, or one or more short chain heteroatomic or heterocyclic internucleoside linkages. These include those having morpholino linkages (formed in part from the sugar portion of a nucleoside); siloxane backbones; sulfide, sulfoxide and sulfone backbones; 35 formacetyl and thioformacetyl backbones; methylene

-12-

formacetyl and thioformacetyl backbones; alkene containing backbones; sulfamate backbones; methyleneimino and methylenehydrazino backbones; sulfonate and sulfonamide backbones; amide backbones; and others having mixed N, O, S and CH₂ component parts.

Representative United States patents that teach the preparation of the above oligonucleosides include, but are not limited to, U.S.: 5,034,506; 5,166,315; 5,185,444; 5,214,134; 5,216,141; 5,235,033; 5,264,562; 5,264,564; 5,405,938; 5,434,257; 5,466,677; 5,470,967; 5,489,677; 5,541,307; 5,561,225; 5,596,086; 5,602,240; 5,610,289; 5,602,240; 5,608,046; 5,610,289; 5,618,704; 5,623,070; 5,663,312; 5,633,360; 5,677,437; and 5,677,439, certain of which are commonly owned with this application, and each of which is herein incorporated by reference.

In other preferred oligonucleotide mimetics, both the sugar and the internucleoside linkage, i.e., the backbone, of the nucleotide units are replaced with novel groups. The base units are maintained for hybridization with an appropriate nucleic acid target compound. One such oligomeric compound, an oligonucleotide mimetic that has been shown to have excellent hybridization properties, is referred to as a peptide nucleic acid (PNA). In PNA compounds, the sugar-backbone of an oligonucleotide is replaced with an amide containing backbone, in particular an aminoethylglycine backbone. The nucleobases are retained and are bound directly or indirectly to aza nitrogen atoms of the amide portion of the backbone. Representative United States patents that teach the preparation of PNA compounds include, but are not limited to, U.S.: 5,539,082; 5,714,331; and 5,719,262, each of which is herein incorporated by reference. Further teaching of PNA compounds can be found in Nielsen et al., *Science*, **1991**, 254, 1497-1500.

Most preferred embodiments of the invention are oligonucleotides with phosphorothioate backbones and

-13-

oligonucleosides with heteroatom backbones, and in particular $-\text{CH}_2-\text{NH}-\text{O}-\text{CH}_2-$, $-\text{CH}_2-\text{N}(\text{CH}_3)-\text{O}-\text{CH}_2-$ [known as a methylene (methylimino) or MMI backbone], $-\text{CH}_2-\text{O}-\text{N}(\text{CH}_3)-\text{CH}_2-$, $-\text{CH}_2-\text{N}(\text{CH}_3)-\text{N}(\text{CH}_3)-\text{CH}_2-$ and $-\text{O}-\text{N}(\text{CH}_3)-\text{CH}_2-\text{CH}_2-$ [wherein the native phosphodiester backbone is represented as $-\text{O}-\text{P}-\text{O}-\text{CH}_2-$] of the above referenced U.S. patent 5,489,677, and the amide backbones of the above referenced U.S. patent 5,602,240. Also preferred are oligonucleotides having morpholino backbone structures of the above-referenced U.S. patent

10 5,034,506.

Modified oligonucleotides may also contain one or more substituted sugar moieties. Preferred oligonucleotides comprise one of the following at the 2' position: OH; F; O-, S-, or N-alkyl; O-, S-, or N-alkenyl; O-, S- or N-alkynyl; or O-alkyl-O-alkyl, wherein the alkyl, alkenyl and alkynyl may be substituted or unsubstituted C_1 to C_{10} alkyl or C_2 to C_{10} alkenyl and alkynyl. Particularly preferred are $\text{O}[(\text{CH}_2)_n\text{O}]_m\text{CH}_3$, $\text{O}(\text{CH}_2)_n\text{OCH}_3$, $\text{O}(\text{CH}_2)_n\text{NH}_2$, $\text{O}(\text{CH}_2)_n\text{CH}_3$, $\text{O}(\text{CH}_2)_n\text{ONH}_2$, and $\text{O}(\text{CH}_2)_n\text{ON}[(\text{CH}_2)_n\text{CH}_3]_2$, where n and m are from 1 to about

15 10. Other preferred oligonucleotides comprise one of the following at the 2' position: C_1 to C_{10} lower alkyl, substituted lower alkyl, alkaryl, aralkyl, O-alkaryl or O-aralkyl, SH, SCH_3 , OCN, Cl, Br, CN, CF_3 , OCF_3 , SOCH_3 , SO_2CH_3 , ONO_2 , NO_2 , N_3 , NH_2 , heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalkylamino, substituted silyl, an RNA cleaving group, a reporter group, an intercalator, a group for improving the pharmacokinetic properties of an oligonucleotide, or a group for improving the pharmacodynamic properties of an oligonucleotide, and other

25 substituents having similar properties. A preferred modification includes 2'-methoxyethoxy ($2'-\text{O}-\text{CH}_2\text{CH}_2\text{OCH}_3$, also known as 2'-O-(2-methoxyethyl) or 2'-MOE) (Martin et al., *Helv. Chim. Acta*, 1995, 78, 486-504) i.e., an alkoxyalkoxy group. A further preferred modification includes 2'-

30 dimethylaminoethoxy, i.e., a $\text{O}(\text{CH}_2)_2\text{ON}(\text{CH}_3)_2$ group, also

known as 2'-DMAOE, as described in examples hereinbelow, and 2'-dimethylaminoethoxyethoxy (also known in the art as 2'-O-dimethylaminoethoxyethyl or 2'-DMAEOE), i.e., 2'-O-CH₂-O-CH₂-N(CH₂)₂, also described in examples hereinbelow.

5 Other preferred modifications include 2'-methoxy (2'-O-CH₃), 2'-aminopropoxy (2'-OCH₂CH₂CH₂NH₂) and 2'-fluoro (2'-F). Similar modifications may also be made at other positions on the oligonucleotide, particularly the 3' position of the sugar on the 3' terminal nucleotide or in 2'-5' linked
10 oligonucleotides and the 5' position of 5' terminal nucleotide. Oligonucleotides may also have sugar mimetics such as cyclobutyl moieties in place of the pentofuranosyl sugar. Representative United States patents that teach the preparation of such modified sugar structures include, but
15 are not limited to, U.S.: 4,981,957; 5,118,800; 5,319,080; 5,359,044; 5,393,878; 5,446,137; 5,466,786; 5,514,785; 5,519,134; 5,567,811; 5,576,427; 5,591,722; 5,597,909; 5,610,300; 5,627,053; 5,639,873; 5,646,265; 5,658,873; 5,670,633; and 5,700,920, certain of which are commonly
20 owned with the instant application, and each of which is herein incorporated by reference in its entirety.

Oligonucleotides may also include nucleobase (often referred to in the art simply as "base") modifications or substitutions. As used herein, "unmodified" or "natural"
25 nucleobases include the purine bases adenine (A) and guanine (G), and the pyrimidine bases thymine (T), cytosine (C) and uracil (U). Modified nucleobases include other synthetic and natural nucleobases such as 5-methylcytosine (5-me-C), 5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2-
30 aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil and cytosine, 5-propynyl uracil and cytosine, 6-azo uracil, cytosine and thymine, 5-uracil
35 (pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-

-15-

thioalkyl, 8-hydroxyl and other 8-substituted adenines and guanines, 5-halo particularly 5-bromo, 5-trifluoromethyl and other 5-substituted uracils and cytosines, 7-methylguanine and 7-methyladenine, 8-azaguanine and 8-azaadenine, 7-deazaguanine and 7-deazaadenine and 3-deazaguanine and 3-deazaadenine. Further nucleobases include those disclosed in United States Patent No. 3,687,808, those disclosed in *The Concise Encyclopedia Of Polymer Science And Engineering*, pages 858-859, Kroschwitz, J.I., ed. John Wiley & Sons, 1990, those disclosed by Englisch et al., *Angewandte Chemie*, International Edition, 1991, 30, 613, and those disclosed by Sanghvi, Y.S., Chapter 15, *Antisense Research and Applications*, pages 289-302, Crooke, S.T. and Lebleu, B., ed., CRC Press, 1993. Certain of these nucleobases are particularly useful for increasing the binding affinity of the oligomeric compounds of the invention. These include 5-substituted pyrimidines, 6-azapyrimidines and N-2, N-6 and O-6 substituted purines, including 2-aminopropyladenine, 5-propynyluracil and 5-propynylcytosine. 5-methylcytosine substitutions have been shown to increase nucleic acid duplex stability by 0.6-1.2°C (Sanghvi, Y.S., Crooke, S.T. and Lebleu, B., eds., *Antisense Research and Applications*, CRC Press, Boca Raton, 1993, pp. 276-278) and are presently preferred base substitutions, even more particularly when combined with 2'-O-methoxyethyl sugar modifications.

Representative United States patents that teach the preparation of certain of the above noted modified nucleobases as well as other modified nucleobases include, but are not limited to, the above noted U.S. 3,687,808, as well as U.S.: 4,845,205; 5,130,302; 5,134,066; 5,175,273; 5,367,066; 5,432,272; 5,457,187; 5,459,255; 5,484,908; 5,502,177; 5,525,711; 5,552,540; 5,587,469; 5,594,121, 5,596,091; 5,614,617; and 5,681,941, certain of which are commonly owned with the instant application, and each of which is herein incorporated by reference, and United States

-16-

patent 5,750,692, which is commonly owned with the instant application and also herein incorporated by reference.

Another modification of the oligonucleotides of the invention involves chemically linking to the oligonucleotide one or more moieties or conjugates which enhance the activity, cellular distribution or cellular uptake of the oligonucleotide. Such moieties include but are not limited to lipid moieties such as a cholesterol moiety (Letsinger et al., *Proc. Natl. Acad. Sci. USA*, **1989**, *86*, 6553-6556), cholic acid (Manoharan et al., *Bioorg. Med. Chem. Lett.*, **1994**, *4*, 1053-1060), a thioether, e.g., hexyl-S-tritylthiol (Manoharan et al., *Ann. N.Y. Acad. Sci.*, **1992**, *660*, 306-309; Manoharan et al., *Bioorg. Med. Chem. Lett.*, **1993**, *3*, 2765-2770), a thiocholesterol (Oberhauser et al., *Nucl. Acids Res.*, **1992**, *20*, 533-538), an aliphatic chain, e.g., dodecandiol or undecyl residues (Saison-Behmoaras et al., *EMBO J.*, **1991**, *10*, 1111-1118; Kabanov et al., *FEBS Lett.*, **1990**, *259*, 327-330; Svinarchuk et al., *Biochimie*, **1993**, *75*, 49-54), a phospholipid, e.g., di-hexadecyl-rac-glycerol or triethylammonium 1,2-di-O-hexadecyl-rac-glycero-3-H-phosphonate (Manoharan et al., *Tetrahedron Lett.*, **1995**, *36*, 3651-3654; Shea et al., *Nucl. Acids Res.*, **1990**, *18*, 3777-3783), a polyamine or a polyethylene glycol chain (Manoharan et al., *Nucleosides & Nucleotides*, **1995**, *14*, 969-973), or adamantane acetic acid (Manoharan et al., *Tetrahedron Lett.*, **1995**, *36*, 3651-3654), a palmityl moiety (Mishra et al., *Biochim. Biophys. Acta*, **1995**, *1264*, 229-237), or an octadecylamine or hexylamino-carbonyl-oxycholesterol moiety (Crooke et al., *J. Pharmacol. Exp. Ther.*, **1996**, *277*, 923-937).

Representative United States patents that teach the preparation of such oligonucleotide conjugates include, but are not limited to, U.S.: 4,828,979; 4,948,882; 5,218,105; 5,525,465; 5,541,313; 5,545,730; 5,552,538; 5,578,717,

-17-

5,580,731; 5,580,731; 5,591,584; 5,109,124; 5,118,802;
5,138,045; 5,414,077; 5,486,603; 5,512,439; 5,578,718;
5,608,046; 4,587,044; 4,605,735; 4,667,025; 4,762,779;
4,789,737; 4,824,941; 4,835,263; 4,876,335; 4,904,582;
5 4,958,013; 5,082,830; 5,112,963; 5,214,136; 5,082,830;
5,112,963; 5,214,136; 5,245,022; 5,254,469; 5,258,506;
5,262,536; 5,272,250; 5,292,873; 5,317,098; 5,371,241,
5,391,723; 5,416,203, 5,451,463; 5,510,475; 5,512,667;
5,514,785; 5,565,552; 5,567,810; 5,574,142; 5,585,481;
10 5,587,371; 5,595,726; 5,597,696; 5,599,923; 5,599,928 and
5,688,941, certain of which are commonly owned with the
instant application, and each of which is herein
incorporated by reference.

It is not necessary for all positions in a given
15 compound to be uniformly modified, and in fact more than one
of the aforementioned modifications may be incorporated in a
single compound or even at a single nucleoside within an
oligonucleotide. The present invention also includes
antisense compounds which are chimeric compounds.
20 "Chimeric" antisense compounds or "chimeras," in the context
of this invention, are antisense compounds, particularly
oligonucleotides, which contain two or more chemically
distinct regions, each made up of at least one monomer unit,
i.e., a nucleotide in the case of an oligonucleotide
25 compound. These oligonucleotides typically contain at least
one region wherein the oligonucleotide is modified so as to
confer upon the oligonucleotide increased resistance to
nuclease degradation, increased cellular uptake, and/or
increased binding affinity for the target nucleic acid. An
30 additional region of the oligonucleotide may serve as a
substrate for enzymes capable of cleaving RNA:DNA or RNA:RNA
hybrids. By way of example, RNase H is a cellular
endonuclease which cleaves the RNA strand of an RNA:DNA
duplex. Activation of RNase H, therefore, results in
35 cleavage of the RNA target, thereby greatly enhancing the

-18-

efficiency of oligonucleotide inhibition of gene expression. Consequently, comparable results can often be obtained with shorter oligonucleotides when chimeric oligonucleotides are used, compared to phosphorothioate deoxyoligonucleotides
5 hybridizing to the same target region. Cleavage of the RNA target can be routinely detected by gel electrophoresis and, if necessary, associated nucleic acid hybridization techniques known in the art.

Chimeric antisense compounds of the invention may be
10 formed as composite structures of two or more oligonucleotides, modified oligonucleotides, oligonucleosides and/or oligonucleotide mimetics as described above. Such compounds have also been referred to in the art as hybrids or gapmers. Representative United
15 States patents that teach the preparation of such hybrid structures include, but are not limited to, U.S.: 5,013,830; 5,149,797; 5,220,007; 5,256,775; 5,366,878; 5,403,711; 5,491,133; 5,565,350; 5,623,065; 5,652,355; 5,652,356; and 5,700,922, certain of which are commonly owned with the
20 instant application, and each of which is herein incorporated by reference in its entirety.

The antisense compounds used in accordance with this invention may be conveniently and routinely made through the well-known technique of solid phase synthesis. Equipment
25 for such synthesis is sold by several vendors including, for example, Applied Biosystems (Foster City, CA). Any other means for such synthesis known in the art may additionally or alternatively be employed. It is well known to use similar techniques to prepare oligonucleotides such as the
30 phosphorothioates and alkylated derivatives.

The antisense compounds of the invention are synthesized in vitro and do not include antisense compositions of biological origin, or genetic vector constructs designed to direct the in vivo synthesis of
35 antisense molecules.

The compounds of the invention may also be admixed, encapsulated, conjugated or otherwise associated with other molecules, molecule structures or mixtures of compounds, as for example, liposomes, receptor targeted molecules, oral, 5 rectal, topical or other formulations, for assisting in uptake, distribution and/or absorption. Representative United States patents that teach the preparation of such uptake, distribution and/or absorption assisting formulations include, but are not limited to, U.S.:

10 5,108,921; 5,354,844; 5,416,016; 5,459,127; 5,521,291; 5,543,158; 5,547,932; 5,583,020; 5,591,721; 4,426,330; 4,534,899; 5,013,556; 5,108,921; 5,213,804; 5,227,170; 5,264,221; 5,356,633; 5,395,619; 5,416,016; 5,417,978; 5,462,854; 5,469,854; 5,512,295; 5,527,528; 5,534,259;

15 5,543,152; 5,556,948; 5,580,575; and 5,595,756, each of which is herein incorporated by reference.

The antisense compounds of the invention encompass any pharmaceutically acceptable salts, esters, or salts of such esters, or any other compound which, upon administration to 20 an animal including a human, is capable of providing (directly or indirectly) the biologically active metabolite or residue thereof. Accordingly, for example, the disclosure is also drawn to prodrugs and pharmaceutically acceptable salts of the compounds of the invention,

25 pharmaceutically acceptable salts of such prodrugs, and other bioequivalents.

The term "prodrug" indicates a therapeutic agent that is prepared in an inactive form that is converted to an active form (i.e., drug) within the body or cells thereof by 30 the action of endogenous enzymes or other chemicals and/or conditions. In particular, prodrug versions of the oligonucleotides of the invention are prepared as SATE [(S-acetyl-2-thioethyl) phosphate] derivatives according to the methods disclosed in WO 93/24510 to Gosselin et al.,

35 published December 9, 1993 or in WO 94/26764 and U.S.

5,770,713 to Imbach et al.

The term "pharmaceutically acceptable salts" refers to physiologically and pharmaceutically acceptable salts of the compounds of the invention: i.e., salts that retain the
5 desired biological activity of the parent compound and do not impart undesired toxicological effects thereto.

Pharmaceutically acceptable base addition salts are formed with metals or amines, such as alkali and alkaline earth metals or organic amines. Examples of metals used as
10 cations are sodium, potassium, magnesium, calcium, and the like. Examples of suitable amines are N,N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, dicyclohexylamine, ethylenediamine, N-methylglucamine, and procaine (see, for example, Berge et
15 al., "Pharmaceutical Salts," *J. of Pharma Sci.*, 1977, 66, 1-19). The base addition salts of said acidic compounds are prepared by contacting the free acid form with a sufficient amount of the desired base to produce the salt in the conventional manner. The free acid form may be regenerated
20 by contacting the salt form with an acid and isolating the free acid in the conventional manner. The free acid forms differ from their respective salt forms somewhat in certain physical properties such as solubility in polar solvents, but otherwise the salts are equivalent to their respective
25 free acid for purposes of the present invention. As used herein, a "pharmaceutical addition salt" includes a pharmaceutically acceptable salt of an acid form of one of the components of the compositions of the invention. These include organic or inorganic acid salts of the amines.
30 Preferred acid salts are the hydrochlorides, acetates, salicylates, nitrates and phosphates. Other suitable pharmaceutically acceptable salts are well known to those skilled in the art and include basic salts of a variety of inorganic and organic acids, such as, for example, with
35 inorganic acids, such as for example hydrochloric acid,

-21-

hydrobromic acid, sulfuric acid or phosphoric acid; with organic carboxylic, sulfonic, sulfo or phospho acids or N-substituted sulfamic acids, for example acetic acid, propionic acid, glycolic acid, succinic acid, maleic acid, 5 hydroxymaleic acid, methylmaleic acid, fumaric acid, malic acid, tartaric acid, lactic acid, oxalic acid, gluconic acid, glucaric acid, glucuronic acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, salicylic acid, 4-aminosalicylic acid, 2-phenoxybenzoic acid, 10 2-acetoxybenzoic acid, embonic acid, nicotinic acid or isonicotinic acid; and with amino acids, such as the 20 alpha-amino acids involved in the synthesis of proteins in nature, for example glutamic acid or aspartic acid, and also with phenylacetic acid, methanesulfonic acid, ethanesulfonic acid, 2-hydroxyethanesulfonic acid, ethane-1,2-disulfonic acid, benzenesulfonic acid, 4-methylbenzenesulfoic acid, naphthalene-2-sulfonic acid, naphthalene-1,5-disulfonic acid, 2- or 3-phosphoglycerate, glucose-6-phosphate, N-cyclohexylsulfamic acid (with the formation of 20 cyclamates), or with other acid organic compounds, such as ascorbic acid. Pharmaceutically acceptable salts of compounds may also be prepared with a pharmaceutically acceptable cation. Suitable pharmaceutically acceptable cations are well known to those skilled in the art and 25 include alkaline, alkaline earth, ammonium and quaternary ammonium cations. Carbonates or hydrogen carbonates are also possible.

For oligonucleotides, preferred examples of pharmaceutically acceptable salts include but are not 30 limited to (a) salts formed with cations such as sodium, potassium, ammonium, magnesium, calcium, polyamines such as spermine and spermidine, etc.; (b) acid addition salts formed with inorganic acids, for example hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid and the like; (c) salts formed with organic acids 35

-22-

such as, for example, acetic acid, oxalic acid, tartaric acid, succinic acid, maleic acid, fumaric acid, gluconic acid, citric acid, malic acid, ascorbic acid, benzoic acid, tannic acid, palmitic acid, alginic acid, polyglutamic acid, naphthalenesulfonic acid, methanesulfonic acid, p-toluenesulfonic acid, naphthalenedisulfonic acid, polygalacturonic acid, and the like; and (d) salts formed from elemental anions such as chlorine, bromine, and iodine.

The antisense compounds of the present invention can be utilized for diagnostics, therapeutics, prophylaxis and as research reagents and kits. For therapeutics, an animal, preferably a human, suspected of having a disease or disorder which can be treated by modulating the expression of Her-3 is treated by administering antisense compounds in accordance with this invention. The compounds of the invention can be utilized in pharmaceutical compositions by adding an effective amount of an antisense compound to a suitable pharmaceutically acceptable diluent or carrier. Use of the antisense compounds and methods of the invention may also be useful prophylactically, e.g., to prevent or delay infection, inflammation or tumor formation, for example.

The antisense compounds of the invention are useful for research and diagnostics, because these compounds hybridize to nucleic acids encoding Her-3, enabling sandwich and other assays to easily be constructed to exploit this fact. Hybridization of the antisense oligonucleotides of the invention with a nucleic acid encoding Her-3 can be detected by means known in the art. Such means may include conjugation of an enzyme to the oligonucleotide, radiolabelling of the oligonucleotide or any other suitable detection means. Kits using such detection means for detecting the level of Her-3 in a sample may also be prepared.

The present invention also includes pharmaceutical

compositions and formulations which include the antisense compounds of the invention. The pharmaceutical compositions of the present invention may be administered in a number of ways depending upon whether local or systemic treatment is
5 desired and upon the area to be treated. Administration may be topical (including ophthalmic and to mucous membranes including vaginal and rectal delivery), pulmonary, e.g., by inhalation or insufflation of powders or aerosols, including by nebulizer; intratracheal, intranasal, epidermal and
10 transdermal), oral or parenteral. Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal or intramuscular injection or infusion; or intracranial, e.g., intrathecal or intraventricular, administration. Oligonucleotides with at least one 2'-O-
15 methoxyethyl modification are believed to be particularly useful for oral administration.

Pharmaceutical compositions and formulations for topical administration may include transdermal patches, ointments, lotions, creams, gels, drops, suppositories,
20 sprays, liquids and powders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable. Coated condoms, gloves and the like may also be useful.

Compositions and formulations for oral administration
25 include powders or granules, suspensions or solutions in water or non-aqueous media, capsules, sachets or tablets. Thickeners, flavoring agents, diluents, emulsifiers, dispersing aids or binders may be desirable.

Compositions and formulations for parenteral,
30 intrathecal or intraventricular administration may include sterile aqueous solutions which may also contain buffers, diluents and other suitable additives such as, but not limited to, penetration enhancers, carrier compounds and other pharmaceutically acceptable carriers or excipients.

35 Pharmaceutical compositions of the present invention

-24-

include, but are not limited to, solutions, emulsions, and liposome-containing formulations. These compositions may be generated from a variety of components that include, but are not limited to, preformed liquids, self-emulsifying solids
5 and self-emulsifying semisolids.

The pharmaceutical formulations of the present invention, which may conveniently be presented in unit dosage form, may be prepared according to conventional techniques well known in the pharmaceutical industry. Such
10 techniques include the step of bringing into association the active ingredients with the pharmaceutical carrier(s) or excipient(s). In general the formulations are prepared by uniformly and intimately bringing into association the active ingredients with liquid carriers or finely divided
15 solid carriers or both, and then, if necessary, shaping the product.

The compositions of the present invention may be formulated into any of many possible dosage forms such as, but not limited to, tablets, capsules, liquid syrups, soft
20 gels, suppositories, and enemas. The compositions of the present invention may also be formulated as suspensions in aqueous, non-aqueous or mixed media. Aqueous suspensions may further contain substances which increase the viscosity of the suspension including, for example, sodium
25 carboxymethylcellulose, sorbitol and/or dextran. The suspension may also contain stabilizers.

In one embodiment of the present invention the pharmaceutical compositions may be formulated and used as foams. Pharmaceutical foams include formulations such as,
30 but not limited to, emulsions, microemulsions, creams, jellies and liposomes. While basically similar in nature these formulations vary in the components and the consistency of the final product. The preparation of such compositions and formulations is generally known to those
35 skilled in the pharmaceutical and formulation arts and may

-25-

be applied to the formulation of the compositions of the present invention.

Emulsions

The compositions of the present invention may be prepared and formulated as emulsions. Emulsions are typically heterogenous systems of one liquid dispersed in another in the form of droplets usually exceeding 0.1 μm in diameter. (Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199; Rosoff, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., Volume 1, p. 245; Block in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 2, p. 335; Higuchi et al., in *Remington's Pharmaceutical Sciences*, Mack Publishing Co., Easton, PA, 1985, p. 301). Emulsions are often biphasic systems comprising of two immiscible liquid phases intimately mixed and dispersed with each other. In general, emulsions may be either water-in-oil (w/o) or of the oil-in-water (o/w) variety. When an aqueous phase is finely divided into and dispersed as minute droplets into a bulk oily phase the resulting composition is called a water-in-oil (w/o) emulsion. Alternatively, when an oily phase is finely divided into and dispersed as minute droplets into a bulk aqueous phase the resulting composition is called an oil-in-water (o/w) emulsion. Emulsions may contain additional components in addition to the dispersed phases and the active drug which may be present as a solution in either the aqueous phase, oily phase or itself as a separate phase. Pharmaceutical excipients such as emulsifiers, stabilizers, dyes, and anti-oxidants may also be present in emulsions as needed. Pharmaceutical emulsions may also be multiple emulsions that are comprised of more than two phases such

-26-

as, for example, in the case of oil-in-water-in-oil (o/w/o) and water-in-oil-in-water (w/o/w) emulsions. Such complex formulations often provide certain advantages that simple binary emulsions do not. Multiple emulsions in which
5 individual oil droplets of an o/w emulsion enclose small water droplets constitute a w/o/w emulsion. Likewise a system of oil droplets enclosed in globules of water stabilized in an oily continuous provides an o/w/o emulsion.

Emulsions are characterized by little or no
10 thermodynamic stability. Often, the dispersed or discontinuous phase of the emulsion is well dispersed into the external or continuous phase and maintained in this form through the means of emulsifiers or the viscosity of the formulation. Either of the phases of the emulsion may be a
15 semisolid or a solid, as is the case of emulsion-style ointment bases and creams. Other means of stabilizing emulsions entail the use of emulsifiers that may be incorporated into either phase of the emulsion. Emulsifiers may broadly be classified into four categories: synthetic
20 surfactants, naturally occurring emulsifiers, absorption bases, and finely dispersed solids (Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199).

Synthetic surfactants, also known as surface active
25 agents, have found wide applicability in the formulation of emulsions and have been reviewed in the literature (Rieger, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 285; Idson, in *Pharmaceutical Dosage Forms*, Lieberman,
30 Rieger and Banker (Eds.), Marcel Dekker, Inc., New York, N.Y., 1988, volume 1, p. 199). Surfactants are typically amphiphilic and comprise a hydrophilic and a hydrophobic portion. The ratio of the hydrophilic to the hydrophobic nature of the surfactant has been termed the
35 hydrophile/lipophile balance (HLB) and is a valuable tool in

categorizing and selecting surfactants in the preparation of formulations. Surfactants may be classified into different classes based on the nature of the hydrophilic group: nonionic, anionic, cationic and amphoteric (Rieger, in
5 *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 285).

Naturally occurring emulsifiers used in emulsion formulations include lanolin, beeswax, phosphatides,
10 lecithin and acacia. Absorption bases possess hydrophilic properties such that they can soak up water to form w/o emulsions yet retain their semisolid consistencies, such as anhydrous lanolin and hydrophilic petrolatum. Finely divided solids have also been used as good emulsifiers
15 especially in combination with surfactants and in viscous preparations. These include polar inorganic solids, such as heavy metal hydroxides, nonswelling clays such as bentonite, attapulgite, hectorite, kaolin, montmorillonite, colloidal aluminum silicate and colloidal magnesium aluminum silicate,
20 pigments and nonpolar solids such as carbon or glyceryl tristearate.

A large variety of non-emulsifying materials are also included in emulsion formulations and contribute to the properties of emulsions. These include fats, oils, waxes,
25 fatty acids, fatty alcohols, fatty esters, humectants, hydrophilic colloids, preservatives and antioxidants (Block, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 335; Idson, in *Pharmaceutical Dosage Forms*, Lieberman,
30 Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199).

Hydrophilic colloids or hydrocolloids include naturally occurring gums and synthetic polymers such as polysaccharides (for example, acacia, agar, alginic acid,
35 carrageenan, guar gum, karaya gum, and tragacanth),

cellulose derivatives (for example, carboxymethylcellulose and carboxypropylcellulose), and synthetic polymers (for example, carbomers, cellulose ethers, and carboxyvinyl polymers). These disperse or swell in water to form
5 colloidal solutions that stabilize emulsions by forming strong interfacial films around the dispersed-phase droplets and by increasing the viscosity of the external phase.

Since emulsions often contain a number of ingredients such as carbohydrates, proteins, sterols and phosphatides
10 that may readily support the growth of microbes, these formulations often incorporate preservatives. Commonly used preservatives included in emulsion formulations include methyl paraben, propyl paraben, quaternary ammonium salts, benzalkonium chloride, esters of p-hydroxybenzoic acid, and
15 boric acid. Antioxidants are also commonly added to emulsion formulations to prevent deterioration of the formulation. Antioxidants used may be free radical scavengers such as tocopherols, alkyl gallates, butylated hydroxyanisole, butylated hydroxytoluene, or reducing agents
20 such as ascorbic acid and sodium metabisulfite, and antioxidant synergists such as citric acid, tartaric acid, and lecithin.

The application of emulsion formulations via dermatological, oral and parenteral routes and methods for
25 their manufacture have been reviewed in the literature (Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199). Emulsion formulations for oral delivery have been very widely used because of reasons of
30 ease of formulation, efficacy from an absorption and bioavailability standpoint. (Rosoff, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245; Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and
35 Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y.,

-29-

volume 1, p. 199). Mineral-oil base laxatives, oil-soluble vitamins and high fat nutritive preparations are among the materials that have commonly been administered orally as o/w emulsions.

5 In one embodiment of the present invention, the compositions of oligonucleotides and nucleic acids are formulated as microemulsions. A microemulsion may be defined as a system of water, oil and amphiphile which is a single optically isotropic and thermodynamically stable
10 liquid solution (Rosoff, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245). Typically microemulsions are systems that are prepared by first dispersing an oil in an aqueous surfactant solution and then
15 adding a sufficient amount of a fourth component, generally an intermediate chain-length alcohol to form a transparent system. Therefore, microemulsions have also been described as thermodynamically stable, isotropically clear dispersions of two immiscible liquids that are stabilized by interfacial
20 films of surface-active molecules (Leung and Shah, in: *Controlled Release of Drugs: Polymers and Aggregate Systems*, Rosoff, M., Ed., 1989, VCH Publishers, New York, pages 185-215). Microemulsions commonly are prepared via a combination of three to five components that include oil,
25 water, surfactant, cosurfactant and electrolyte. Whether the microemulsion is of the water-in-oil (w/o) or an oil-in-water (o/w) type is dependent on the properties of the oil and surfactant used and on the structure and geometric packing of the polar heads and hydrocarbon tails of the
30 surfactant molecules (Schott, in *Remington's Pharmaceutical Sciences*, Mack Publishing Co., Easton, PA, 1985, p. 271).

The phenomenological approach utilizing phase diagrams has been extensively studied and has yielded a comprehensive knowledge, to one skilled in the art, of how to formulate
35 microemulsions (Rosoff, in *Pharmaceutical Dosage Forms*,

Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245; Block, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, 5 p. 335). Compared to conventional emulsions, microemulsions offer the advantage of solubilizing water-insoluble drugs in a formulation of thermodynamically stable droplets that are formed spontaneously.

Surfactants used in the preparation of microemulsions 10 include, but are not limited to, ionic surfactants, non-ionic surfactants, Brij 96, polyoxyethylene oleyl ethers, polyglycerol fatty acid esters, tetraglycerol monolaurate (ML310), tetraglycerol monooleate (MO310), hexaglycerol monooleate (PO310), hexaglycerol pentaoleate (PO500), 15 decaglycerol monocaprate (MCA750), decaglycerol monooleate (MO750), decaglycerol sequioleate (SO750), decaglycerol decaoleate (DAO750), alone or in combination with cosurfactants. The cosurfactant, usually a short-chain alcohol such as ethanol, 1-propanol, and 1-butanol, serves 20 to increase the interfacial fluidity by penetrating into the surfactant film and consequently creating a disordered film because of the void space generated among surfactant molecules. Microemulsions may, however, be prepared without the use of cosurfactants and alcohol-free self-emulsifying 25 microemulsion systems are known in the art. The aqueous phase may typically be, but is not limited to, water, an aqueous solution of the drug, glycerol, PEG300, PEG400, polyglycerols, propylene glycols, and derivatives of ethylene glycol. The oil phase may include, but is not 30 limited to, materials such as Captex 300, Captex 355, Capmul MCM, fatty acid esters, medium chain (C8-C12) mono, di, and tri-glycerides, polyoxyethylated glyceryl fatty acid esters, fatty alcohols, polyglycolized glycerides, saturated polyglycolized C8-C10 glycerides, vegetable oils and 35 silicone oil.

-31-

Microemulsions are particularly of interest from the standpoint of drug solubilization and the enhanced absorption of drugs. Lipid based microemulsions (both o/w and w/o) have been proposed to enhance the oral

5 bioavailability of drugs, including peptides (Constantinides et al., *Pharmaceutical Research*, **1994**, *11*, 1385-1390; Ritschel, *Meth. Find. Exp. Clin. Pharmacol.*, **1993**, *13*, 205). Microemulsions afford advantages of improved drug solubilization, protection of drug from enzymatic

10 hydrolysis, possible enhancement of drug absorption due to surfactant-induced alterations in membrane fluidity and permeability, ease of preparation, ease of oral administration over solid dosage forms, improved clinical potency, and decreased toxicity (Constantinides et al.,

15 *Pharmaceutical Research*, **1994**, *11*, 1385; Ho et al., *J. Pharm. Sci.*, **1996**, *85*, 138-143). Often microemulsions may form spontaneously when their components are brought together at ambient temperature. This may be particularly advantageous when formulating thermolabile drugs, peptides

20 or oligonucleotides. Microemulsions have also been effective in the transdermal delivery of active components in both cosmetic and pharmaceutical applications. It is expected that the microemulsion compositions and formulations of the present invention will facilitate the

25 increased systemic absorption of oligonucleotides and nucleic acids from the gastrointestinal tract, as well as improve the local cellular uptake of oligonucleotides and nucleic acids within the gastrointestinal tract, vagina, buccal cavity and other areas of administration.

30 Microemulsions of the present invention may also contain additional components and additives such as sorbitan monostearate (Grill 3), Labrasol, and penetration enhancers to improve the properties of the formulation and to enhance the absorption of the oligonucleotides and nucleic acids of

35 the present invention. Penetration enhancers used in the

microemulsions of the present invention may be classified as belonging to one of five broad categories - surfactants, fatty acids, bile salts, chelating agents, and non-chelating non-surfactants (Lee et al., *Critical Reviews in Therapeutic*
5 *Drug Carrier Systems*, 1991, p. 92). Each of these classes has been discussed above.

Liposomes

There are many organized surfactant structures besides microemulsions that have been studied and used for the
10 formulation of drugs. These include monolayers, micelles, bilayers and vesicles. Vesicles, such as liposomes, have attracted great interest because of their specificity and the duration of action they offer from the standpoint of drug delivery. As used in the present invention, the term
15 "liposome" means a vesicle composed of amphiphilic lipids arranged in a spherical bilayer or bilayers.

Liposomes are unilamellar or multilamellar vesicles which have a membrane formed from a lipophilic material and an aqueous interior. The aqueous portion contains the
20 composition to be delivered. Cationic liposomes possess the advantage of being able to fuse to the cell wall. Non-cationic liposomes, although not able to fuse as efficiently with the cell wall, are taken up by macrophages *in vivo*.

In order to cross intact mammalian skin, lipid vesicles
25 must pass through a series of fine pores, each with a diameter less than 50 nm, under the influence of a suitable transdermal gradient. Therefore, it is desirable to use a liposome which is highly deformable and able to pass through such fine pores.

Further advantages of liposomes include; liposomes
30 obtained from natural phospholipids are biocompatible and biodegradable; liposomes can incorporate a wide range of water and lipid soluble drugs; liposomes can protect encapsulated drugs in their internal compartments from
35 metabolism and degradation (Rosoff, in *Pharmaceutical Dosage*

Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245). Important considerations in the preparation of liposome formulations are the lipid surface charge, vesicle size and the aqueous
5 volume of the liposomes.

Liposomes are useful for the transfer and delivery of active ingredients to the site of action. Because the liposomal membrane is structurally similar to biological membranes, when liposomes are applied to a tissue, the
10 liposomes start to merge with the cellular membranes. As the merging of the liposome and cell progresses, the liposomal contents are emptied into the cell where the active agent may act.

Liposomal formulations have been the focus of extensive
15 investigation as the mode of delivery for many drugs. There is growing evidence that for topical administration, liposomes present several advantages over other formulations. Such advantages include reduced side-effects related to high systemic absorption of the administered
20 drug, increased accumulation of the administered drug at the desired target, and the ability to administer a wide variety of drugs, both hydrophilic and hydrophobic, into the skin.

Several reports have detailed the ability of liposomes to deliver agents including high-molecular weight DNA into
25 the skin. Compounds including analgesics, antibodies, hormones and high-molecular weight DNAs have been administered to the skin. The majority of applications resulted in the targeting of the upper epidermis.

Liposomes fall into two broad classes. Cationic
30 liposomes are positively charged liposomes which interact with the negatively charged DNA molecules to form a stable complex. The positively charged DNA/liposome complex binds to the negatively charged cell surface and is internalized in an endosome. Due to the acidic pH within the endosome,
35 the liposomes are ruptured, releasing their contents into

the cell cytoplasm (Wang et al., *Biochem. Biophys. Res. Commun.*, **1987**, 147, 980-985).

Liposomes which are pH-sensitive or negatively-charged, entrap DNA rather than complex with it. Since both the DNA
5 and the lipid are similarly charged, repulsion rather than complex formation occurs. Nevertheless, some DNA is entrapped within the aqueous interior of these liposomes. pH-sensitive liposomes have been used to deliver DNA encoding the thymidine kinase gene to cell monolayers in
10 culture. Expression of the exogenous gene was detected in the target cells (Zhou et al., *Journal of Controlled Release*, **1992**, 19, 269-274).

One major type of liposomal composition includes phospholipids other than naturally-derived
15 phosphatidylcholine. Neutral liposome compositions, for example, can be formed from dimyristoyl phosphatidylcholine (DMPC) or dipalmitoyl phosphatidylcholine (DPPC). Anionic liposome compositions generally are formed from dimyristoyl phosphatidylglycerol, while anionic fusogenic liposomes are
20 formed primarily from dioleoyl phosphatidylethanolamine (DOPE). Another type of liposomal composition is formed from phosphatidylcholine (PC) such as, for example, soybean PC, and egg PC. Another type is formed from mixtures of phospholipid and/or phosphatidylcholine and/or cholesterol.

25 Several studies have assessed the topical delivery of liposomal drug formulations to the skin. Application of liposomes containing interferon to guinea pig skin resulted in a reduction of skin herpes sores while delivery of interferon via other means (e.g. as a solution or as an
30 emulsion) were ineffective (Weiner et al., *Journal of Drug Targeting*, **1992**, 2, 405-410). Further, an additional study tested the efficacy of interferon administered as part of a liposomal formulation to the administration of interferon using an aqueous system, and concluded that the liposomal
35 formulation was superior to aqueous administration (du

Plessis et al., *Antiviral Research*, **1992**, 18, 259-265).

Non-ionic liposomal systems have also been examined to determine their utility in the delivery of drugs to the skin, in particular systems comprising non-ionic surfactant and cholesterol. Non-ionic liposomal formulations comprising Novasome™ I (glyceryl dilaurate/cholesterol/polyoxyethylene-10-stearyl ether) and Novasome™ II (glyceryl distearate/cholesterol/polyoxyethylene-10-stearyl ether) were used to deliver cyclosporin-A into the dermis of mouse skin. Results indicated that such non-ionic liposomal systems were effective in facilitating the deposition of cyclosporin-A into different layers of the skin (Hu et al. *S.T.P. Pharma. Sci.*, **1994**, 4, 6, 466).

Liposomes also include "sterically stabilized" liposomes, a term which, as used herein, refers to liposomes comprising one or more specialized lipids that, when incorporated into liposomes, result in enhanced circulation lifetimes relative to liposomes lacking such specialized lipids. Examples of sterically stabilized liposomes are those in which part of the vesicle-forming lipid portion of the liposome (A) comprises one or more glycolipids, such as monosialoganglioside G_{M1}, or (B) is derivatized with one or more hydrophilic polymers, such as a polyethylene glycol (PEG) moiety. While not wishing to be bound by any particular theory, it is thought in the art that, at least for sterically stabilized liposomes containing gangliosides, sphingomyelin, or PEG-derivatized lipids, the enhanced circulation half-life of these sterically stabilized liposomes derives from a reduced uptake into cells of the reticuloendothelial system (RES) (Allen et al., *FEBS Letters*, **1987**, 223, 42; Wu et al., *Cancer Research*, **1993**, 53, 3765). Various liposomes comprising one or more glycolipids are known in the art. Papahadjopoulos et al. (*Ann. N.Y. Acad. Sci.*, **1987**, 507, 64) reported the ability

-36-

of monosialoganglioside G_{M1}, galactocerebroside sulfate and phosphatidylinositol to improve blood half-lives of liposomes. These findings were expounded upon by Gabizon *et al.* (*Proc. Natl. Acad. Sci. U.S.A.*, **1988**, 85, 6949). U.S. Patent No. 4,837,028 and WO 88/04924, both to Allen *et al.*, disclose liposomes comprising (1) sphingomyelin and (2) the ganglioside G_{M1} or a galactocerebroside sulfate ester. U.S. Patent No. 5,543,152 (Webb *et al.*) discloses liposomes comprising sphingomyelin. Liposomes comprising 1,2-*sn*-dimyristoylphosphatidylcholine are disclosed in WO 97/13499 (Lim *et al.*).

Many liposomes comprising lipids derivatized with one or more hydrophilic polymers, and methods of preparation thereof, are known in the art. Sunamoto *et al.* (*Bull. Chem. Soc. Jpn.*, **1980**, 53, 2778) described liposomes comprising a nonionic detergent, 2C₁₂15G, that contains a PEG moiety. Illum *et al.* (*FEBS Lett.*, **1984**, 167, 79) noted that hydrophilic coating of polystyrene particles with polymeric glycols results in significantly enhanced blood half-lives. Synthetic phospholipids modified by the attachment of carboxylic groups of polyalkylene glycols (e.g., PEG) are described by Sears (U.S. Patent Nos. 4,426,330 and 4,534,899). Klibanov *et al.* (*FEBS Lett.*, **1990**, 268, 235) described experiments demonstrating that liposomes comprising phosphatidylethanolamine (PE) derivatized with PEG or PEG stearate have significant increases in blood circulation half-lives. Blume *et al.* (*Biochimica et Biophysica Acta*, **1990**, 1029, 91) extended such observations to other PEG-derivatized phospholipids, e.g., DSPE-PEG, formed from the combination of distearoylphosphatidylethanolamine (DSPE) and PEG. Liposomes having covalently bound PEG moieties on their external surface are described in European Patent No. EP 0 445 131 B1 and WO 90/04384 to Fisher. Liposome compositions

-37-

containing 1-20 mole percent of PE derivatized with PEG, and methods of use thereof, are described by Woodle *et al.* (U.S. Patent Nos. 5,013,556 and 5,356,633) and Martin *et al.* (U.S. Patent No. 5,213,804 and European Patent No. EP 0 496 813 B1). Liposomes comprising a number of other lipid-polymer conjugates are disclosed in WO 91/05545 and U.S. Patent No. 5,225,212 (both to Martin *et al.*) and in WO 94/20073 (Zalipsky *et al.*) Liposomes comprising PEG-modified ceramide lipids are described in WO 96/10391 (Choi *et al.*). U.S. Patent Nos. 5,540,935 (Miyazaki *et al.*) and 5,556,948 (Tagawa *et al.*) describe PEG-containing liposomes that can be further derivatized with functional moieties on their surfaces.

A limited number of liposomes comprising nucleic acids are known in the art. WO 96/40062 to Thierry *et al.* discloses methods for encapsulating high molecular weight nucleic acids in liposomes. U.S. Patent No. 5,264,221 to Tagawa *et al.* discloses protein-bonded liposomes and asserts that the contents of such liposomes may include an antisense RNA. U.S. Patent No. 5,665,710 to Rahman *et al.* describes certain methods of encapsulating oligodeoxynucleotides in liposomes. WO 97/04787 to Love *et al.* discloses liposomes comprising antisense oligonucleotides targeted to the raf gene.

Transfersomes are yet another type of liposomes, and are highly deformable lipid aggregates which are attractive candidates for drug delivery vehicles. Transfersomes may be described as lipid droplets which are so highly deformable that they are easily able to penetrate through pores which are smaller than the droplet. Transfersomes are adaptable to the environment in which they are used, *e.g.* they are self-optimizing (adaptive to the shape of pores in the skin), self-repairing, frequently reach their targets without fragmenting, and often self-loading. To make transfersomes it is possible to add surface edge-activators,

-38-

usually surfactants, to a standard liposomal composition. Transfersomes have been used to deliver serum albumin to the skin. The transfersome-mediated delivery of serum albumin has been shown to be as effective as subcutaneous injection
5 of a solution containing serum albumin.

Surfactants find wide application in formulations such as emulsions (including microemulsions) and liposomes. The most common way of classifying and ranking the properties of the many different types of surfactants, both natural and
10 synthetic, is by the use of the hydrophile/lipophile balance (HLB). The nature of the hydrophilic group (also known as the "head") provides the most useful means for categorizing the different surfactants used in formulations (Rieger, in *Pharmaceutical Dosage Forms*, Marcel Dekker, Inc., New York,
15 NY, 1988, p. 285).

If the surfactant molecule is not ionized, it is classified as a nonionic surfactant. Nonionic surfactants find wide application in pharmaceutical and cosmetic products and are usable over a wide range of pH values. In
20 general their HLB values range from 2 to about 18 depending on their structure. Nonionic surfactants include nonionic esters such as ethylene glycol esters, propylene glycol esters, glyceryl esters, polyglyceryl esters, sorbitan esters, sucrose esters, and ethoxylated esters. Nonionic
25 alkanolamides and ethers such as fatty alcohol ethoxylates, propoxylated alcohols, and ethoxylated/propoxylated block polymers are also included in this class. The polyoxyethylene surfactants are the most popular members of the nonionic surfactant class.

30 If the surfactant molecule carries a negative charge when it is dissolved or dispersed in water, the surfactant is classified as anionic. Anionic surfactants include carboxylates such as soaps, acyl lactylates, acyl amides of amino acids, esters of sulfuric acid such as alkyl sulfates
35 and ethoxylated alkyl sulfates, sulfonates such as alkyl

benzene sulfonates, acyl isethionates, acyl taurates and sulfosuccinates, and phosphates. The most important members of the anionic surfactant class are the alkyl sulfates and the soaps.

5 If the surfactant molecule carries a positive charge when it is dissolved or dispersed in water, the surfactant is classified as cationic. Cationic surfactants include quaternary ammonium salts and ethoxylated amines. The quaternary ammonium salts are the most used members of this
10 class.

 If the surfactant molecule has the ability to carry either a positive or negative charge, the surfactant is classified as amphoteric. Amphoteric surfactants include acrylic acid derivatives, substituted alkylamides, N-
15 alkylbetaines and phosphatides.

 The use of surfactants in drug products, formulations and in emulsions has been reviewed (Rieger, in *Pharmaceutical Dosage Forms*, Marcel Dekker, Inc., New York, NY, 1988, p. 285).

20 Penetration Enhancers

 In one embodiment, the present invention employs various penetration enhancers to effect the efficient delivery of nucleic acids, particularly oligonucleotides, to the skin of animals. Most drugs are present in solution in
25 both ionized and nonionized forms. However, usually only lipid soluble or lipophilic drugs readily cross cell membranes. It has been discovered that even non-lipophilic drugs may cross cell membranes if the membrane to be crossed is treated with a penetration enhancer. In addition to
30 aiding the diffusion of non-lipophilic drugs across cell membranes, penetration enhancers also enhance the permeability of lipophilic drugs.

 Penetration enhancers may be classified as belonging to one of five broad categories, i.e., surfactants, fatty
35 acids, bile salts, chelating agents, and non-chelating non-

surfactants (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, p.92). Each of the above mentioned classes of penetration enhancers are described below in greater detail.

5 Surfactants: In connection with the present invention, surfactants (or "surface-active agents") are chemical entities which, when dissolved in an aqueous solution, reduce the surface tension of the solution or the
interfacial tension between the aqueous solution and another
10 liquid, with the result that absorption of oligonucleotides through the mucosa is enhanced. In addition to bile salts and fatty acids, these penetration enhancers include, for example, sodium lauryl sulfate, polyoxyethylene-9-lauryl ether and polyoxyethylene-20-cetyl ether) (Lee et al.,
15 *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, p.92); and perfluorochemical emulsions, such as FC-43. Takahashi et al., *J. Pharm. Pharmacol.*, 1988, 40, 252).

Fatty acids: Various fatty acids and their derivatives which act as penetration enhancers include, for example,
20 oleic acid, lauric acid, capric acid (n-decanoic acid), myristic acid, palmitic acid, stearic acid, linoleic acid, linolenic acid, dicaprate, tricaprate, monoolein (1-monooleoyl-rac-glycerol), dilaurin, caprylic acid, arachidonic acid, glycerol 1-monocaprate, 1-
25 dodecylazacycloheptan-2-one, acylcarnitines, acylcholines, C₁₋₁₀ alkyl esters thereof (e.g., methyl, isopropyl and t-butyl), and mono- and di-glycerides thereof (i.e., oleate, laurate, caprate, myristate, palmitate, stearate, linoleate, etc.) (Lee et al., *Critical Reviews in Therapeutic Drug*
30 *Carrier Systems*, 1991, p.92; Muranishi, *Critical Reviews in Therapeutic Drug Carrier Systems*, 1990, 7, 1-33; El Hariri et al., *J. Pharm. Pharmacol.*, 1992, 44, 651-654).

Bile salts: The physiological role of bile includes the facilitation of dispersion and absorption of lipids and fat-

soluble vitamins (Brunton, Chapter 38 in: Goodman & Gilman's *The Pharmacological Basis of Therapeutics*, 9th Ed., Hardman et al. Eds., McGraw-Hill, New York, 1996, pp. 934-935).

Various natural bile salts, and their synthetic derivatives,
5 act as penetration enhancers. Thus the term "bile salts" includes any of the naturally occurring components of bile as well as any of their synthetic derivatives. The bile salts of the invention include, for example, cholic acid (or its pharmaceutically acceptable sodium salt, sodium
10 cholate), dehydrocholic acid (sodium dehydrocholate), deoxycholic acid (sodium deoxycholate), glucolic acid (sodium glucolate), glycholic acid (sodium glycocholate), glycodeoxycholic acid (sodium glycodeoxycholate), taurocholic acid (sodium taurocholate), taurodeoxycholic
15 acid (sodium taurodeoxycholate), chenodeoxycholic acid (sodium chenodeoxycholate), ursodeoxycholic acid (UDCA), sodium tauro-24,25-dihydro-fusidate (STDHF), sodium glycodihydrofusidate and polyoxyethylene-9-lauryl ether (POE) (Lee et al., *Critical Reviews in Therapeutic Drug*
20 *Carrier Systems*, 1991, page 92; Swinyard, Chapter 39 In: *Remington's Pharmaceutical Sciences*, 18th Ed., Gennaro, ed., Mack Publishing Co., Easton, PA, 1990, pages 782-783; Muranishi, *Critical Reviews in Therapeutic Drug Carrier Systems*, 1990, 7, 1-33; Yamamoto et al., *J. Pharm. Exp. Ther.*, 1992, 263, 25; Yamashita et al., *J. Pharm. Sci.*,
25 1990, 79, 579-583).

Chelating Agents: Chelating agents, as used in connection with the present invention, can be defined as compounds that remove metallic ions from solution by forming
30 complexes therewith, with the result that absorption of oligonucleotides through the mucosa is enhanced. With regards to their use as penetration enhancers in the present invention, chelating agents have the added advantage of also serving as DNase inhibitors, as most characterized DNA

-42-

nucleases require a divalent metal ion for catalysis and are thus inhibited by chelating agents (Jarrett, *J. Chromatogr.*, **1993**, *618*, 315-339). Chelating agents of the invention include but are not limited to disodium

5 ethylenediaminetetraacetate (EDTA), citric acid, salicylates (e.g., sodium salicylate, 5-methoxysalicylate and homovanilate), *N*-acyl derivatives of collagen, laureth-9 and *N*-amino acyl derivatives of beta-diketones (enamines) (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*,
10 **1991**, page 92; Muranishi, *Critical Reviews in Therapeutic Drug Carrier Systems*, **1990**, *7*, 1-33; Buur et al., *J. Control Rel.*, **1990**, *14*, 43-51).

Non-chelating non-surfactants: As used herein, non-chelating non-surfactant penetration enhancing compounds can

15 be defined as compounds that demonstrate insignificant activity as chelating agents or as surfactants but that nonetheless enhance absorption of oligonucleotides through the alimentary mucosa (Muranishi, *Critical Reviews in Therapeutic Drug Carrier Systems*, **1990**, *7*, 1-33). This
20 class of penetration enhancers include, for example, unsaturated cyclic ureas, 1-alkyl- and 1-alkenylazacycloalkanone derivatives (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, **1991**, page 92); and non-steroidal anti-inflammatory agents such as diclofenac
25 sodium, indomethacin and phenylbutazone (Yamashita et al., *J. Pharm. Pharmacol.*, **1987**, *39*, 621-626).

Agents that enhance uptake of oligonucleotides at the cellular level may also be added to the pharmaceutical and other compositions of the present invention. For example,
30 cationic lipids, such as lipofectin (Junichi et al, U.S. Patent No. 5,705,188), cationic glycerol derivatives, and polycationic molecules, such as polylysine (Lollo et al., PCT Application WO 97/30731), are also known to enhance the cellular uptake of oligonucleotides.

-43-

Other agents may be utilized to enhance the penetration of the administered nucleic acids, including glycols such as ethylene glycol and propylene glycol, pyrrols such as 2-pyrrol, azones, and terpenes such as limonene and menthone.

5 Carriers

Certain compositions of the present invention also incorporate carrier compounds in the formulation. As used herein, "carrier compound" or "carrier" can refer to a nucleic acid, or analog thereof, which is inert (*i.e.*, does not possess biological activity *per se*) but is recognized as
10 a nucleic acid by *in vivo* processes that reduce the bioavailability of a nucleic acid having biological activity by, for example, degrading the biologically active nucleic acid or promoting its removal from circulation. The
15 coadministration of a nucleic acid and a carrier compound, typically with an excess of the latter substance, can result in a substantial reduction of the amount of nucleic acid recovered in the liver, kidney or other extracirculatory reservoirs, presumably due to competition between the
20 carrier compound and the nucleic acid for a common receptor. For example, the recovery of a partially phosphorothioate oligonucleotide in hepatic tissue can be reduced when it is coadministered with polyinosinic acid, dextran sulfate, polycytidic acid or 4-acetamido-4'-isothiocyano-stilbene-
25 2,2'-disulfonic acid (Miyao *et al.*, *Antisense Res. Dev.*, **1995**, *5*, 115-121; Takakura *et al.*, *Antisense & Nucl. Acid Drug Dev.*, **1996**, *6*, 177-183).

Excipients

In contrast to a carrier compound, a "pharmaceutical
30 carrier" or "excipient" is a pharmaceutically acceptable solvent, suspending agent or any other pharmacologically inert vehicle for delivering one or more nucleic acids to an animal. The excipient may be liquid or solid and is selected, with the planned manner of administration in mind,
35 so as to provide for the desired bulk, consistency, *etc.*,

-44-

when combined with a nucleic acid and the other components of a given pharmaceutical composition. Typical pharmaceutical carriers include, but are not limited to, binding agents (e.g., pregelatinized maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose, etc.); fillers (e.g., lactose and other sugars, microcrystalline cellulose, pectin, gelatin, calcium sulfate, ethyl cellulose, polyacrylates or calcium hydrogen phosphate, etc.); lubricants (e.g., magnesium stearate, talc, silica, colloidal silicon dioxide, stearic acid, metallic stearates, hydrogenated vegetable oils, corn starch, polyethylene glycols, sodium benzoate, sodium acetate, etc.); disintegrants (e.g., starch, sodium starch glycolate, etc.); and wetting agents (e.g., sodium lauryl sulphate, etc.).

Pharmaceutically acceptable organic or inorganic excipient suitable for non-parenteral administration which do not deleteriously react with nucleic acids can also be used to formulate the compositions of the present invention. Suitable pharmaceutically acceptable carriers include, but are not limited to, water, salt solutions, alcohols, polyethylene glycols, gelatin, lactose, amylose, magnesium stearate, talc, silicic acid, viscous paraffin, hydroxymethylcellulose, polyvinylpyrrolidone and the like.

Formulations for topical administration of nucleic acids may include sterile and non-sterile aqueous solutions, non-aqueous solutions in common solvents such as alcohols, or solutions of the nucleic acids in liquid or solid oil bases. The solutions may also contain buffers, diluents and other suitable additives. Pharmaceutically acceptable organic or inorganic excipients suitable for non-parenteral administration which do not deleteriously react with nucleic acids can be used.

Suitable pharmaceutically acceptable excipients include, but are not limited to, water, salt solutions,

alcohol, polyethylene glycols, gelatin, lactose, amylose, magnesium stearate, talc, silicic acid, viscous paraffin, hydroxymethylcellulose, polyvinylpyrrolidone and the like.

Other Components

5 The compositions of the present invention may additionally contain other adjunct components conventionally found in pharmaceutical compositions, at their art-established usage levels. Thus, for example, the compositions may contain additional, compatible,
10 pharmaceutically-active materials such as, for example, antipruritics, astringents, local anesthetics or anti-inflammatory agents, or may contain additional materials useful in physically formulating various dosage forms of the compositions of the present invention, such as
15 dyes, flavoring agents, preservatives, antioxidants, opacifiers, thickening agents and stabilizers. However, such materials, when added, should not unduly interfere with the biological activities of the components of the compositions of the present invention. The formulations can
20 be sterilized and, if desired, mixed with auxiliary agents, e.g., lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, colorings, flavorings and/or aromatic substances and the like which do not deleteriously interact with the
25 nucleic acid(s) of the formulation.

Aqueous suspensions may contain substances which increase the viscosity of the suspension including, for example, sodium carboxymethylcellulose, sorbitol and/or dextran. The suspension may also contain stabilizers.

30 Certain embodiments of the invention provide pharmaceutical compositions containing (a) one or more antisense compounds and (b) one or more other chemotherapeutic agents which function by a non-antisense mechanism. Examples of such chemotherapeutic agents
35 include, but are not limited to, anticancer drugs such as

-46-

daunorubicin, dactinomycin, doxorubicin, bleomycin, mitomycin, nitrogen mustard, chlorambucil, melphalan, cyclophosphamide, 6-mercaptopurine, 6-thioguanine, cytarabine (CA), 5-fluorouracil (5-FU), floxuridine
5 (5-FUdR), methotrexate (MTX), colchicine, vincristine, vinblastine, etoposide, teniposide, cisplatin and diethylstilbestrol (DES). See, generally, *The Merck Manual of Diagnosis and Therapy*, 15th Ed., Berkow et al., eds., 1987, Rahway, N.J., pages 1206-1228). Anti-inflammatory
10 drugs, including but not limited to nonsteroidal anti-inflammatory drugs and corticosteroids, and antiviral drugs, including but not limited to ribivirin, vidarabine, acyclovir and ganciclovir, may also be combined in compositions of the invention. See, generally, *The Merck*
15 *Manual of Diagnosis and Therapy*, 15th Ed., Berkow et al., eds., 1987, Rahway, N.J., pages 2499-2506 and 46-49, respectively). Other non-antisense chemotherapeutic agents are also within the scope of this invention. Two or more combined compounds may be used together or sequentially.

20 In another related embodiment, compositions of the invention may contain one or more antisense compounds, particularly oligonucleotides, targeted to a first nucleic acid and one or more additional antisense compounds targeted to a second nucleic acid target. Numerous examples of
25 antisense compounds are known in the art. Two or more combined compounds may be used together or sequentially.

The formulation of therapeutic compositions and their subsequent administration is believed to be within the skill of those in the art. Dosing is dependent on severity and
30 responsiveness of the disease state to be treated, with the course of treatment lasting from several days to several months, or until a cure is effected or a diminution of the disease state is achieved. Optimal dosing schedules can be calculated from measurements of drug accumulation in the
35 body of the patient. Persons of ordinary skill can easily

-47-

determine optimum dosages, dosing methodologies and repetition rates. Optimum dosages may vary depending on the relative potency of individual oligonucleotides, and can generally be estimated based on EC_{50} s found to be effective
5 in in vitro and in vivo animal models. In general, dosage is from 0.01 ug to 100 g per kg of body weight, and may be given once or more daily, weekly, monthly or yearly, or even once every 2 to 20 years. Persons of ordinary skill in the art can easily estimate repetition rates for dosing based on
10 measured residence times and concentrations of the drug in bodily fluids or tissues. Following successful treatment, it may be desirable to have the patient undergo maintenance therapy to prevent the recurrence of the disease state, wherein the oligonucleotide is administered in maintenance
15 doses, ranging from 0.01 ug to 100 g per kg of body weight, once or more daily, to once every 20 years.

While the present invention has been described with specificity in accordance with certain of its preferred embodiments, the following examples serve only to illustrate
20 the invention and are not intended to limit the same.

EXAMPLES

Example 1

Nucleoside Phosphoramidites for Oligonucleotide Synthesis

25 Deoxy and 2'-alkoxy amidites

2'-Deoxy and 2'-methoxy beta-cyanoethyl-diisopropyl phosphoramidites were purchased from commercial sources (e.g. Chemgenes, Needham MA or Glen Research, Inc. Sterling VA). Other 2'-O-alkoxy substituted nucleoside amidites are
30 prepared as described in U.S. Patent 5,506,351, herein incorporated by reference. For oligonucleotides synthesized using 2'-alkoxy amidites, the standard cycle for unmodified oligonucleotides was utilized, except the wait step after pulse delivery of tetrazole and base was increased to 360
35 seconds.

Oligonucleotides containing 5-methyl-2'-deoxycytidine (5-Me-C) nucleotides were synthesized according to published methods [Sanghvi, et. al., *Nucleic Acids Research*, **1993**, *21*, 3197-3203] using commercially available phosphoramidites
5 (Glen Research, Sterling VA or ChemGenes, Needham MA).

2'-Fluoro amidites

2'-Fluorodeoxyadenosine amidites

2'-fluoro oligonucleotides were synthesized as described previously [Kawasaki, et. al., *J. Med. Chem.*,
10 **1993**, *36*, 831-841] and United States patent 5,670,633, herein incorporated by reference. Briefly, the protected nucleoside N6-benzoyl-2'-deoxy-2'-fluoroadenosine was synthesized utilizing commercially available 9-beta-D-arabinofuranosyladenine as starting material and by
15 modifying literature procedures whereby the 2'-alpha-fluoro atom is introduced by a S_N2-displacement of a 2'-beta-trityl group. Thus N6-benzoyl-9-beta-D-arabinofuranosyladenine was selectively protected in moderate yield as the 3',5'-ditetrahydropyranyl (THP) intermediate. Deprotection of the
20 THP and N6-benzoyl groups was accomplished using standard methodologies and standard methods were used to obtain the 5'-dimethoxytrityl-(DMT) and 5'-DMT-3'-phosphoramidite intermediates.

2'-Fluorodeoxyguanosine

25 The synthesis of 2'-deoxy-2'-fluoroguanosine was accomplished using tetraisopropylidisiloxanyl (TPDS) protected 9-beta-D-arabinofuranosylguanine as starting material, and conversion to the intermediate diisobutyryl-arabinofuranosylguanosine. Deprotection of the TPDS group
30 was followed by protection of the hydroxyl group with THP to give diisobutyryl di-THP protected arabinofuranosylguanine. Selective O-deacylation and triflation was followed by treatment of the crude product with fluoride, then deprotection of the THP groups. Standard methodologies were
35 used to obtain the 5'-DMT- and 5'-DMT-3'-phosphoramidites.

2'-Fluorouridine

Synthesis of 2'-deoxy-2'-fluorouridine was accomplished by the modification of a literature procedure in which 2,2'-anhydro-1-beta-D-arabinofuranosyluracil was treated with 70%
5 hydrogen fluoride-pyridine. Standard procedures were used to obtain the 5'-DMT and 5'-DMT-3'phosphoramidites.

2'-Fluorodeoxycytidine

2'-deoxy-2'-fluorocytidine was synthesized via amination of 2'-deoxy-2'-fluorouridine, followed by
10 selective protection to give N4-benzoyl-2'-deoxy-2'-fluorocytidine. Standard procedures were used to obtain the 5'-DMT and 5'-DMT-3'phosphoramidites.

2'-O-(2-Methoxyethyl) modified amidites

2'-O-Methoxyethyl-substituted nucleoside amidites are
15 prepared as follows, or alternatively, as per the methods of Martin, P., *Helvetica Chimica Acta*, 1995, 78, 486-504.

2,2'-Anhydro[1-(beta-D-arabinofuranosyl)-5-methyluridine]

5-Methyluridine (ribosylthymine, commercially available
20 through Yamasa, Choshi, Japan) (72.0 g, 0.279 M), diphenylcarbonate (90.0 g, 0.420 M) and sodium bicarbonate (2.0 g, 0.024 M) were added to DMF (300 mL). The mixture was heated to reflux, with stirring, allowing the evolved carbon dioxide gas to be released in a controlled manner. After 1
25 hour, the slightly darkened solution was concentrated under reduced pressure. The resulting syrup was poured into diethylether (2.5 L), with stirring. The product formed a gum. The ether was decanted and the residue was dissolved in a minimum amount of methanol (ca. 400 mL). The solution
30 was poured into fresh ether (2.5 L) to yield a stiff gum. The ether was decanted and the gum was dried in a vacuum oven (60°C at 1 mm Hg for 24 h) to give a solid that was crushed to a light tan powder (57 g, 85% crude yield). The NMR spectrum was consistent with the structure, contaminated

with phenol as its sodium salt (ca. 5%). The material was used as is for further reactions (or it can be purified further by column chromatography using a gradient of methanol in ethyl acetate (10-25%) to give a white solid, mp 5 222-4°C).

2'-O-Methoxyethyl-5-methyluridine

2,2'-Anhydro-5-methyluridine (195 g, 0.81 M), tris(2-methoxyethyl)borate (231 g, 0.98 M) and 2-methoxyethanol (1.2 L) were added to a 2 L stainless steel pressure vessel and placed in a pre-heated oil bath at 160°C. After heating 10 for 48 hours at 155-160°C, the vessel was opened and the solution evaporated to dryness and triturated with MeOH (200 mL). The residue was suspended in hot acetone (1 L). The insoluble salts were filtered, washed with acetone (150 mL) 15 and the filtrate evaporated. The residue (280 g) was dissolved in CH₃CN (600 mL) and evaporated. A silica gel column (3 kg) was packed in CH₂Cl₂/acetone/MeOH (20:5:3) containing 0.5% Et₃NH. The residue was dissolved in CH₂Cl₂ (250 mL) and adsorbed onto silica (150 g) prior to loading 20 onto the column. The product was eluted with the packing solvent to give 160 g (63%) of product. Additional material was obtained by reworking impure fractions.

2'-O-Methoxyethyl-5'-O-dimethoxytrityl-5-methyluridine

2'-O-Methoxyethyl-5-methyluridine (160 g, 0.506 M) was 25 co-evaporated with pyridine (250 mL) and the dried residue dissolved in pyridine (1.3 L). A first aliquot of dimethoxytrityl chloride (94.3 g, 0.278 M) was added and the mixture stirred at room temperature for one hour. A second aliquot of dimethoxytrityl chloride (94.3 g, 0.278 M) was 30 added and the reaction stirred for an additional one hour. Methanol (170 mL) was then added to stop the reaction. HPLC showed the presence of approximately 70% product. The solvent was evaporated and triturated with CH₃CN (200 mL). The residue was dissolved in CHCl₃ (1.5 L) and extracted with 35 2x500 mL of saturated NaHCO₃ and 2x500 mL of saturated NaCl.

-51-

The organic phase was dried over Na_2SO_4 , filtered and evaporated. 275 g of residue was obtained. The residue was purified on a 3.5 kg silica gel column, packed and eluted with EtOAc/hexane/acetone (5:5:1) containing 0.5% Et_3NH . The
5 pure fractions were evaporated to give 164 g of product. Approximately 20 g additional was obtained from the impure fractions to give a total yield of 183 g (57%).

3'-O-Acetyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methyluridine

10 2'-O-Methoxyethyl-5'-O-dimethoxytrityl-5-methyluridine (106 g, 0.167 M), DMF/pyridine (750 mL of a 3:1 mixture prepared from 562 mL of DMF and 188 mL of pyridine) and acetic anhydride (24.38 mL, 0.258 M) were combined and stirred at room temperature for 24 hours. The reaction was
15 monitored by TLC by first quenching the TLC sample with the addition of MeOH. Upon completion of the reaction, as judged by TLC, MeOH (50 mL) was added and the mixture evaporated at 35°C. The residue was dissolved in CHCl_3 (800 mL) and extracted with 2x200 mL of saturated sodium
20 bicarbonate and 2x200 mL of saturated NaCl. The water layers were back extracted with 200 mL of CHCl_3 . The combined organics were dried with sodium sulfate and evaporated to give 122 g of residue (approx. 90% product). The residue was purified on a 3.5 kg silica gel column and
25 eluted using EtOAc/hexane(4:1). Pure product fractions were evaporated to yield 96 g (84%). An additional 1.5 g was recovered from later fractions.

3'-O-Acetyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methyl-4-triazoleuridine

30 A first solution was prepared by dissolving 3'-O-acetyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methyluridine (96 g, 0.144 M) in CH_3CN (700 mL) and set aside. Triethylamine (189 mL, 1.44 M) was added to a solution of triazole (90 g, 1.3 M) in CH_3CN (1 L), cooled to
35 -5°C and stirred for 0.5 h using an overhead stirrer. POCl_3

-52-

was added dropwise, over a 30 minute period, to the stirred solution maintained at 0-10°C, and the resulting mixture stirred for an additional 2 hours. The first solution was added dropwise, over a 45 minute period, to the latter
5 solution. The resulting reaction mixture was stored overnight in a cold room. Salts were filtered from the reaction mixture and the solution was evaporated. The residue was dissolved in EtOAc (1 L) and the insoluble solids were removed by filtration. The filtrate was washed
10 with 1x300 mL of NaHCO₃ and 2x300 mL of saturated NaCl, dried over sodium sulfate and evaporated. The residue was triturated with EtOAc to give the title compound.

2'-O-Methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine

A solution of 3'-O-acetyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methyl-4-triazoleuridine (103 g, 0.141 M)
15 in dioxane (500 mL) and NH₄OH (30 mL) was stirred at room temperature for 2 hours. The dioxane solution was evaporated and the residue azeotroped with MeOH (2x200 mL). The residue was dissolved in MeOH (300 mL) and transferred
20 to a 2 liter stainless steel pressure vessel. MeOH (400 mL) saturated with NH₃ gas was added and the vessel heated to 100°C for 2 hours (TLC showed complete conversion). The vessel contents were evaporated to dryness and the residue
25 was dissolved in EtOAc (500 mL) and washed once with saturated NaCl (200 mL). The organics were dried over sodium sulfate and the solvent was evaporated to give 85 g (95%) of the title compound.

N4-Benzoyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine

2'-O-Methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine
30 (85 g, 0.134 M) was dissolved in DMF (800 mL) and benzoic anhydride (37.2 g, 0.165 M) was added with stirring. After stirring for 3 hours, TLC showed the reaction to be approximately 95% complete. The solvent was evaporated and
35 the residue azeotroped with MeOH (200 mL). The residue was

-53-

dissolved in CHCl_3 (700 mL) and extracted with saturated NaHCO_3 (2x300 mL) and saturated NaCl (2x300 mL), dried over MgSO_4 and evaporated to give a residue (96 g). The residue was chromatographed on a 1.5 kg silica column using
5 EtOAc/hexane (1:1) containing 0.5% Et_3NH as the eluting solvent. The pure product fractions were evaporated to give 90 g (90%) of the title compound.

N4-Benzoyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine-3'-amidite

10 N4-Benzoyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine (74 g, 0.10 M) was dissolved in CH_2Cl_2 (1 L). Tetrazole diisopropylamine (7.1 g) and 2-cyanoethoxy-tetra-(isopropyl)phosphite (40.5 mL, 0.123 M) were added with stirring, under a nitrogen atmosphere. The resulting
15 mixture was stirred for 20 hours at room temperature (TLC showed the reaction to be 95% complete). The reaction mixture was extracted with saturated NaHCO_3 (1x300 mL) and saturated NaCl (3x300 mL). The aqueous washes were back-extracted with CH_2Cl_2 (300 mL), and the extracts were
20 combined, dried over MgSO_4 and concentrated. The residue obtained was chromatographed on a 1.5 kg silica column using EtOAc/hexane (3:1) as the eluting solvent. The pure fractions were combined to give 90.6 g (87%) of the title compound.

25 **2'-O-(Aminooxyethyl) nucleoside amidites and 2'-O-(dimethylaminooxyethyl) nucleoside amidites**

2'-(Dimethylaminooxyethoxy) nucleoside amidites

2'-(Dimethylaminooxyethoxy) nucleoside amidites [also known in the art as 2'-O-(dimethylaminooxyethyl) nucleoside
30 amidites] are prepared as described in the following paragraphs. Adenosine, cytidine and guanosine nucleoside amidites are prepared similarly to the thymidine (5-methyluridine) except the exocyclic amines are protected with a benzoyl moiety in the case of adenosine and cytidine
35 and with isobutyryl in the case of guanosine.

-54-

5'-O-tert-Butyldiphenylsilyl-O²-2'-anhydro-5-methyluridine

O²-2'-anhydro-5-methyluridine (Pro. Bio. Sint., Varese, Italy, 100.0g, 0.416 mmol), dimethylaminopyridine (0.66g, 0.013eq, 0.0054mmol) were dissolved in dry pyridine (500 ml) at ambient temperature under an argon atmosphere and with mechanical stirring. *tert*-Butyldiphenylchlorosilane (125.8g, 119.0mL, 1.1eq, 0.458mmol) was added in one portion. The reaction was stirred for 16 h at ambient temperature. TLC (R_f 0.22, ethyl acetate) indicated a complete reaction. The solution was concentrated under reduced pressure to a thick oil. This was partitioned between dichloromethane (1 L) and saturated sodium bicarbonate (2x1 L) and brine (1 L). The organic layer was dried over sodium sulfate and concentrated under reduced pressure to a thick oil. The oil was dissolved in a 1:1 mixture of ethyl acetate and ethyl ether (600mL) and the solution was cooled to -10°C. The resulting crystalline product was collected by filtration, washed with ethyl ether (3x200 mL) and dried (40°C, 1mm Hg, 24 h) to 149g (74.8%) of white solid. TLC and NMR were consistent with pure product.

5'-O-tert-Butyldiphenylsilyl-2'-O-(2-hydroxyethyl)-5-methyluridine

In a 2 L stainless steel, unstirred pressure reactor was added borane in tetrahydrofuran (1.0 M, 2.0 eq, 622 mL). In the fume hood and with manual stirring, ethylene glycol (350 mL, excess) was added cautiously at first until the evolution of hydrogen gas subsided. 5'-O-tert-Butyldiphenylsilyl-O²-2'-anhydro-5-methyluridine (149 g, 0.311 mol) and sodium bicarbonate (0.074 g, 0.003 eq) were added with manual stirring. The reactor was sealed and heated in an oil bath until an internal temperature of 160 °C was reached and then maintained for 16 h (pressure < 100 psig). The reaction vessel was cooled to ambient and

-55-

opened. TLC (Rf 0.67 for desired product and Rf 0.82 for ara-T side product, ethyl acetate) indicated about 70% conversion to the product. In order to avoid additional side product formation, the reaction was stopped, concentrated under reduced pressure (10 to 1mm Hg) in a warm water bath (40-100°C) with the more extreme conditions used to remove the ethylene glycol. [Alternatively, once the low boiling solvent is gone, the remaining solution can be partitioned between ethyl acetate and water. The product will be in the organic phase.] The residue was purified by column chromatography (2kg silica gel, ethyl acetate-hexanes gradient 1:1 to 4:1). The appropriate fractions were combined, stripped and dried to product as a white crisp foam (84g, 50%), contaminated starting material (17.4g) and pure reusable starting material 20g. The yield based on starting material less pure recovered starting material was 58%. TLC and NMR were consistent with 99% pure product.

2'-O-([2-phthalimidoxy)ethyl]-5'-*t*-butyldiphenylsilyl-5-methyluridine

5'-O-tert-Butyldiphenylsilyl-2'-O-(2-hydroxyethyl)-5-methyluridine (20g, 36.98mmol) was mixed with triphenylphosphine (11.63g, 44.36mmol) and N-hydroxyphthalimide (7.24g, 44.36mmol). It was then dried over P₂O₅ under high vacuum for two days at 40°C. The reaction mixture was flushed with argon and dry THF (369.8mL, Aldrich, sure seal bottle) was added to get a clear solution. Diethyl-azodicarboxylate (6.98mL, 44.36mmol) was added dropwise to the reaction mixture. The rate of addition is maintained such that resulting deep red coloration is just discharged before adding the next drop. After the addition was complete, the reaction was stirred for 4 hrs. By that time TLC showed the completion of the reaction (ethylacetate:hexane, 60:40). The solvent was evaporated in vacuum. Residue obtained was placed on a flash column and eluted with ethyl acetate:hexane (60:40),

-56-

to get 2'-O-([2-phthalimidoxy)ethyl]-5'-*t*-butyldiphenylsilyl-5-methyluridine as white foam (21.819 g, 86%).

5 **5'-O-*tert*-butyldiphenylsilyl-2'-O-[(2-formadoximinooxy)ethyl]-5-methyluridine**

2'-O-([2-phthalimidoxy)ethyl]-5'-*t*-butyldiphenylsilyl-5-methyluridine (3.1g, 4.5mmol) was dissolved in dry CH₂Cl₂ (4.5mL) and methylhydrazine (300mL, 4.64mmol) was added dropwise at -10°C to 0°C. After 1 h the mixture was
10 filtered, the filtrate was washed with ice cold CH₂Cl₂ and the combined organic phase was washed with water, brine and dried over anhydrous Na₂SO₄. The solution was concentrated to get 2'-O-(aminooxyethyl) thymidine, which was then dissolved in MeOH (67.5mL). To this formaldehyde (20%
15 aqueous solution, w/w, 1.1 eq.) was added and the resulting mixture was stirred for 1 h. Solvent was removed under vacuum; residue chromatographed to get 5'-O-*tert*-butyldiphenylsilyl-2'-O-[(2-formadoximinooxy)ethyl]-5-methyluridine as white foam (1.95 g, 78%).

20 **5'-O-*tert*-Butyldiphenylsilyl-2'-O-[N,N-dimethylaminooxyethyl]-5-methyluridine**

5'-O-*tert*-butyldiphenylsilyl-2'-O-[(2-formadoximinooxy)ethyl]-5-methyluridine (1.77g, 3.12mmol) was dissolved in a solution of 1M pyridinium *p*-toluenesulfonate (PPTS) in dry MeOH (30.6mL). Sodium
25 cyanoborohydride (0.39g, 6.13mmol) was added to this solution at 10°C under inert atmosphere. The reaction mixture was stirred for 10 minutes at 10°C. After that the reaction vessel was removed from the ice bath and stirred at
30 room temperature for 2 h, the reaction monitored by TLC (5% MeOH in CH₂Cl₂). Aqueous NaHCO₃ solution (5%, 10mL) was added and extracted with ethyl acetate (2x20mL). Ethyl acetate phase was dried over anhydrous Na₂SO₄, evaporated to dryness. Residue was dissolved in a solution of 1M PPTS in MeOH

-57-

(30.6mL). Formaldehyde (20% w/w, 30mL, 3.37mmol) was added and the reaction mixture was stirred at room temperature for 10 minutes. Reaction mixture cooled to 10°C in an ice bath, sodium cyanoborohydride (0.39g, 6.13mmol) was added and
5 reaction mixture stirred at 10°C for 10 minutes. After 10 minutes, the reaction mixture was removed from the ice bath and stirred at room temperature for 2 hrs. To the reaction mixture 5% NaHCO₃ (25mL) solution was added and extracted with ethyl acetate (2x25mL). Ethyl acetate layer was dried
10 over anhydrous Na₂SO₄ and evaporated to dryness. The residue obtained was purified by flash column chromatography and eluted with 5% MeOH in CH₂Cl₂ to get 5'-O-*tert*-butyldiphenylsilyl-2'-O-[N,N-dimethylaminooxyethyl]-5-methyluridine as a white foam (14.6g, 80%).

15 **2'-O-(dimethylaminooxyethyl)-5-methyluridine**

Triethylamine trihydrofluoride (3.91mL, 24.0mmol) was dissolved in dry THF and triethylamine (1.67mL, 12mmol, dry, kept over KOH). This mixture of triethylamine-2HF was then added to 5'-O-*tert*-butyldiphenylsilyl-2'-O-[N,N-
20 dimethylaminooxyethyl]-5-methyluridine (1.40g, 2.4mmol) and stirred at room temperature for 24 hrs. Reaction was monitored by TLC (5% MeOH in CH₂Cl₂). Solvent was removed under vacuum and the residue placed on a flash column and eluted with 10% MeOH in CH₂Cl₂ to get 2'-O-
25 (dimethylaminooxyethyl)-5-methyluridine (766mg, 92.5%).

5'-O-DMT-2'-O-(dimethylaminooxyethyl)-5-methyluridine

2'-O-(dimethylaminooxyethyl)-5-methyluridine (750mg, 2.17mmol) was dried over P₂O₅ under high vacuum overnight at 40°C. It was then co-evaporated with anhydrous pyridine
30 (20mL). The residue obtained was dissolved in pyridine (11mL) under argon atmosphere. 4-dimethylaminopyridine (26.5mg, 2.60mmol), 4,4'-dimethoxytrityl chloride (880mg, 2.60mmol) was added to the mixture and the reaction mixture was stirred at room temperature until all of the starting
35 material disappeared. Pyridine was removed under vacuum and

-58-

the residue chromatographed and eluted with 10% MeOH in CH_2Cl_2 (containing a few drops of pyridine) to get 5'-O-DMT-2'-O-(dimethylamino-oxyethyl)-5-methyluridine (1.13g, 80%).

5 **5'-O-DMT-2'-O-(2-N,N-dimethylaminooxyethyl)-5-methyluridine-3'-[(2-cyanoethyl)-N,N-diisopropylphosphoramidite]**

5'-O-DMT-2'-O-(dimethylaminooxyethyl)-5-methyluridine (1.08g, 1.67mmol) was co-evaporated with toluene (20mL). To the residue N,N-diisopropylamine tetrazonide (0.29g, 1.67mmol) was added and dried over P_2O_5 under high vacuum overnight at 40°C. Then the reaction mixture was dissolved in anhydrous acetonitrile (8.4mL) and 2-cyanoethyl-N,N,Nⁱ,Nⁱ-tetraisopropylphosphoramidite (2.12mL, 6.08mmol) was added. The reaction mixture was stirred at ambient temperature for 4 hrs under inert atmosphere. The progress of the reaction was monitored by TLC (hexane:ethyl acetate 1:1). The solvent was evaporated, then the residue was dissolved in ethyl acetate (70mL) and washed with 5% aqueous NaHCO_3 (40mL). Ethyl acetate layer was dried over anhydrous Na_2SO_4 and concentrated. Residue obtained was chromatographed (ethyl acetate as eluent) to get 5'-O-DMT-2'-O-(2-N,N-dimethylaminooxyethyl)-5-methyluridine-3'-[(2-cyanoethyl)-N,N-diisopropylphosphoramidite] as a foam (1.04g, 74.9%).

25 **2'-(Aminooxyethoxy) nucleoside amidites**

2'-(Aminooxyethoxy) nucleoside amidites [also known in the art as 2'-O-(aminooxyethyl) nucleoside amidites] are prepared as described in the following paragraphs. Adenosine, cytidine and thymidine nucleoside amidites are prepared similarly.

30

N2-isobutyryl-6-O-diphenylcarbamoyl-2'-O-(2-ethylacetyl)-5'-O-(4,4'-dimethoxytrityl)guanosine-3'-[(2-cyanoethyl)-N,N-diisopropylphosphoramidite]

The 2'-O-aminooxyethyl guanosine analog may be obtained
5 by selective 2'-O-alkylation of diaminopurine riboside. Multigram quantities of diaminopurine riboside may be purchased from Schering AG (Berlin) to provide 2'-O-(2-ethylacetyl) diaminopurine riboside along with a minor amount of the 3'-O-isomer. 2'-O-(2-ethylacetyl)
10 diaminopurine riboside may be resolved and converted to 2'-O-(2-ethylacetyl)guanosine by treatment with adenosine deaminase. (McGee, D. P. C., Cook, P. D., Guinosso, C. J., WO 94/02501 A1 940203.) Standard protection procedures should afford 2'-O-(2-ethylacetyl)-5'-O-(4,4'-
15 dimethoxytrityl)guanosine and 2-N-isobutyryl-6-O-diphenylcarbamoyl-2'-O-(2-ethylacetyl)-5'-O-(4,4'-dimethoxytrityl)guanosine which may be reduced to provide 2-N-isobutyryl-6-O-diphenylcarbamoyl-2'-O-(2-ethylacetyl)-5'-O-(4,4'-dimethoxytrityl)guanosine. As before the hydroxyl
20 group may be displaced by N-hydroxyphthalimide via a Mitsunobu reaction, and the protected nucleoside may phosphitylated as usual to yield 2-N-isobutyryl-6-O-diphenylcarbamoyl-2'-O-(2-ethylacetyl)-5'-O-(4,4'-dimethoxytrityl)guanosine-3'-[(2-cyanoethyl)-N,N-
25 diisopropylphosphoramidite].

2'-dimethylaminoethoxyethoxy (2'-DMAEOE) nucleoside amidites

2'-dimethylaminoethoxyethoxy nucleoside amidites (also known in the art as 2'-O-dimethylaminoethoxyethyl, i.e., 2'-O-CH₂-O-CH₂-N(CH₂)₂, or 2'-DMAEOE nucleoside amidites) are
30 prepared as follows. Other nucleoside amidites are prepared similarly.

2'-O-[2(2-N,N-dimethylaminoethoxy)ethyl]-5-methyl uridine

2[2-(Dimethylamino)ethoxy]ethanol (Aldrich, 6.66 g, 50 mmol) is slowly added to a solution of borane in tetra-

-60-

hydrofuran (1 M, 10 mL, 10 mmol) with stirring in a 100 mL bomb. Hydrogen gas evolves as the solid dissolves. O²-,2'-anhydro-5-methyluridine (1.2 g, 5 mmol), and sodium bicarbonate (2.5 mg) are added and the bomb is sealed, placed in an oil bath and heated to 155°C for 26 hours. The bomb is cooled to room temperature and opened. The crude solution is concentrated and the residue partitioned between water (200 mL) and hexanes (200 mL). The excess phenol is extracted into the hexane layer. The aqueous layer is extracted with ethyl acetate (3x200 mL) and the combined organic layers are washed once with water, dried over anhydrous sodium sulfate and concentrated. The residue is columned on silica gel using methanol/methylene chloride 1:20 (which has 2% triethylamine) as the eluent. As the column fractions are concentrated a colorless solid forms which is collected to give the title compound as a white solid.

5'-O-dimethoxytrityl-2'-O-[2(2-N,N-dimethylaminoethoxy)ethyl]-5-methyl uridine

To 0.5 g (1.3 mmol) of 2'-O-[2(2-N,N-dimethylaminoethoxy)ethyl]-5-methyl uridine in anhydrous pyridine (8 mL), triethylamine (0.36 mL) and dimethoxytrityl chloride (DMT-Cl, 0.87 g, 2 eq.) are added and stirred for 1 hour. The reaction mixture is poured into water (200 mL) and extracted with CH₂Cl₂ (2x200 mL). The combined CH₂Cl₂ layers are washed with saturated NaHCO₃ solution, followed by saturated NaCl solution and dried over anhydrous sodium sulfate. Evaporation of the solvent followed by silica gel chromatography using MeOH:CH₂Cl₂:Et₃N (20:1, v/v, with 1% triethylamine) gives the title compound.

5'-O-Dimethoxytrityl-2'-O-[2(2-N,N-dimethylaminoethoxy)ethyl]-5-methyl uridine-3'-O-(cyanoethyl-N,N-diisopropyl)phosphoramidite

Diisopropylaminotetrazolide (0.6 g) and 2-cyanoethoxy-N,N-diisopropyl phosphoramidite (1.1 mL, 2 eq.) are added to

a solution of 5'-O-dimethoxytrityl-2'-O-[2(2-N,N-dimethylaminoethoxy)ethyl]]-5-methyluridine (2.17 g, 3 mmol) dissolved in CH_2Cl_2 (20 mL) under an atmosphere of argon. The reaction mixture is stirred overnight and the solvent
5 evaporated. The resulting residue is purified by silica gel flash column chromatography with ethyl acetate as the eluent to give the title compound.

Example 2

Oligonucleotide synthesis

10 Unsubstituted and substituted phosphodiester (P=O) oligonucleotides are synthesized on an automated DNA synthesizer (Applied Biosystems model 380B) using standard phosphoramidite chemistry with oxidation by iodine.

Phosphorothioates (P=S) are synthesized as for the
15 phosphodiester oligonucleotides except the standard oxidation bottle was replaced by 0.2 M solution of 3H-1,2-benzodithiole-3-one 1,1-dioxide in acetonitrile for the stepwise thiation of the phosphite linkages. The thiation wait step was increased to 68 sec and was followed by the
20 capping step. After cleavage from the CPG column and deblocking in concentrated ammonium hydroxide at 55°C (18 h), the oligonucleotides were purified by precipitating twice with 2.5 volumes of ethanol from a 0.5 M NaCl solution. Phosphinate oligonucleotides are prepared as described in
25 U.S. Patent 5,508,270, herein incorporated by reference.

Alkyl phosphonate oligonucleotides are prepared as described in U.S. Patent 4,469,863, herein incorporated by reference.

3'-Deoxy-3'-methylene phosphonate oligonucleotides are
30 prepared as described in U.S. Patents 5,610,289 or 5,625,050, herein incorporated by reference.

Phosphoramidite oligonucleotides are prepared as described in U.S. Patent, 5,256,775 or U.S. Patent 5,366,878, herein incorporated by reference.

35 Alkylphosphonothioate oligonucleotides are prepared as

-62-

described in published PCT applications PCT/US94/00902 and PCT/US93/06976 (published as WO 94/17093 and WO 94/02499, respectively), herein incorporated by reference.

3'-Deoxy-3'-amino phosphoramidate oligonucleotides are prepared as described in U.S. Patent 5,476,925, herein incorporated by reference.

Phosphotriester oligonucleotides are prepared as described in U.S. Patent 5,023,243, herein incorporated by reference.

10 Borano phosphate oligonucleotides are prepared as described in U.S. Patents 5,130,302 and 5,177,198, both herein incorporated by reference.

Example 3

Oligonucleoside Synthesis

15 Methylenemethylimino linked oligonucleosides, also identified as MMI linked oligonucleosides, methylenedimethylhydrazo linked oligonucleosides, also identified as MDH linked oligonucleosides, and methylenecarbonylamino linked oligonucleosides, also identified as amide-3 linked
20 oligonucleosides, and methyleneaminocarbonyl linked oligonucleosides, also identified as amide-4 linked oligonucleosides, as well as mixed backbone compounds having, for instance, alternating MMI and P=O or P=S linkages are prepared as described in U.S. Patents 5,378,825, 5,386,023,
25 5,489,677, 5,602,240 and 5,610,289, all of which are herein incorporated by reference.

Formacetal and thioformacetal linked oligonucleosides are prepared as described in U.S. Patents 5,264,562 and 5,264,564, herein incorporated by reference.

30 Ethylene oxide linked oligonucleosides are prepared as described in U.S. Patent 5,223,618, herein incorporated by reference.

Example 4

PNA Synthesis

35 Peptide nucleic acids (PNAs) are prepared in accordance

with any of the various procedures referred to in Peptide Nucleic Acids (PNA): Synthesis, Properties and Potential Applications, *Bioorganic & Medicinal Chemistry*, 1996, 4, 5-23. They may also be prepared in accordance with U.S.

5 Patents 5,539,082, 5,700,922, and 5,719,262, herein incorporated by reference.

Example 5

Synthesis of Chimeric Oligonucleotides

Chimeric oligonucleotides, oligonucleosides or mixed
10 oligonucleotides/oligonucleosides of the invention can be of several different types. These include a first type wherein the "gap" segment of linked nucleosides is positioned between 5' and 3' "wing" segments of linked nucleosides and a second "open end" type wherein the "gap" segment is
15 located at either the 3' or the 5' terminus of the oligomeric compound. Oligonucleotides of the first type are also known in the art as "gapmers" or gapped oligonucleotides. Oligonucleotides of the second type are also known in the art as "hemimers" or "wingmers".

20 [2'-O-Me]--[2'-deoxy]--[2'-O-Me] Chimeric Phosphorothioate Oligonucleotides

Chimeric oligonucleotides having 2'-O-alkyl phosphorothioate and 2'-deoxy phosphorothioate oligonucleotide segments are synthesized using an Applied
25 Biosystems automated DNA synthesizer Model 380B, as above. Oligonucleotides are synthesized using the automated synthesizer and 2'-deoxy-5'-dimethoxytrityl-3'-O-phosphoramidite for the DNA portion and 5'-dimethoxytrityl-2'-O-methyl-3'-O-phosphoramidite for 5' and 3' wings. The
30 standard synthesis cycle is modified by increasing the wait step after the delivery of tetrazole and base to 600 s repeated four times for RNA and twice for 2'-O-methyl. The fully protected oligonucleotide is cleaved from the support and the phosphate group is deprotected in 3:1
35 ammonia/ethanol at room temperature overnight then

-64-

lyophilized to dryness. Treatment in methanolic ammonia for 24 hrs at room temperature is then done to deprotect all bases and sample was again lyophilized to dryness. The pellet is resuspended in 1M TBAF in THF for 24 hrs at room
 5 temperature to deprotect the 2' positions. The reaction is then quenched with 1M TEAA and the sample is then reduced to 1/2 volume by rotovac before being desalted on a G25 size exclusion column. The oligo recovered is then analyzed spectrophotometrically for yield and for purity by capillary
 10 electrophoresis and by mass spectrometry.

[2'-O-(2-Methoxyethyl)]--[2'-deoxy]--[2'-O-(Methoxyethyl)] Chimeric Phosphorothioate Oligonucleotides

[2'-O-(2-methoxyethyl)]--[2'-deoxy]--[2'-O-(methoxy-
 15 ethyl)] chimeric phosphorothioate oligonucleotides were prepared as per the procedure above for the 2'-O-methyl chimeric oligonucleotide, with the substitution of 2'-O-(methoxyethyl) amidites for the 2'-O-methyl amidites.

[2'-O-(2-Methoxyethyl)Phosphodiester]--[2'-deoxy Phosphorothioate]--[2'-O-(2-Methoxyethyl) Phosphodiester] Chimeric Oligonucleotides

[2'-O-(2-methoxyethyl phosphodiester)]--[2'-deoxy phosphorothioate]--[2'-O-(methoxyethyl) phosphodiester] chimeric oligonucleotides are prepared as per the above procedure for
 25 the 2'-O-methyl chimeric oligonucleotide with the substitution of 2'-O-(methoxyethyl) amidites for the 2'-O-methyl amidites, oxidization with iodine to generate the phosphodiester internucleotide linkages within the wing portions of the chimeric structures and sulfurization
 30 utilizing 3,4-benzodithiole-3-one 1,1 dioxide (Beaucage Reagent) to generate the phosphorothioate internucleotide linkages for the center gap.

Other chimeric oligonucleotides, chimeric oligonucleosides and mixed chimeric oligonucleotides/oligonucleosides

are synthesized according to United States patent 5,623,065, herein incorporated by reference.

Example 6

Oligonucleotide Isolation

5 After cleavage from the controlled pore glass column (Applied Biosystems) and deblocking in concentrated ammonium hydroxide at 55°C for 18 hours, the oligonucleotides or oligonucleosides are purified by precipitation twice out of 0.5 M NaCl with 2.5 volumes ethanol. Synthesized
10 oligonucleotides were analyzed by polyacrylamide gel electrophoresis on denaturing gels and judged to be at least 85% full length material. The relative amounts of phosphorothioate and phosphodiester linkages obtained in synthesis were periodically checked by ³¹P nuclear magnetic
15 resonance spectroscopy, and for some studies oligonucleotides were purified by HPLC, as described by Chiang et al., *J. Biol. Chem.* **1991**, 266, 18162-18171. Results obtained with HPLC-purified material were similar to those obtained with non-HPLC purified material.

Example 7

Oligonucleotide Synthesis - 96 Well Plate Format

Oligonucleotides were synthesized via solid phase P(III) phosphoramidite chemistry on an automated synthesizer capable of assembling 96 sequences simultaneously in a
25 standard 96 well format. Phosphodiester internucleotide linkages were afforded by oxidation with aqueous iodine. Phosphorothioate internucleotide linkages were generated by sulfurization utilizing 3,4-dithiolane-2-one 1,1-dioxide (Beaucage Reagent) in anhydrous acetonitrile.
30 Standard base-protected beta-cyanoethyldiisopropyl phosphoramidites were purchased from commercial vendors (e.g. PE-Applied Biosystems, Foster City, CA, or Pharmacia, Piscataway, NJ). Non-standard nucleosides are synthesized as per known literature or patented methods. They are
35 utilized as base protected beta-cyanoethyldiisopropyl

phosphoramidites.

Oligonucleotides were cleaved from support and deprotected with concentrated NH_4OH at elevated temperature (55-60°C) for 12-16 hours and the released product then dried
5 in vacuo. The dried product was then re-suspended in sterile water to afford a master plate from which all analytical and test plate samples are then diluted utilizing robotic pipettors.

Example 8

10 Oligonucleotide Analysis - 96 Well Plate Format

The concentration of oligonucleotide in each well was assessed by dilution of samples and UV absorption spectroscopy. The full-length integrity of the individual products was evaluated by capillary electrophoresis (CE) in
15 either the 96 well format (Beckman P/ACE™ MDQ) or, for individually prepared samples, on a commercial CE apparatus (e.g., Beckman P/ACE™ 5000, ABI 270). Base and backbone composition was confirmed by mass analysis of the compounds utilizing electrospray-mass spectroscopy. All assay test
20 plates were diluted from the master plate using single and multi-channel robotic pipettors. Plates were judged to be acceptable if at least 85% of the compounds on the plate were at least 85% full length.

Example 9

25 Cell culture and oligonucleotide treatment

The effect of antisense compounds on target nucleic acid expression can be tested in any of a variety of cell types provided that the target nucleic acid is present at measurable levels. This can be routinely determined using,
30 for example, PCR or Northern blot analysis. The following 5 cell types are provided for illustrative purposes, but other cell types can be routinely used, provided that the target is expressed in the cell type chosen. This can be readily determined by methods routine in the art, for example
35 Northern blot analysis, Ribonuclease protection assays, or

-67-

RT-PCR.

T-24 cells:

The human transitional cell bladder carcinoma cell line T-24 was obtained from the American Type Culture Collection (ATCC) (Manassas, VA). T-24 cells were routinely cultured in complete McCoy's 5A basal media (Gibco/Life Technologies, Gaithersburg, MD) supplemented with 10% fetal calf serum (Gibco/Life Technologies, Gaithersburg, MD), penicillin 100 units per mL, and streptomycin 100 micrograms per mL (Gibco/Life Technologies, Gaithersburg, MD). Cells were routinely passaged by trypsinization and dilution when they reached 90% confluence. Cells were seeded into 96-well plates (Falcon-Primaria #3872) at a density of 7000 cells/well for use in RT-PCR analysis.

For Northern blotting or other analysis, cells may be seeded onto 100 mm or other standard tissue culture plates and treated similarly, using appropriate volumes of medium and oligonucleotide.

A549 cells:

The human lung carcinoma cell line A549 was obtained from the American Type Culture Collection (ATCC) (Manassas, VA). A549 cells were routinely cultured in DMEM basal media (Gibco/Life Technologies, Gaithersburg, MD) supplemented with 10% fetal calf serum (Gibco/Life Technologies, Gaithersburg, MD), penicillin 100 units per mL, and streptomycin 100 micrograms per mL (Gibco/Life Technologies, Gaithersburg, MD). Cells were routinely passaged by trypsinization and dilution when they reached 90% confluence.

NHDF cells:

Human neonatal dermal fibroblast (NHDF) were obtained from the Clonetics Corporation (Walkersville MD). NHDFs were routinely maintained in Fibroblast Growth Medium (Clonetics Corporation, Walkersville MD) supplemented as recommended by the supplier. Cells were maintained for up

-68-

to 10 passages as recommended by the supplier.

HEK cells:

Human embryonic keratinocytes (HEK) were obtained from the Clonetics Corporation (Walkersville MD). HEKs were routinely maintained in Keratinocyte Growth Medium (Clonetics Corporation, Walkersville MD) formulated as recommended by the supplier. Cells were routinely maintained for up to 10 passages as recommended by the supplier.

10 MCF-7 cells:

The human breast carcinoma cell line MCF-7 was obtained from the American Type Culture Collection (Manassas, VA). MCF-7 cells were routinely cultured in DMEM low glucose (Gibco/Life Technologies, Gaithersburg, MD) supplemented with 10% fetal calf serum (Gibco/Life Technologies, Gaithersburg, MD). Cells were routinely passaged by trypsinization and dilution when they reached 90% confluence. Cells were seeded into 96-well plates (Falcon-Primaria #3872) at a density of 7000 cells/well for use in RT-PCR analysis.

For Northern blotting or other analyses, cells may be seeded onto 100 mm or other standard tissue culture plates and treated similarly, using appropriate volumes of medium and oligonucleotide.

25 Treatment with antisense compounds:

When cells reached 80% confluency, they were treated with oligonucleotide. For cells grown in 96-well plates, wells were washed once with 200 μ L OPTI-MEM™-1 reduced-serum medium (Gibco BRL) and then treated with 130 μ L of OPTI-MEM™-1 containing 3.75 μ g/mL LIPOFECTIN™ (Gibco BRL) and the desired concentration of oligonucleotide. After 4-7 hours of treatment, the medium was replaced with fresh medium. Cells were harvested 16-24 hours after oligonucleotide treatment.

35 The concentration of oligonucleotide used varies from

cell line to cell line. To determine the optimal oligonucleotide concentration for a particular cell line, the cells are treated with a positive control oligonucleotide at a range of concentrations. For human
5 cells the positive control oligonucleotide is ISIS 13920, **TCCGTCATCGCTCCTCAGGG**, SEQ ID NO: 1, a 2'-O-methoxyethyl gapmer (2'-O-methoxyethyls shown in bold) with a phosphorothioate backbone which is targeted to human H-ras. For mouse or rat cells the positive control oligonucleotide
10 is ISIS 15770, **ATGCATTCTGCCCCAAGGA**, SEQ ID NO: 2, a 2'-O-methoxyethyl gapmer (2'-O-methoxyethyls shown in bold) with a phosphorothioate backbone which is targeted to both mouse and rat c-raf. The concentration of positive control oligonucleotide that results in 80% inhibition of c-Ha-ras
15 (for ISIS 13920) or c-raf (for ISIS 15770) mRNA is then utilized as the screening concentration for new oligonucleotides in subsequent experiments for that cell line. If 80% inhibition is not achieved, the lowest concentration of positive control oligonucleotide that
20 results in 60% inhibition of H-ras or c-raf mRNA is then utilized as the oligonucleotide screening concentration in subsequent experiments for that cell line. If 60% inhibition is not achieved, that particular cell line is deemed as unsuitable for oligonucleotide transfection
25 experiments.

Example 10

Analysis of oligonucleotide inhibition of Her-3 expression

Antisense modulation of Her-3 expression can be assayed in a variety of ways known in the art. For example, Her-3
30 mRNA levels can be quantitated by, e.g., Northern blot analysis, competitive polymerase chain reaction (PCR), or real-time PCR (RT-PCR). Real-time quantitative PCR is presently preferred. RNA analysis can be performed on total cellular RNA or poly(A)+ mRNA. Methods of RNA isolation are
35 taught in, for example, Ausubel, F.M. et al., *Current*

-70-

Protocols in Molecular Biology, Volume 1, pp. 4.1.1-4.2.9 and 4.5.1-4.5.3, John Wiley & Sons, Inc., 1993. Northern blot analysis is routine in the art and is taught in, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 1, pp. 4.2.1-4.2.9, John Wiley & Sons, Inc., 1996. Real-time quantitative (PCR) can be conveniently accomplished using the commercially available ABI PRISM™ 7700 Sequence Detection System, available from PE-Applied Biosystems, Foster City, CA and used according to manufacturer's instructions. Prior to quantitative PCR analysis, primer-probe sets specific to the target gene being measured are evaluated for their ability to be "multiplexed" with a GAPDH amplification reaction. In multiplexing, both the target gene and the internal standard gene GAPDH are amplified concurrently in a single sample. In this analysis, mRNA isolated from untreated cells is serially diluted. Each dilution is amplified in the presence of primer-probe sets specific for GAPDH only, target gene only ("single-plexing"), or both (multiplexing). Following PCR amplification, standard curves of GAPDH and target mRNA signal as a function of dilution are generated from both the single-plexed and multiplexed samples. If both the slope and correlation coefficient of the GAPDH and target signals generated from the multiplexed samples fall within 10% of their corresponding values generated from the single-plexed samples, the primer-probe set specific for that target is deemed as multiplexable. Other methods of PCR are also known in the art.

Protein levels of Her-3 can be quantitated in a variety of ways well known in the art, such as immunoprecipitation, Western blot analysis (immunoblotting), ELISA or fluorescence-activated cell sorting (FACS). Antibodies directed to Her-3 can be identified and obtained from a variety of sources, such as the MSRS catalog of antibodies (Aerie Corporation, Birmingham, MI), or can be prepared via

-71-

conventional antibody generation methods. Methods for preparation of polyclonal antisera are taught in, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 2, pp. 11.12.1-11.12.9, John Wiley & Sons, Inc., 1997. Preparation of monoclonal antibodies is taught in, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 2, pp. 11.4.1-11.11.5, John Wiley & Sons, Inc., 1997.

Immunoprecipitation methods are standard in the art and can be found at, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 2, pp. 10.16.1-10.16.11, John Wiley & Sons, Inc., 1998. Western blot (immunoblot) analysis is standard in the art and can be found at, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 2, pp. 10.8.1-10.8.21, John Wiley & Sons, Inc., 1997. Enzyme-linked immunosorbent assays (ELISA) are standard in the art and can be found at, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 2, pp. 11.2.1-11.2.22, John Wiley & Sons, Inc., 1991.

Example 11

Poly(A)+ mRNA isolation

Poly(A)+ mRNA was isolated according to Miura et al., *Clin. Chem.*, 1996, 42, 1758-1764. Other methods for poly(A)+ mRNA isolation are taught in, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 1, pp. 4.5.1-4.5.3, John Wiley & Sons, Inc., 1993. Briefly, for cells grown on 96-well plates, growth medium was removed from the cells and each well was washed with 200 μ L cold PBS. 60 μ L lysis buffer (10 mM Tris-HCl, pH 7.6, 1 mM EDTA, 0.5 M NaCl, 0.5% NP-40, 20 mM vanadyl-ribonucleoside complex) was added to each well, the plate was gently agitated and then incubated at room temperature for five minutes. 55 μ L of lysate was transferred to Oligo d(T)

-72-

coated 96-well plates (AGCT Inc., Irvine CA). Plates were incubated for 60 minutes at room temperature, washed 3 times with 200 μ L of wash buffer (10 mM Tris-HCl pH 7.6, 1 mM EDTA, 0.3 M NaCl). After the final wash, the plate was
5 blotted on paper towels to remove excess wash buffer and then air-dried for 5 minutes. 60 μ L of elution buffer (5 mM Tris-HCl pH 7.6), preheated to 70°C was added to each well, the plate was incubated on a 90°C hot plate for 5 minutes, and the eluate was then transferred to a fresh 96-well
10 plate.

Cells grown on 100 mm or other standard plates may be treated similarly, using appropriate volumes of all solutions.

Example 12

15 Total RNA Isolation

Total mRNA was isolated using an RNEASY 96™ kit and buffers purchased from Qiagen Inc. (Valencia CA) following the manufacturer's recommended procedures. Briefly, for cells grown on 96-well plates, growth medium was removed
20 from the cells and each well was washed with 200 μ L cold PBS. 100 μ L Buffer RLT was added to each well and the plate vigorously agitated for 20 seconds. 100 μ L of 70% ethanol was then added to each well and the contents mixed by pipetting three times up and down. The samples were then
25 transferred to the RNEASY 96™ well plate attached to a QIAVAC™ manifold fitted with a waste collection tray and attached to a vacuum source. Vacuum was applied for 15 seconds. 1 mL of Buffer RW1 was added to each well of the RNEASY 96™ plate and the vacuum again applied for 15
30 seconds. 1 mL of Buffer RPE was then added to each well of the RNEASY 96™ plate and the vacuum applied for a period of 15 seconds. The Buffer RPE wash was then repeated and the vacuum was applied for an additional 10 minutes. The plate was then removed from the QIAVAC™ manifold and blotted dry
35 on paper towels. The plate was then re-attached to the

-73-

QIAVAC™ manifold fitted with a collection tube rack containing 1.2 mL collection tubes. RNA was then eluted by pipetting 60 µL water into each well, incubating 1 minute, and then applying the vacuum for 30 seconds. The elution
5 step was repeated with an additional 60 µL water.

The repetitive pipetting and elution steps may be automated using a QIAGEN Bio-Robot 9604 (Qiagen, Inc., Valencia CA). Essentially, after lysing of the cells on the culture plate, the plate is transferred to the robot deck
10 where the pipetting, DNase treatment and elution steps are carried out.

Example 13

Real-time Quantitative PCR Analysis of Her-3 mRNA Levels

Quantitation of Her-3 mRNA levels was determined by
15 real-time quantitative PCR using the ABI PRISM™ 7700 Sequence Detection System (PE-Applied Biosystems, Foster City, CA) according to manufacturer's instructions. This is a closed-tube, non-gel-based, fluorescence detection system which allows high-throughput quantitation of polymerase
20 chain reaction (PCR) products in real-time. As opposed to standard PCR, in which amplification products are quantitated after the PCR is completed, products in real-time quantitative PCR are quantitated as they accumulate. This is accomplished by including in the PCR reaction an
25 oligonucleotide probe that anneals specifically between the forward and reverse PCR primers, and contains two fluorescent dyes. A reporter dye (e.g., JOE, FAM, or VIC, obtained from either Operon Technologies Inc., Alameda, CA or PE-Applied Biosystems, Foster City, CA) is attached to
30 the 5' end of the probe and a quencher dye (e.g., TAMRA, obtained from either Operon Technologies Inc., Alameda, CA or PE-Applied Biosystems, Foster City, CA) is attached to the 3' end of the probe. When the probe and dyes are intact, reporter dye emission is quenched by the proximity
35 of the 3' quencher dye. During amplification, annealing of

-74-

the probe to the target sequence creates a substrate that can be cleaved by the 5'-exonuclease activity of Taq polymerase. During the extension phase of the PCR amplification cycle, cleavage of the probe by Taq polymerase releases the reporter dye from the remainder of the probe (and hence from the quencher moiety) and a sequence-specific fluorescent signal is generated. With each cycle, additional reporter dye molecules are cleaved from their respective probes, and the fluorescence intensity is monitored at regular intervals by laser optics built into the ABI PRISM™ 7700 Sequence Detection System. In each assay, a series of parallel reactions containing serial dilutions of mRNA from untreated control samples generates a standard curve that is used to quantitate the percent inhibition after antisense oligonucleotide treatment of test samples.

PCR reagents were obtained from PE-Applied Biosystems, Foster City, CA. RT-PCR reactions were carried out by adding 25 μ L PCR cocktail (1x TAQMAN™ buffer A, 5.5 mM $MgCl_2$, 300 μ M each of dATP, dCTP and dGTP, 600 μ M of dUTP, 100 nM each of forward primer, reverse primer, and probe, 20 Units RNase inhibitor, 1.25 Units AMPLITAQ GOLD™, and 12.5 Units MuLV reverse transcriptase) to 96 well plates containing 25 μ L poly(A) mRNA solution. The RT reaction was carried out by incubation for 30 minutes at 48°C. Following a 10 minute incubation at 95°C to activate the AMPLITAQ GOLD™, 40 cycles of a two-step PCR protocol were carried out: 95°C for 15 seconds (denaturation) followed by 60°C for 1.5 minutes (annealing/extension).

Probes and primers to human Her-3 were designed to hybridize to a human Her-3 sequence, using published sequence information (GenBank accession number M34309, incorporated herein as SEQ ID NO:3). For human Her-3 the PCR primers were:

forward primer: TCGTCATGTTGAACTATAACACCAACT (SEQ ID NO: 4)

-75-

reverse primer: TGACAAAGCTTATCGTTCTTCTCAAT (SEQ ID NO: 5)
and the PCR probe was: FAM-CCGCTTGACTCAGCTCACCGAGATTC-TAMRA
(SEQ ID NO: 6) where FAM (PE-Applied Biosystems, Foster
City, CA) is the fluorescent reporter dye) and TAMRA (PE-
5 Applied Biosystems, Foster City, CA) is the quencher dye.
For human GAPDH the PCR primers were:

forward primer: CAACGGATTTGGTCGTATTGG (SEQ ID NO: 7)
reverse primer: GGCAACAATATCCACTTTACCAGAGT (SEQ ID NO: 8)
and the PCR probe was: 5' JOE-CGCCTGGTCACCAGGGCTGCT- TAMRA
10 3' (SEQ ID NO: 9) where JOE (PE-Applied Biosystems, Foster
City, CA) is the fluorescent reporter dye) and TAMRA (PE-
Applied Biosystems, Foster City, CA) is the quencher dye.

Example 14

Northern blot analysis of Her-3 mRNA levels

15 Eighteen hours after antisense treatment, cell
monolayers were washed twice with cold PBS and lysed in 1 mL
RNAZOL™ (TEL-TEST "B" Inc., Friendswood, TX). Total RNA was
prepared following manufacturer's recommended protocols.
Twenty micrograms of total RNA was fractionated by
20 electrophoresis through 1.2% agarose gels containing 1.1%
formaldehyde using a MOPS buffer system (AMRESCO, Inc.
Solon, OH). RNA was transferred from the gel to HYBOND™-N+
nylon membranes (Amersham Pharmacia Biotech, Piscataway, NJ)
by overnight capillary transfer using a Northern/Southern
25 Transfer buffer system (TEL-TEST "B" Inc., Friendswood, TX).
RNA transfer was confirmed by UV visualization. Membranes
were fixed by UV cross-linking using a STRATALINKER™ UV
Crosslinker 2400 (Stratagene, Inc, La Jolla, CA) and then
robed using QUICKHYB™ hybridization solution (Stratagene, La
30 Jolla, CA) using manufacturer's recommendations for
stringent conditions.

To detect human Her-3, a human Her-3 specific probe was
prepared by PCR using the forward primer
TCGTCATGTTGAACTATAACACCAACT (SEQ ID NO: 4) and the reverse
35 primer TGACAAAGCTTATCGTTCTTCTCAAT (SEQ ID NO: 5). To

-76-

normalize for variations in loading and transfer efficiency membranes were stripped and probed for human glyceraldehyde-3-phosphate dehydrogenase (GAPDH) RNA (Clontech, Palo Alto, CA).

5 Hybridized membranes were visualized and quantitated using a PHOSPHORIMAGER™ and IMAGEQUANT™ Software V3.3 (Molecular Dynamics, Sunnyvale, CA). Data was normalized to GAPDH levels in untreated controls.

Example 15

10 **Antisense inhibition of human Her-3 expression by chimeric phosphorothioate oligonucleotides having 2'-MOE wings and a deoxy gap**

In accordance with the present invention, a series of oligonucleotides were designed to target different regions
15 of the human Her-3 RNA, using published sequences (GenBank accession number M34309, incorporated herein as SEQ ID NO: 3, and GenBank accession number U75285, incorporated herein as SEQ ID NO: 10). The oligonucleotides are shown in Table 1. "Target site" indicates the first (5'-most) nucleotide
20 number on the particular target sequence to which the oligonucleotide binds. All compounds in Table 1 are chimeric oligonucleotides ("gapmers") 18 nucleotides in length, composed of a central "gap" region consisting of ten 2'-deoxynucleotides, which is flanked on both sides (5' and
25 3' directions) by four-nucleotide "wings". The wings are composed of 2'-methoxyethyl (2'-MOE)nucleotides. The internucleoside (backbone) linkages are phosphorothioate (P=S) throughout the oligonucleotide. All cytidine residues are 5-methylcytidines. The compounds were analyzed for
30 their effect on human Her-3 mRNA levels by quantitative real-time PCR as described in other examples herein. Data are averages from two experiments. If present, "N.D." indicates "no data".

-77-

Table 1

Inhibition of human Her-3 mRNA levels by chimeric
phosphorothioate oligonucleotides having 2'-MOE wings and a
deoxy gap

5	ISIS #	REGION	TARGET	TARGET	SEQUENCE	%INHIB	SEQ ID
			SEQ ID NO	SITE			NO
5	19547	5' UTR	3	71	cgacggcagcggaggttg	28	11
	19548	5' UTR	3	112	aagagccacctgaaccgc	57	12
	19549	5' UTR	3	176	cgcagagggtgaagggag	4	13
	19550	Coding	3	253	gttgcccacctcggagcc	59	14
10	19551	Coding	3	266	acactgcctgagagttgc	43	15
	19552	Coding	3	326	gtgtctggtattggttct	61	16
	19553	Coding	3	360	atcaccacctcacacctc	65	17
	19554	Coding	3	390	tgtcccgtagcacaatc	41	18
15	19555	Coding	3	403	gaggtcggcattgtgtcc	24	19
	19556	Coding	3	414	tgcaggaaggagaggtcg	48	20
	19557	Coding	3	490	gcggaggttgggcaatgg	37	21
	19558	Coding	3	569	cgtggctggagttggtgt	96	22
20	19559	Coding	3	615	cctgacagaatctcggtg	87	23
	19560	Coding	3	689	ggtcacctcacgatgtccc	80	24
	19561	Coding	3	706	cactatctcagcatctcg	59	25
	19562	Coding	3	720	ccattgtccttcaccact	36	26
25	19563	Coding	3	772	aggaccccagcatcgccc	65	27
	19564	Coding	3	797	tcaatgtctggcagtctt	63	28
	19565	Coding	3	813	gcacagatggtcttggtc	80	29
	19566	Coding	3	828	ccattacactgaggagca	57	30
30	19567	Coding	3	866	catggcagcactgggttg	65	31
	19568	Coding	3	918	caggcaaagcagtctgtg	48	32
	19569	Coding	3	977	tgtagacaagaggctgtg	49	33
	19570	Coding	3	1039	acaaactcctccatactg	33	34
35	19571	Coding	3	1089	ctgacacaggatgtttga	37	35
	19572	Coding	3	1139	acatcttgagcccatttt	44	36
	19573	Coding	3	1191	ccagagcctgttcctca	38	37
	19574	Coding	3	1239	ttcacaaatccatcaatg	10	38
40	19575	Coding	3	1383	gactggatgttcaggtaa	72	39
	19576	Coding	3	1458	cggttgtagaggcttctg	24	40
	19577	Coding	3	1513	tcggaagcccagagatgt	53	41
	19578	Coding	3	1582	agagtggtagcagag	5	42
45	19579	Coding	3	1603	aagcaccttggtccagtt	67	43
	19580	Coding	3	1738	ggacaagcactgaccagg	49	44
	19581	Coding	3	1839	tggcaggagaagcattcg	32	45
	19582	Coding	3	1900	acaagtatcagagcccga	60	46
50	19583	Coding	3	1913	gggcacattgagcacaag	11	47
	19584	Coding	3	2076	tgtcctaaacagtcttga	41	48
	19585	Coding	3	2110	tgtcagatgggttttgcc	46	49
	19586	Coding	3	2133	cctgctatcactgtcaaa	7	50
55	19587	Coding	3	2146	aatcactaccaatcctgc	0	51
	19588	Coding	3	2179	ccagtagagaaaagtgcc	46	52
	19589	Coding	3	2215	cctcatagcccttttatt	51	53
	19590	Coding	3	2232	ccccgttccaagtatcgc	47	54
60	19591	Coding	3	2242	tatgctctcaccctgttc	14	55
	19592	Coding	3	2278	gactttgttagccttctc	68	56
	19593	Coding	3	2339	agacacccgagccaagca	30	57
	19594	Coding	3	2388	ttgattgattcacccctca	72	58

-78-

	19595	Coding	3	2427	ccactcttgtcctcaatg	72	59
	19596	Coding	3	2440	aaaactctgccgtccact	43	60
	19597	Coding	3	2512	tagtcccagcagccttac	42	61
	19598	Coding	3	2564	gagaacccagaggcaaat	54	62
5	19599	Coding	3	2627	ctccccagttgagcagca	70	63
	19600	Coding	3	2694	cgggcagccagggtttcta	65	64
	19601	Coding	3	2731	cacctgaacctgactggg	43	65
	19602	Coding	3	2744	cacaaaaatctgccacct	59	66
	19603	Coding	3	2770	atcatcaggaggcagcag	52	67
10	19604	Coding	3	2839	cccaaagtggatactctc	73	68
	19605	Coding	3	2893	caactcccaaactgtcac	69	69
	19606	Coding	3	2906	ccccgaaggtcatcaact	36	70
	19607	Coding	3	2943	ggtacttcagccaatcgt	62	71
	19608	Coding	3	3034	atcaatcatccaacactt	12	72
15	19609	Coding	3	3048	gggcgaatgttctcatca	30	73
	19610	Coding	3	3178	cttcttgtttgtcagacc	77	74
	19611	Coding	3	3293	gtgttccaactggtaggc	20	75
	19612	Coding	3	3446	gtggcattgggtgtagag	43	76
	19613	Coding	3	3524	acattgacactttctcct	46	77
20	19614	Coding	3	3654	ccgttgacatcctcttcc	30	78
	19615	Coding	3	3736	gacagaactgagaccac	35	79
	19616	Coding	3	3776	attcatactcctcatctt	21	80
	19617	Coding	3	3957	tcttcactctggagttgtg	55	81
	19618	Coding	3	4051	ttcatacccttgctcaga	56	82
25	19619	Coding	3	4161	tcagggttatcaaaggca	64	83
	19620	Coding	3	4209	tacgttctctgggcatta	54	84
	19621	3' UTR	3	4353	agcctccaaagattgaat	35	85
	19622	3' UTR	3	4467	ggaatgggactgggaaag	16	86
	19623	3' UTR	3	4572	acaaaggcacacataaga	34	87
30	19624	3' UTR	3	4603	ccctttcctcttcttgac	29	88
	19625	3' UTR	3	4697	tcctaacctctttcttca	0	89
	19626	3' UTR	3	4766	gtaggtgaagtttagtat	53	90
	19627	3' UTR	3	4794	aggatgataaaggactaa	2	91
	19629	3' UTR	3	4928	tggctctcaaactccttgc	39	92
35	19630	3' UTR	3	4951	gggtcttactatgttggc	60	93
	19628	Intron	10	6560	caaagtgtgagattaca	29	94

As shown in Table 1, SEQ ID NOs 11, 12, 14, 15, 16, 17, 18, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 39, 41, 43, 44, 45, 46, 48, 49, 52, 53, 54, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 73, 74, 76, 77, 78, 79, 81, 82, 83, 84, 85, 87, 88, 90, 92, 93 and 94 demonstrated at least 25% inhibition of human Her-3 expression in this assay and are therefore preferred.

The target sites to which these preferred sequences are complementary are herein referred to as "active sites" and are therefore preferred sites for targeting by compounds of the present invention.

-79-

Example 16**Western blot analysis of Her-3 protein levels**

Western blot analysis (immunoblot analysis) is carried out using standard methods. Cells are harvested 16-20 h
5 after oligonucleotide treatment, washed once with PBS, suspended in Laemmli buffer (100 ul/well), boiled for 5 minutes and loaded on a 16% SDS-PAGE gel. Gels are run for 1.5 hours at 150 V, and transferred to membrane for western blotting. Appropriate primary antibody directed to Her-3 is
10 used, with a radiolabelled or fluorescently labeled secondary antibody directed against the primary antibody species. Bands are visualized using a PHOSPHORIMAGER™ (Molecular Dynamics, Sunnyvale CA).

What is claimed is:

1. A compound 8 to 50 nucleobases in length targeted to a nucleic acid molecule encoding Her-3, wherein said compound specifically hybridizes with and inhibits the expression of Her-3.

2. The compound of claim 1 which is an antisense oligonucleotide.

3. The compound of claim 2 wherein the antisense oligonucleotide has a sequence comprising SEQ ID NO: 11, 12, 14, 15, 16, 17, 18, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 39, 41, 43, 44, 45, 46, 48, 49, 52, 53, 54, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 73, 74, 76, 77, 78, 79, 81, 82, 83, 84, 85, 87, 88, 90, 92, 93 or 94.

4. The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.

5. The compound of claim 4 wherein the modified internucleoside linkage is a phosphorothioate linkage.

6. The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.

7. The compound of claim 6 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.

8. The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase.

9. The compound of claim 8 wherein the modified nucleobase is a 5-methylcytosine.

10. The compound of claim 2 wherein the antisense oligonucleotide is a chimeric oligonucleotide.

11. A compound 8 to 50 nucleobases in length which specifically hybridizes with at least an 8-nucleobase portion of an active site on a nucleic acid molecule encoding Her-3.

12. A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier or diluent.

-81-

13. The composition of claim 12 further comprising a colloidal dispersion system.

14. The composition of claim 12 wherein the compound is an antisense oligonucleotide.

15. A method of inhibiting the expression of Her-3 in cells or tissues comprising contacting said cells or tissues with the compound of claim 1 so that expression of Her-3 is inhibited.

16. A method of treating an animal having a disease or condition associated with Her-3 comprising administering to said animal a therapeutically or prophylactically effective amount of the compound of claim 1 so that expression of Her-3 is inhibited.

17. The method of claim 16 wherein the disease or condition is a hyperproliferative disorder.

18. The method of claim 17 wherein the hyperproliferative disorder is cancer.

19. The method of claim 16 wherein the disease or condition is a developmental disorder.

20. The method of claim 16 wherein the disease or condition is a neurological disorder.

SEQUENCE LISTING

<110> Isis Pharmaceuticals, Inc.
C. Frank Bennett
Lex M. Cowser

<120> ANTISENSE MODULATION OF HER-3 EXPRESSION

<130> RTSP-0148

<150> 09/630,706

<151> 2000-07-31

<160> 94

<210> 1

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 1

tccgtcatcg ctccctcaggg 20

<210> 2

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 2

atgcattctg cccccaagga 20

<210> 3

<211> 4975

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (199)...(4227)

<400> 3

ctctcacaca cacacacccc tcccctgcc tccctccccg gactccggct ccggctccga 60

ttgcaatttg caacctccgc tgccgtcgcc gcagcagcca ccaattcgcc agcgggttcag 120

gtggctcttg cctcgatgtc ctagcctagg ggcccccggg ccggacttgg ctgggctccc 180

ttcacccctct gcggagtc atg agg gcg aac gac gct ctg cag gtg ctg ggc 231
Met Arg Ala Asn Asp Ala Leu Gln Val Leu Gly
1 5 10

ttg ctt ttc agc ctg gcc cgg ggc tcc gag gtg ggc aac tct cag gca 279
Leu Leu Phe Ser Leu Ala Arg Gly Ser Glu Val Gly Asn Ser Gln Ala
15 20 25

gtg tgt cct ggg act ctg aat ggc ctg agt gtg acc ggc gat gct gag 327
Val Cys Pro Gly Thr Leu Asn Gly Leu Ser Val Thr Gly Asp Ala Glu

30	35	40	
aac caa tac cag aca ctg tac aag ctc tac gag agg tgt gag gtg gtg Asn Gln Tyr Gln Thr Leu Tyr Lys Leu Tyr Glu Arg Cys Glu Val Val 45 50 55			375
atg ggg aac ctt gag att gtg ctc acg gga cac aat gcc gac ctc tcc Met Gly Asn Leu Glu Ile Val Leu Thr Gly His Asn Ala Asp Leu Ser 60 65 70 75			423
ttc ctg cag tgg att cga gaa gtg aca ggc tat gtc ctc gtg gcc atg Phe Leu Gln Trp Ile Arg Glu Val Thr Gly Tyr Val Leu Val Ala Met 80 85 90			471
aat gaa ttc tct act cta cca ttg ccc aac ctc cgc gtg gtg cga ggg Asn Glu Phe Ser Thr Leu Pro Leu Pro Asn Leu Arg Val Val Arg Gly 95 100 105			519
acc cag gtc tac gat ggg aag ttt gcc atc ttc gtc atg ttg aac tat Thr Gln Val Tyr Asp Gly Lys Phe Ala Ile Phe Val Met Leu Asn Tyr 110 115 120			567
aac acc aac tcc agc cac gct ctg cgc cag ctc cgc ttg act cag ctc Asn Thr Asn Ser Ser His Ala Leu Arg Gln Leu Arg Leu Thr Gln Leu 125 130 135			615
acc gag att ctg tca ggg ggt gtt tat att gag aag aac gat aag ctt Thr Glu Ile Leu Ser Gly Gly Val Tyr Ile Glu Lys Asn Asp Lys Leu 140 145 150 155			663
tgt cac atg gac aca att gac tgg agg gac atc gtg agg gac cga gat Cys His Met Asp Thr Ile Asp Trp Arg Asp Ile Val Arg Asp Arg Asp 160 165 170			711
gct gag ata gtg gtg aag gac aat ggc aga agc tgt ccc ccc tgt cat Ala Glu Ile Val Val Lys Asp Asn Gly Arg Ser Cys Pro Pro Cys His 175 180 185			759
gag gtt tgc aag ggg cga tgc tgg ggt cct gga tca gaa gac tgc cag Glu Val Cys Lys Gly Arg Cys Trp Gly Pro Gly Ser Glu Asp Cys Gln 190 195 200			807
aca ttg acc aag acc atc tgt gct cct cag tgt aat ggt cac tgc ttt Thr Leu Thr Lys Thr Ile Cys Ala Pro Gln Cys Asn Gly His Cys Phe 205 210 215			855
ggg ccc aac ccc aac cag tgc tgc cat gat gag tgt gcc ggg ggc tgc Gly Pro Asn Pro Asn Gln Cys Cys His Asp Glu Cys Ala Gly Gly Cys 220 225 230 235			903
tca ggc cct cag gac aca gac tgc ttt gcc tgc cgg cac ttc aat gac Ser Gly Pro Gln Asp Thr Asp Cys Phe Ala Cys Arg His Phe Asn Asp 240 245 250			951
agt gga gcc tgt gta cct cgc tgt cca cag cct ctt gtc tac aac aag Ser Gly Ala Cys Val Pro Arg Cys Pro Gln Pro Leu Val Tyr Asn Lys 255 260 265			999
cta act ttc cag ctg gaa ccc aat ccc cac acc aag tat cag tat gga Leu Thr Phe Gln Leu Glu Pro Asn Pro His Thr Lys Tyr Gln Tyr Gly 270 275 280			1047
gga gtt tgt gta gcc agc tgt ccc cat aac ttt gtg gtg gat caa aca Gly Val Cys Val Ala Ser Cys Pro His Asn Phe Val Val Asp Gln Thr 285 290 295			1095

tcc tgt gtc agg gcc tgt cct cct gac aag atg gaa gta gat aaa aat	1143
Ser Cys Val Arg Ala Cys Pro Pro Asp Lys Met Glu Val Asp Lys Asn	
300 305 310 315	
ggg ctc aag atg tgt gag cct tgt ggg gga cta tgt ccc aaa gcc tgt	1191
Gly Leu Lys Met Cys Glu Pro Cys Gly Gly Leu Cys Pro Lys Ala Cys	
320 325 330	
gag gga aca ggc tct ggg agc cgc ttc cag act gtg gac tcg agc aac	1239
Glu Gly Thr Gly Ser Gly Ser Arg Phe Gln Thr Val Asp Ser Ser Asn	
335 340 345	
att gat gga ttt gtg aac tgc acc aag atc ctg ggc aac ctg gac ttt	1287
Ile Asp Gly Phe Val Asn Cys Thr Lys Ile Leu Gly Asn Leu Asp Phe	
350 355 360	
ctg atc acc ggc ctc aat gga gac ccc tgg cac aag atc cct gcc ctg	1335
Leu Ile Thr Gly Leu Asn Gly Asp Pro Trp His Lys Ile Pro Ala Leu	
365 370 375	
gac cca gag aag ctc aat gtc ttc cgg aca gta cgg gag atc aca ggt	1383
Asp Pro Glu Lys Leu Asn Val Phe Arg Thr Val Arg Glu Ile Thr Gly	
380 385 390 395	
tac ctg aac atc cag tcc tgg ccg ccc cac atg cac aac ttc agt gtt	1431
Tyr Leu Asn Ile Gln Ser Trp Pro Pro His Met His Asn Phe Ser Val	
400 405 410	
ttt tcc aat ttg aca acc att gga ggc aga agc ctc tac aac cgg ggc	1479
Phe Ser Asn Leu Thr Thr Ile Gly Gly Arg Ser Leu Tyr Asn Arg Gly	
415 420 425	
ttc tca ttg ttg atc atg aag aac ttg aat gtc aca tct ctg ggc ttc	1527
Phe Ser Leu Leu Ile Met Lys Asn Leu Asn Val Thr Ser Leu Gly Phe	
430 435 440	
cga tcc ctg aag gaa att agt gct ggg cgt atc tat ata agt gcc aat	1575
Arg Ser Leu Lys Glu Ile Ser Ala Gly Arg Ile Tyr Ile Ser Ala Asn	
445 450 455	
agg cag ctc tgc tac cac cac tct ttg aac tgg acc aag gtg ctt cgg	1623
Arg Gln Leu Cys Tyr His His Ser Leu Asn Trp Thr Lys Val Leu Arg	
460 465 470 475	
ggg cct acg gaa gag cga cta gac atc aag cat aat cgg ccg cgc aga	1671
Gly Pro Thr Glu Glu Arg Leu Asp Ile Lys His Asn Arg Pro Arg Arg	
480 485 490	
gac tgc gtg gca gag ggc aaa gtg tgt gac cca ctg tgc tcc tct ggg	1719
Asp Cys Val Ala Glu Gly Lys Val Cys Asp Pro Leu Cys Ser Ser Gly	
495 500 505	
gga tgc tgg ggc cca ggc cct ggt cag tgc ttg tcc tgt cga aat tat	1767
Gly Cys Trp Gly Pro Gly Pro Gly Gln Cys Leu Ser Cys Arg Asn Tyr	
510 515 520	
agc cga gga ggt gtc tgt gtg acc cac tgc aac ttt ctg aat ggg gag	1815
Ser Arg Gly Gly Val Cys Val Thr His Cys Asn Phe Leu Asn Gly Glu	
525 530 535	
cct cga gaa ttt gcc cat gag gcc gaa tgc ttc tcc tgc cac ccg gaa	1863
Pro Arg Glu Phe Ala His Glu Ala Glu Cys Phe Ser Cys His Pro Glu	
540 545 550 555	
tgc caa ccc atg ggg ggc act gcc aca tgc aat ggc tcg ggc tct gat	1911

Cys	Gln	Pro	Met	Gly 560	Gly	Thr	Ala	Thr	Cys 565	Asn	Gly	Ser	Gly	Ser	Asp 570		
act	tgt	gct	caa	tgt	gcc	cat	ttt	cga	gat	ggg	ccc	cac	tgt	gtg	agc	1959	
Thr	Cys	Ala	Gln	Cys	Ala	His	Phe	Arg	Asp	Gly	Pro	His	Cys	Val	Ser		
			575					580					585				
agc	tgc	ccc	cat	gga	gtc	cta	ggg	gcc	aag	ggc	cca	atc	tac	aag	tac	2007	
Ser	Cys	Pro	His	Gly	Val	Leu	Gly	Ala	Lys	Gly	Pro	Ile	Tyr	Lys	Tyr		
		590					595					600					
cca	gat	gtt	cag	aat	gaa	tgt	cgg	ccc	tgc	cat	gag	aac	tgc	acc	cag	2055	
Pro	Asp	Val	Gln	Asn	Glu	Cys	Arg	Pro	Cys	His	Glu	Asn	Cys	Thr	Gln		
		605				610					615						
ggg	tgt	aaa	gga	cca	gag	ctt	caa	gac	tgt	tta	gga	caa	aca	ctg	gtg	2103	
Gly	Cys	Lys	Gly	Pro	Glu	Leu	Gln	Asp	Cys	Leu	Gly	Gln	Thr	Leu	Val		
620					625					630					635		
ctg	atc	ggc	aaa	acc	cat	ctg	aca	atg	gct	ttg	aca	gtg	ata	gca	gga	2151	
Leu	Ile	Gly	Lys	Thr	His	Leu	Thr	Met	Ala	Leu	Thr	Val	Ile	Ala	Gly		
				640					645					650			
ttg	gta	gtg	att	ttc	atg	atg	ctg	ggc	ggc	act	ttt	ctc	tac	tgg	cgt	2199	
Leu	Val	Val	Ile	Phe	Met	Met	Leu	Gly	Gly	Thr	Phe	Leu	Tyr	Trp	Arg		
			655					660					665				
ggg	cgc	cgg	att	cag	aat	aaa	agg	gct	atg	agg	cga	tac	ttg	gaa	cgg	2247	
Gly	Arg	Arg	Ile	Gln	Asn	Lys	Arg	Ala	Met	Arg	Arg	Tyr	Leu	Glu	Arg		
		670					675					680					
ggg	gag	agc	ata	gag	cct	ctg	gac	ccc	agt	gag	aag	gct	aac	aaa	gtc	2295	
Gly	Glu	Ser	Ile	Glu	Pro	Leu	Asp	Pro	Ser	Glu	Lys	Ala	Asn	Lys	Val		
		685				690					695						
ttg	gcc	aga	atc	ttc	aaa	gag	aca	gag	cta	agg	aag	ctt	aaa	gtg	ctt	2343	
Leu	Ala	Arg	Ile	Phe	Lys	Glu	Thr	Glu	Leu	Arg	Lys	Leu	Lys	Val	Leu		
700					705					710					715		
ggc	tcg	ggg	gtc	ttt	gga	act	gtg	cac	aaa	gga	gtg	tgg	atc	cct	gag	2391	
Gly	Ser	Gly	Val	Phe	Gly	Thr	Val	His	Lys	Gly	Val	Trp	Ile	Pro	Glu		
				720					725					730			
ggg	gaa	tca	atc	aag	att	cca	gtc	tgc	att	aaa	gtc	att	gag	gac	aag	2439	
Gly	Glu	Ser	Ile	Lys	Ile	Pro	Val	Cys	Ile	Lys	Val	Ile	Glu	Asp	Lys		
			735					740					745				
agt	gga	cgg	cag	agt	ttt	caa	gct	gtg	aca	gat	cat	atg	ctg	gcc	att	2487	
Ser	Gly	Arg	Gln	Ser	Phe	Gln	Ala	Val	Thr	Asp	His	Met	Leu	Ala	Ile		
		750					755					760					
ggc	agc	ctg	gac	cat	gcc	cac	att	gta	agg	ctg	ctg	gga	cta	tgc	cca	2535	
Gly	Ser	Leu	Asp	His	Ala	His	Ile	Val	Arg	Leu	Leu	Gly	Leu	Cys	Pro		
		765				770					775						
ggg	tca	tct	ctg	cag	ctt	gtc	act	caa	tat	ttg	cct	ctg	ggg	tct	ctg	2583	
Gly	Ser	Ser	Leu	Gln	Leu	Val	Thr	Gln	Tyr	Leu	Pro	Leu	Gly	Ser	Leu		
780					785					790					795		
ctg	gat	cat	gtg	aga	caa	cac	cgg	ggg	gca	ctg	ggg	cca	cag	ctg	ctg	2631	
Leu	Asp	His	Val	Arg	Gln	His	Arg	Gly	Ala	Leu	Gly	Pro	Gln	Leu	Leu		
				800					805					810			
ctc	aac	tgg	gga	gta	caa	att	gcc	aag	gga	atg	tac	tac	ctt	gag	gaa	2679	
Leu	Asn	Trp	Gly	Val	Gln	Ile	Ala	Lys	Gly	Met	Tyr	Tyr	Leu	Glu	Glu		

815				820				825								
cat	ggt	atg	gtg	cat	aga	aac	ctg	gct	gcc	cga	aac	gtg	cta	ctc	aag	2727
His	Gly	Met	Val	His	Arg	Asn	Leu	Ala	Ala	Arg	Asn	Val	Leu	Leu	Lys	
830				835				840								
tca	ccc	agt	cag	gtt	cag	gtg	gca	gat	ttt	ggt	gtg	gct	gac	ctg	ctg	2775
Ser	Pro	Ser	Gln	Val	Gln	Val	Ala	Asp	Phe	Gly	Val	Ala	Asp	Leu	Leu	
845				850				855								
cct	cct	gat	gat	aag	cag	ctg	cta	tac	agt	gag	gcc	aag	act	cca	att	2823
Pro	Pro	Asp	Asp	Lys	Gln	Leu	Leu	Tyr	Ser	Glu	Ala	Lys	Thr	Pro	Ile	
860				865				870				875				
aag	tgg	atg	gcc	ctt	gag	agt	atc	cac	ttt	ggg	aaa	tac	aca	cac	cag	2871
Lys	Trp	Met	Ala	Leu	Glu	Ser	Ile	His	Phe	Gly	Lys	Tyr	Thr	His	Gln	
880				885				890								
agt	gat	gtc	tgg	agc	tat	ggg	gtg	aca	gtt	tgg	gag	ttg	atg	acc	ttc	2919
Ser	Asp	Val	Trp	Ser	Tyr	Gly	Val	Thr	Val	Trp	Glu	Leu	Met	Thr	Phe	
895				900				905								
ggg	gca	gag	ccc	tat	gca	ggg	cta	cga	ttg	gct	gaa	gta	cca	gac	ctg	2967
Gly	Ala	Glu	Pro	Tyr	Ala	Gly	Leu	Arg	Leu	Ala	Glu	Val	Pro	Asp	Leu	
910				915				920								
cta	gag	aag	ggg	gag	cgg	ttg	gca	cag	ccc	cag	atc	tgc	aca	att	gat	3015
Leu	Glu	Lys	Gly	Glu	Arg	Leu	Ala	Gln	Pro	Gln	Ile	Cys	Thr	Ile	Asp	
925				930				935								
gtc	tac	atg	gtg	atg	gtc	aag	tgt	tgg	atg	att	gat	gag	aac	att	cgc	3063
Val	Tyr	Met	Val	Met	Val	Lys	Cys	Trp	Met	Ile	Asp	Glu	Asn	Ile	Arg	
940				945				950				955				
cca	acc	ttt	aaa	gaa	cta	gcc	aat	gag	ttc	acc	agg	atg	gcc	cga	gac	3111
Pro	Thr	Phe	Lys	Glu	Leu	Ala	Asn	Glu	Phe	Thr	Arg	Met	Ala	Arg	Asp	
960				965				970								
cca	cca	cgg	tat	ctg	gtc	ata	aag	aga	gag	agt	ggg	cct	gga	ata	gcc	3159
Pro	Pro	Arg	Tyr	Leu	Val	Ile	Lys	Arg	Glu	Ser	Gly	Pro	Gly	Ile	Ala	
975				980				985								
cct	ggg	cca	gag	ccc	cat	ggg	ctg	aca	aac	aag	aag	cta	gag	gaa	gta	3207
Pro	Gly	Pro	Glu	Pro	His	Gly	Leu	Thr	Asn	Lys	Lys	Leu	Glu	Glu	Val	
990				995				1000								
gag	ctg	gag	cca	gaa	cta	gac	cta	gac	cta	gac	ttg	gaa	gca	gag	gag	3255
Glu	Leu	Glu	Pro	Glu	Leu	Asp	Leu	Asp	Leu	Asp	Leu	Glu	Ala	Glu	Glu	
1005				1010				1015								
gac	aac	ctg	gca	acc	acc	aca	ctg	ggc	tcc	gcc	ctc	agc	cta	cca	gtt	3303
Asp	Asn	Leu	Ala	Thr	Thr	Thr	Leu	Gly	Ser	Ala	Leu	Ser	Leu	Pro	Val	
1020				1025				1030				1035				
gga	aca	ctt	aat	cgg	cca	cgt	ggg	agc	cag	agc	ctt	tta	agt	cca	tca	3351
Gly	Thr	Leu	Asn	Arg	Pro	Arg	Gly	Ser	Gln	Ser	Leu	Leu	Ser	Pro	Ser	
1040				1045				1050								
tct	gga	tac	atg	ccc	atg	aac	cag	ggg	aat	ctt	ggg	ggg	tct	tgc	cag	3399
Ser	Gly	Tyr	Met	Pro	Met	Asn	Gln	Gly	Asn	Leu	Gly	Gly	Ser	Cys	Gln	
1055				1060				1065								
gag	tct	gca	gtt	tct	ggg	agc	agt	gaa	cgg	tgc	ccc	cgt	cca	gtc	tct	3447
Glu	Ser	Ala	Val	Ser	Gly	Ser	Ser	Glu	Arg	Cys	Pro	Arg	Pro	Val	Ser	
1070				1075				1080								

cta cac cca atg cca cgg gga tgc ctg gca tca gag tca tca gag ggg Leu His Pro Met Pro Arg Gly Cys Leu Ala Ser Glu Ser Ser Glu Gly 1085 1090 1095	3495
cat gta aca ggc tct gag gct gag ctc cag gag aaa gtg tca atg tgt His Val Thr Gly Ser Glu Ala Glu Leu Gln Glu Lys Val Ser Met Cys 1100 1105 1110 1115	3543
aga agc cgg agc agg agc cgg agc cca cgg cca cgc gga gat agc gcc Arg Ser Arg Ser Arg Ser Arg Ser Pro Arg Pro Arg Gly Asp Ser Ala 1120 1125 1130	3591
tac cat tcc cag cgc cac agt ctg ctg act cct gtt acc cca ctc tcc Tyr His Ser Gln Arg His Ser Leu Leu Thr Pro Val Thr Pro Leu Ser 1135 1140 1145	3639
cca ccc ggg tta gag gaa gag gat gtc aac ggt tat gtc atg cca gat Pro Pro Gly Leu Glu Glu Glu Asp Val Asn Gly Tyr Val Met Pro Asp 1150 1155 1160	3687
aca cac ctc aaa ggt act ccc tcc tcc cgg gaa ggc acc ctt tct tca Thr His Leu Lys Gly Thr Pro Ser Ser Arg Glu Gly Thr Leu Ser Ser 1165 1170 1175	3735
gtg ggt ctc agt tct gtc ctg ggt act gaa gaa gaa gat gaa gat gag Val Gly Leu Ser Ser Val Leu Gly Thr Glu Glu Glu Asp Glu Asp Glu 1180 1185 1190 1195	3783
gag tat gaa tac atg aac cgg agg aga agg cac agt cca cct cat ccc Glu Tyr Glu Tyr Met Asn Arg Arg Arg Arg His Ser Pro Pro His Pro 1200 1205 1210	3831
cct agg cca agt tcc ctt gag gag ctg ggt tat gag tac atg gat gtg Pro Arg Pro Ser Ser Leu Glu Glu Leu Gly Tyr Glu Tyr Met Asp Val 1215 1220 1225	3879
ggg tca gac ctc agt gcc tct ctg ggc agc aca cag agt tgc cca ctc Gly Ser Asp Leu Ser Ala Ser Leu Gly Ser Thr Gln Ser Cys Pro Leu 1230 1235 1240	3927
cac cct gta ccc atc atg ccc act gca ggc aca act cca gat gaa gac His Pro Val Pro Ile Met Pro Thr Ala Gly Thr Thr Pro Asp Glu Asp 1245 1250 1255	3975
tat gaa tat atg aat cgg caa cga gat gga ggt ggt cct ggg ggt gat Tyr Glu Tyr Met Asn Arg Gln Arg Asp Gly Gly Gly Pro Gly Gly Asp 1260 1265 1270 1275	4023
tat gca gcc atg ggg gcc tgc cca gca tct gag caa ggg tat gaa gag Tyr Ala Ala Met Gly Ala Cys Pro Ala Ser Glu Gln Gly Tyr Glu Glu 1280 1285 1290	4071
atg aga gct ttt cag ggg cct gga cat cag gcc ccc cat gtc cat tat Met Arg Ala Phe Gln Gly Pro Gly His Gln Ala Pro His Val His Tyr 1295 1300 1305	4119
gcc cgc cta aaa act cta cgt agc tta gag gct aca gac tct gcc ttt Ala Arg Leu Lys Thr Leu Arg Ser Leu Glu Ala Thr Asp Ser Ala Phe 1310 1315 1320	4167
gat aac cct gat tac tgg cat agc agg ctt ttc ccc aag gct aat gcc Asp Asn Pro Asp Tyr Trp His Ser Arg Leu Phe Pro Lys Ala Asn Ala 1325 1330 1335	4215
cag aga acg taa ctctgctcc ctgtggcact caggagcat ttaatggcag	4267

Gln Arg Thr
1340

```

ctagtgcctt tagagggtac cgtcttctcc ctattccctc tctctcccag gtcccagccc 4327
cttttcccca gtcccagaca attccattca atctttggag gcttttaaac attttgacac 4387
aaaattctta tggatatgtag ccagctgtgc actttcttct ctttcccaac cccaggaaag 4447
gttttcccta ttttgtgtgc tttcccagtc ccattcctca gcttcttcac aggcactcct 4507
ggagatatga aggattactc tccatatccc ttcctctcag gctcttgact acttggaact 4567
aggctcttat gtgtgccttt gtttcccato agactgtcaa gaagaggaaa gggaggaaaac 4627
ctagcagagg aaagtgtaat tttggtttat gactcttaac cccctagaaa gacagaagct 4687
taaaatctgt gaagaaagag gttaggagta gatattgatt actatcataa ttcagcactt 4747
aactatgagc caggcatcat actaaacttc acctacatta tctcacttag tcttttatca 4807
tccttaaaac aattctgtga catacatatt atctcatttt acacaaaggg aagtcgggca 4867
tggtggctca tgctgtaat ctcagcactt tgggaggctg aggcagaagg attacctgag 4927
gcaaggagtt tgagaccagc ttagccaaca tagtaagacc cccatctc 4975

```

<210> 4
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> PCR Primer

<400> 4
tcgtcatggt gaactataac accaact 27

<210> 5
<211> 26
<212> DNA
<213> Artificial Sequence

<220>
<223> PCR Primer

<400> 5
tgacaaagct tatcggtctt ctcaat 26

<210> 6
<211> 26
<212> DNA
<213> Artificial Sequence

<220>
<223> PCR Probe

<400> 6
ccgcttgact cagctcaccg agattc 26

<210> 7
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> PCR Primer

<400> 7
caacggatgt ggctgtattg g 21

<210> 8
<211> 26
<212> DNA
<213> Artificial Sequence

<220>

<223> PCR Primer

<400> 8

ggcaacaata tccactttac cagagt

26

<210> 9

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR Probe

<400> 9

cgctgggtca ccagggctgc t

21

<210> 10

<211> 14796

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (2811)...(2921)

<220>

<221> CDS

<222> (3174)...(3283)

<220>

<221> CDS

<222> (5158)...(5275)

<220>

<221> CDS

<222> (11955)...(12044)

<400> 10

tctagacatg	cggatatatt	caagctgggc	acagcacagc	agccccaccc	caggcagctt	60
gaaatcagag	ctgggggtcca	aagggaccac	accccgaggg	actgtgtggg	ggtcggggca	120
cacaggccac	tgcttcccc	cgtctttctc	agccattcct	gaagtcagcc	tcactctgct	180
tctcagggat	ttcaaatgtg	cagagactct	ggcacttttg	tagaagcccc	ttctggtcct	240
aacttacacc	tgcatgctgt	ggggctgcag	ctgctgctcg	ggctcgggag	gatgctgggg	300
gcccgggtgcc	catgagcttt	tgaagctcct	ggaactcggg	tttgaggggtg	ttcaggtcca	360
ggtggacacc	tgggctgtcc	ttgtccatgc	atgtgatgac	attgtgtgca	gaagtgaaaa	420
ggagttaggc	cgggcatgct	ggcttatgcc	tgtaatccca	gcactttggg	aggctgaggc	480
gggtggatca	cgaggtcagg	agttcaatac	cagcctggcc	aagatgggtga	aaccccgctc	540
ctactaaaaa	tacaaaaaaa	ttagccgggc	atggtggcgg	gogcatgtaa	tcccagctac	600
tgggggggct	gaggcagaga	attgctggaa	cccaggagat	ggaggttgca	gtgagccaag	660
attgtgocac	tgcaactgcac	tccagcctgg	cgacagagca	agactctgtc	tcaaaaaaaaa	720
aaaaaaaaag	tgaaggagg	ttgttccttt	cctccctcct	gagggcaggc	aactgctgcg	780
gttgccagtg	gaggtgggtgc	gtccttggtc	tgtgcctggg	ggccacccca	gcagaggcca	840
tggtggtgcc	agggcccggg	tagcgagcca	atcagcagga	cccaggggcg	acctgccaaa	900
gtcaactgga	tttgataact	gcagcgaagt	taagtttctc	gattttgatg	attgtgttgt	960
ggttgtgtaa	gagaatgaag	tatttcgggg	tagtatggta	atgccttcaa	cttacaaacg	1020
gttcaggtaa	accacccata	tacatacata	tacatgcatg	tgatatatac	acatacaggg	1080
atgtgtgtgt	gttcacatat	atgaggggag	agagactagg	ggagagaaag	taggttgggg	1140
agagggagag	agaaaggaaa	acaggagaca	gagagagagc	ggggagtaga	gagagggaag	1200
gggtaagaga	gggagaggag	gagagaaagg	gaggaagaag	cagagagtga	atgttaaagg	1260
aaacaggcaa	aacataaaca	gaaaatctgg	gtgaagggtg	tatgagtatt	ctttgtacta	1320
ttcttgcaat	tatcttttat	ttaaattgac	atcgggccgg	gcgcagtggc	tcacatctgt	1380
aatcccagca	ctttgggagg	ccgaggcagg	cagatcactt	gaggtcagga	gtttgagacc	1440
agcctggcaa	acatggtgaa	accccatctc	tactaaaaat	acaaaaatta	gcctgggtgtg	1500
gtggtgcatg	cctttaatct	cagctactcg	ggaggctgag	gcaggagaaat	cgcttgaacc	1560
cgtggcgggg	aggagggttg	agtgagctga	gatcatgcca	ctgcactcca	gcctgggcga	1620
tagagcgaga	ctcagtttca	aataaataaa	taaacatcaa	aataaaaagt	tactgtatta	1680

aagaatgggg	gcggggtggg	aggggtgggg	agaggttgca	aaaataaata	aataaataaa	1740
taaaccccaa	aatgaaaaag	acagtggagg	caccaggcct	gcgtggggct	ggagggctaa	1800
taaggccagg	cctcttatct	ctggccatag	aaccagagaa	gtgagtggat	gtgatgccca	1860
gctccagaag	tgactccaga	acacctgtt	ccaaagcaga	ggacacactg	atTTTTTTTT	1920
taataggctg	caggacttac	tgttgggtgg	acgcctgct	ttgcgaaggg	aaaggaggag	1980
tttgccctga	gcacaggccc	ccaccctcca	ctgggctttc	cccagctccc	ttgtcttctt	2040
atcacggtag	tggcccagtc	cctggccctt	gactccagaa	ggtggccctc	ctggaaaccc	2100
aggctgtgca	gtcaacgatg	tactcgccgg	gacagcgatg	tctgctgcac	tccatccctc	2160
ccctgttcat	ttgtccttca	tgcccgctctg	gagtagatgc	TTTTTgcaga	ggtggcaccc	2220
tgtaaagctc	tcctgtctga	ctTTTTTTTT	TTTTTtagac	tgagTTTTgc	tcttgttgcc	2280
taggctggag	tgcaatggca	caatctcagc	tcactgcacc	ctctgcctcc	cgggttcaag	2340
cgattctcct	gcctcagcct	cccagtagt	tgggattaca	ggcatgcacc	accacgcca	2400
gctaattttt	gtatttttag	tagagacaag	gtttcacctg	gatggccagg	ctggctctga	2460
actccaggac	tcaagtgatg	ctcctgccta	ggcctctcaa	agtgttgga	ttacaggcgt	2520
gagccactgc	acccggcctg	cacgcgttct	ttgaaagcag	tcgagggggc	gctaggtgtg	2580
ggcagggacg	agctggcgcg	gcgtcgctgg	gtgcaccgcg	accacgggca	gagccacgcg	2640
gcggggaggac	tacaactccc	ggcacacccc	gcgccgcccc	gcctctaactc	ccagaaggcc	2700
gcgggggggtg	gaccgcctaa	gagggcgtgc	gctcccagaca	tgccccgcgg	cgcgccatta	2760
accgccagat	ttgaatcgcg	ggacccgttg	gcagaggtgg	cggcgggcggc	atg ggt	2816
					Met Gly	
					1	
gcc ccg acg ttg ccc cct gcc tgg cag ccc ttt ctc aag gac cac cgc						2864
Ala Pro Thr Leu Pro Pro Ala Trp Gln Pro Phe Leu Lys Asp His Arg						
	5		10		15	
atc tct aca ttc aag aac tgg ccc ttc ttg gag ggc tgc gcc tgc acc						2912
Ile Ser Thr Phe Lys Asn Trp Pro Phe Leu Glu Gly Cys Ala Cys Thr						
	20		25		30	
ccg gag cgg gtgagactgc cgggcctcct ggggtccccc acgcccgcct tgccctgtcc						2971
Pro Glu Arg						
35						
ctagcgaggc cactgtgact gggcctcggg ggtacaagcc gccctcccct ccccgctcctg						3031
tccccagcga ggccactgtg gctgggcccc ttgggtccag gccggcctcc cctccctgct						3091
ttgtcccctat cgaggccttt gtggctgggc ctccgggttc cgggctgcca cgtccactca						3151
cgagctgtgc tgtcccttgc ag atg gcc gag gct ggc ttc atc cac tgc ccc						3203
		Met Ala	Glu Ala Gly	Phe Ile His Cys Pro		
			40	45		
act gag aac gag cca gac ttg gcc cag tgt ttc ttc tgc ttc aag gag						3251
Thr Glu Asn Glu Pro Asp Leu Ala Gln Cys Phe Phe Cys Phe Lys Glu						
	50		55		60	
ctg gaa ggc tgg gag cca gat gac gac ccc at gtaagtcttc tctggccagc						3303
Leu Glu Gly Trp Glu Pro Asp Asp Asp Pro Ile						
	65		70			
ctcgatgggc tttgttttga actgagttgt caaaagattt gagttgcaaa gacacttagt						3363
atgggagggg tgcttttocac cctcattgct tcttaaacag ctggttgtaa cggatacctc						3423
tctatatgct ggtgccttgg tgatgcttac aacctaatTA aatctcattt gacaaaaatg						3483
ccttgggggtg gacgtaagat gcctgatgcc tttcatgttc aacagaatac atcagcagac						3543
cctgttgttg tgaactocca ggaatgtcca agtgcttttt ttgagatttt ttaaaaaaca						3603
gtttaattga aatataacct acacagcaca aaaattaccc tttgaaagtg tgcacttcac						3663
actttcggag gctgaggcgg gcggatcacc tgaggtcagg agttcaagac ctgcctggcc						3723
aacttggcga aaccccgctc ctactaaaaa tacaaaaatt agccgggcat ggtagcgcac						3783
gcccgtaatc ccagctactc gggaggctaa ggcaggagaa tcgcttgaac ctgggaggcg						3843
gaggttgcag tgagccgaga ttgtgccaat gcactccagc ctcggcgaca gagcgagact						3903
ccgtcataaa aataaaaaat tgaaaaaaa aaaagaaaga aagcatatac ttcagtgttg						3963
ttctggattt ttttcttcaa gatgcctagt taatgacaat gaaattctgt actcggttg						4023
tatctgtctt tccacactgt aatgccatat tcttttctca cctttttttc tgtcggattc						4083
agttgcttcc acagctttta tttttttccc ctggagaatc accccagttg tttttctttt						4143
tggccagaag agagttagctg ttttttttct tagtatgttt gctatgggtg ttatactga						4203
tcccgtaat cactgggaaa agatcagtgg tattcttctt gaaaatgaat aagtgttatg						4263
atattttcag attagagtta caactggctg tcttttttga ctttgtgtgg ccatgttttc						4323
attgtaatgc agttctggta acggtgatag tcagttatac agggagactc ccctagcaga						4383
aatgagagt gtgagctagg gggcccttg ggaaccggg ggcaataatg cccttctctg						4443

```

cccttaatcc ttacagtggg ccgggacagg tggtttacgc ctgtaatacc agcacttttg 4503
gaggccgagg cgggcgagatc acgaggtcag gagatcgaga ccatcttggc taatacgggtg 4563
aaaccccgtc tocactaaaa atacaaaaaa ttagccgggc gtgggtgggtg gcgcctgtag 4623
tcccagctac tggggagggtc gaggcaggag aatggcgtga acccaggagg cggagcttgc 4683
agtgaagcca gattgcacca ctgactcca gcctgggcga cagaatgaga ctccgtctca 4743
aaaaaaaaaa aaaaagaaaa aaatctttac agtggattac ataacaattc cagtgaatg 4803
aaattacttc aaacagttcc ttgagaatgt tggagggtat tgacatgtaa ttcctttgga 4863
catataccat gtaacacttt tccaactaat tgctaaggaa gtccagataa aatagataca 4923
ttagccacac agatgtgggg ggagatgtcc acaggagag agaaggtgct aagaggtgcc 4983
atatgggaat gtggcttggg caaagcactg atgccatcaa ctccagactt gacgtcttac 5043
tcctgaggca gagcagggtg tgctgtgga gggcgtgggg aggtggcccg tggggagtgg 5103
actgccgctt taatcccttc agctgccttt ccgctgttgt tttgattttt ctag a gag 5161
                                     Glu
                                     75

gaa cat aaa aag cat tcg tcc ggt tgc gct ttc ctt tct gtc aag aag 5209
Glu His Lys Lys His Ser Ser Gly Cys Ala Phe Leu Ser Val Lys Lys
                                     80                                     85                                     90
cag ttt gaa gaa tta acc ctt ggt gaa ttt ttg aaa ctg gac aga gaa 5257
Gln Phe Glu Glu Leu Thr Leu Gly Glu Phe Leu Lys Leu Asp Arg Glu
                                     95                                     100                                     105
aga gcc aag aac aaa att gtatgtattg ggaataagaa ctgctcaaac cctgttcaat 5315
Arg Ala Lys Asn Lys Ile
                                     110

gtcttttagca ctaaaactacc tagtccctca aagggactct gtgttttcoct caggaagcat 5375
tttttttttt tttctgagat agagttttcac tcttgttgcc caggctggag tgcaatgggtg 5435
caatcttggc tcaactgcaac ctctgcctct cgggttcaag tgattctcct gcctcagcct 5495
cccaagtaac tgggattaca gggaagtgcc accacacca gctaattttt gtatttttag 5555
tagagatggg gtttcaccac attgcccagg ctggctctga actcctgacc tcgtgattcg 5615
cccaccttgg cctcccaaag tgctgggatt acaggcgtga accaccacgc ctggcttttt 5675
tttttttgtt ctgagacaca gtttactct gttaccoagg ctggagtagg gtggcctgat 5735
ctcggatcac tgcaacctcc gcctcctggg ctcaagtgat ttgcctgctt cagcctccca 5795
agtagccgag attacaggca tgtgccacca caccaggtat atttttgtat ttttggtaga 5855
gacgaggttt caccatgttg gccaggctgg ttttgaactc ctgacctcag gtgatccacc 5915
cgctcagcc tcccaaagtg ctgagattat aggtgtgagc caccacaact ggcctcagga 5975
agtattttta tttttaaatt tatttattta tttgagatgg agtcttgctc tgtcgcccag 6035
gctagagtgc agcgacggga tctcggctca ctgcaagctc cgccccccag gttcaagcca 6095
ttctcctgcc tcagcctccc gagtagctgg gactacaggc gcccgcacc acaccgggt 6155
aatttttttg tatttttagt agagacgggt tttcacctgt ttagccagga gggctctgat 6215
ctcctgacct cgtgatctgc ctgcctcggc ctcccaaagt gctgggatta cagggtgtgag 6275
ccaccacacc cggctatgtt tatttttttg agacaggac tactctgtc acctgggtc 6335
cagtgcagtg gtacaccata gtcactgca gcctcgaaact cctgagctca agtgatcctc 6395
ccacctcatc ctcaaaagta attgggacta cagggtgcacc ccacctgcc cacctaattt 6455
atttatttat ttatttattt attttcatag agatgagggt tccctgtgtt gtccaggctg 6515
gtcttgaact cctgagctca cgggatcctt ttgcctgggc ctcccaaagt gctgagatta 6575
caggcatgag ccacctgtgc cagctaggaa tcatttttaa agcccctagg atgtctgtgt 6635
gatttttaag ctctggagt gtggccggta taagtatata ccggtataag taaatccac 6695
attttgtgtc agtatttact agaaacttag tcatttatct gaagttgaaa tgaactggg 6755
ctttatttat ttatttattt atttatttat ttttaatttt tttttttgag acgagtctca 6815
ctttgtcacc caggctggag tgcagtggca cgatctcggc tcaactgcaac ctctgcctcc 6875
cggggtcaag cgattctcct gccttagcct cccgagtagc tgggactaca ggcacgcacc 6935
accatgcctg gctaattttt gtatttttag tagacgggtt tccacctgc tggccaagct 6995
ggtctcaaac tcctgacctt gtgatctgcc cgctttagcc tcccagagtg ctgggattac 7055
aggcatgagc caccatgctt ggtcttttta aaattttttg attttttttt tttttgagac 7115
agagccttgc tctgtgcgcc aggtcggagt gcagtggcac gatctcagct cactacaagc 7175
tccgcctccc ggggtcacgc cattcttctg cctcagcctc ctgagtagct gggactacag 7235
gtgccacca ccacgcctgg ctaatttttt ttggtatttt tattagagac aaggtttcat 7295
catgttggcc aggtcggctt caaactcctg acctcaagt atctgcctgc ctcgccctcc 7355
caaagcgctg agattacagg tgtgatctac tgcgccaggc ctgggcgtca tatattctta 7415
tttgctaagt ctggcagccc cacacagaat aagtactggg ggattccata tccttgtagc 7475
aaagccctgg gtggagagtc aggagatgtt gtagttctgt ctctgccact tgcagacttt 7535
gagtttaagc cagtcgtgct catgctttcc ttgctaaata gaggttagac cccctatccc 7595
atggtttctc aggttgcctt tcagcttgaa aattgtattc cttttagag atcagcgtaa 7655
aataattctg tccttatatg tggctttatt ttaatttgag acagagtgtc actcagtcgc 7715
ccaggctgga gtgtggtggt gcgatcttgg ctcaactgca cctccacctc ccaggttcaa 7775

```

gcgattctcg	tgcctcaggg	tcccaagtag	ctgagattat	aggtgtgtgc	caccaggccc	7835
agctaacttt	tgtattttta	gtagagacag	ggttttgcca	tgttggtctaa	gctgggtctcg	7895
aactcctggc	ctcaagtgat	ctgcccgcct	tggcatccca	aagtgtctggg	attacagggtg	7955
tgaaccacca	cacotggcct	caatatagtg	gcttttaagt	gctaaggact	gagatttgtgt	8015
tttgtcagga	agaggccagt	tgtgggtgaa	gcatgctgtg	agagagcttg	tcacctgggtt	8075
gaggttgttg	gagctgcagc	gtgggaactg	gaaagtgggc	tggggatcat	ctttttccag	8135
gtcaggggtc	agocagcttt	tctgcagcgt	gccatagacc	atctcttagc	cctcgtgggt	8195
cagagtctct	gttgcataatt	gtcttttgtt	gtttttcaca	accttttaga	aacataaaaa	8255
gcattcttag	cccgtgggct	ggacaaaaaa	aggccatgac	gggctgtatg	gattttggccc	8315
agcaggccct	tgcttgccaa	gccctgtttt	agacaaggag	cagcttgtgt	gcctggaacc	8375
atcatgggca	caggggagga	gcagagtggg	tgtggagggtg	tgagctggaa	accagggtccc	8435
agagcgctga	gaaagacaga	gggttttttg	ccttgcaagt	agagcaactg	aaatctgaca	8495
ccatccaggt	ccagaaaagg	ctgaagtgtc	gggtgacgct	gcgggggtgct	ccgctctagg	8555
gttacaggga	tgaagatgca	gtctggtagg	gggtggccac	tcacctgttg	gaagatgtga	8615
ttaagaaaag	tagactttca	gggcccggca	tgggtggtca	cgctgtaat	ccagcactt	8675
tgggaggccg	aggcgggttg	atcacgaggt	caggagatcg	agaccatcct	ggctaacatg	8735
gtgaaacccc	gtctttacta	aaaatacaaa	aaattagctg	ggcgtgggtg	cgggcgccctg	8795
tagtcccagc	tactcgggag	gctgaggcag	gagaatggcg	tgaacctggg	aggtggagct	8855
tgtgtgagc	cgagatcgcg	ccactgcact	ccagcctggg	cgacagagcg	agactccgtc	8915
tcaaaaaaaa	aaaaaaaagt	aggctttcat	gatgtgtgag	ctgaaggcgc	agtgaagcaga	8975
agtagaggcc	tcagtccctg	caggagaccc	ctcggctctc	atctcctgat	agtcagaccc	9035
agccacactg	gaaagagggg	agacattaca	gcctgcgaga	aaagtaggga	gatttaaaaa	9095
ctgottggct	tttattttga	actgtttttt	ttgtttgttt	gttttcccca	attcagaata	9155
cagaatactt	ttatggattt	gtttttatta	ctttaatttt	gaaacaatat	aatctttttt	9215
ttgttgtttt	tttgagacag	ggtcttactc	tgtcacccag	gctgagtgca	gtggtgtgat	9275
cttggctcac	ctcagcctcg	acccctggg	ctcaaattgat	tctcccacct	cagcttccca	9335
agtagctggg	accacaggtg	cgtgtgtttg	gctatacaaa	tccctgaagac	aaggatgctg	9395
ttgctgggtga	tgcctgggat	tcccaagatc	ccagatttga	tggcagggatg	cccctgtctg	9455
ctgccttgcc	agggtgccag	gagggcgctg	ctgtggaagc	tgaggcccgg	ccatccaggg	9515
cgatgcattg	ggcgtgatt	cttgttccctg	ctgctgcctc	ggtgcttagc	ttttgaaaca	9575
atgaaataaa	ttagaaccag	tgtgaaaatc	gatcaggga	taaatttaat	gtggaaataa	9635
actgaacaac	ttagtctctc	ataagagttt	acttggtaaa	tacttgtgat	gaggacaaaa	9695
cgaagcacta	gaaggagagg	cgagttgtag	acctgggtgg	caggagtgtt	ttgtttgttt	9755
tctttggcag	ggtcttgctc	tgttgctcag	ctcggagtac	agtggcacaa	tcacagctca	9815
ctatagcctc	gacctcctgg	actcaagcaa	tctctcctgc	tcagcctccc	agtagctggg	9875
actacaggcg	catgccacca	tgcctggcta	attttaaat	tttttttttc	totttttttga	9935
gatggaatct	cactctgtcg	cccaggctgg	agtgcagtgg	cgtgatctcg	gctgacggca	9995
agctccgcct	cccaggttca	ctccattcgc	ctgcctcagc	ctoccaaagta	gctgggacta	10055
caggcgctgg	gattacaaac	ccaaacccaa	agtgtctggg	ttacaggcgt	gagccactgc	10115
acccggcctg	ttttgtcttt	caatagcaag	agttgtgttt	gcttcgcccc	taccttttagt	10175
ggaaaaatgt	ataaaaatgga	gatattgacc	tccacattgg	ggtgggttaa	ttatagcatg	10235
tatgcaaaag	agcttgccta	atttaaggct	tttttgaaa	agaagaaact	gaataatcca	10295
tgtgtgtata	tatatatttaa	aagccatggt	catctttcca	tatcagtaaa	gctgaggctc	10355
cctgggactg	cagagttgtc	catcacagtc	cattataagt	gcgctgctgg	gccagggtgca	10415
gtggcttgtg	cctgaatccc	agcacttttg	gaggccaagg	caggaggatt	cattgagccc	10475
aggagttttg	aggcgagcct	gggcaatgtg	gccagacctc	atctcttcaa	aaaatacaca	10535
aaaaattagc	caggcatggt	ggcacgtgcc	tgtagtctca	gctactcagg	aggctgaggt	10595
gggaggatca	ctttgagcct	tgcagggtcaa	agctgcagta	agccatgatc	ttgccactgc	10655
attccagcct	ggatgacaga	gcgagaccct	gtctctaaaa	aaaaaaaaaa	ccaaacgggtg	10715
cactgttttc	ttttttctta	tcaattttatt	atttttaaat	taaattttct	tttaataatt	10775
tataaattat	aaattttatat	taaaaaatga	caaattttta	ttacttatac	atgaggtaaa	10835
acttaggata	tataaagtac	atattgaaaa	gtaatttttt	ggctggcaca	gtggctcaca	10895
cctgtaatcc	cagcactttg	ggaggccgtg	gcgggcagat	cacatgagat	catgagttcg	10955
agaccaacct	gaccaacatg	gagagacccc	atctctacta	aaaatacaaa	attagccggg	11015
gtggtggcgc	atgcctgtaa	tcccagctac	tcgggaggct	gaggcaggag	aatctcttga	11075
acccgggagg	cagaggttgc	ggtgagccaa	gtcgtgcct	ttgcacacca	gcttaggcaa	11135
caagagcgaa	agtcogtctc	aaaaaaaaag	taattttttt	taagttaacc	tctgtcagca	11195
aacaaattta	acccaataaa	ggtctttgtt	ttttaatgta	gtagaggagt	tagggtttat	11255
aaaaaatatg	gtagggaagg	gggtccctgg	atttgctaatt	gtgattgtca	tttgccctt	11315
aggagagagc	tctgttagca	gaatgaaaaa	attggaagcc	agattcaggg	agggactgga	11375
agcaaaagaa	tttctgttgc	aggaagagcc	tgatgtttgc	cagggtctgt	ttactggac	11435
atgaagagga	aggctctgga	ctttcctcca	ggagtctcag	gagaaaggta	gggcagtggt	11495
taagagcaga	gctctgccta	gactagctgg	ggtgcctaga	ctagctgggg	tgcccagact	11555
agctgggggtg	cttagactag	ctgggtactt	ttagtggtctc	cttcagcctg	gacctcgggt	11615
tcctcacctg	tatagtagag	atatgggagc	accagcgca	ggatcactgt	gaacataaat	11675

cagttaatgg aggaagcagg tagagtgggtg ctgggtgcat accaagcact ccgtcagtggt 11735
 ttccctgttat tcgatgatta ggaggcagct taaactagag ggagttgagc tgaatcagga 11795
 tgtttgtccc aggtagctgg gaatctgcct agcccagtgcc ccagtttatt taggtgtctct 11855
 ctacgtgttc cctgattgtt ttttcctttg tcatcttatc tacaggatgt gactgggaag 11915
 ctctgggttc agtgtcatgt gtctattctt tatttccag gca aag gaa acc aac 11969
 Ala Lys Glu Thr Asn
 115

aat aag aag aaa gaa ttt gag gaa act gcg aag aaa gtg cgc cgt gcc 12017
 Asn Lys Lys Lys Glu Phe Glu Glu Thr Ala Lys Lys Val Arg Arg Ala
 120 125 130

atc gag cag ctg gct gcc atg gat tga ggcctctggc cggagctgcc 12064
 Ile Glu Gln Leu Ala Ala Met Asp
 135 140

tggtcccaga gtgggtgcac cacttccagg gtttattccc tggtgccacc agccttccctg 12124
 tgggcccctt agcaatgtct taggaaagga gatcaacatt ttcaaattag atgtttcaac 12184
 tgtgctcctg ttttgtcttg aaagtggcac cagaggtgct tctgcctgtg cagcgggtgc 12244
 tgctggtaac agtggtgct tctctctctc tctctctttt ttgggggctc atttttgctg 12304
 ttttgattcc cgggcttacc aggtgagaag tgagggagga agaaggcagt gtcccttttg 12364
 ctagagctga cagctttgtt cgcgtgggca gagccttcca cagtgaatgt gtctggacct 12424
 catgttggtg aggtgtgcac agtcctgagt gtggacttgg cagggtgcctg ttgaatctga 12484
 gctgcagggt ccttatctgt cacacctgtg cctcctcaga ggacagtitt tttgttgttg 12544
 tgtttttttg tttttttttt ttggtagatg catgacttgt gtgtgatgag agaattggaga 12604
 cagagtcctt ggctcctcta ctgtttaaca acatggcttt cttattttgt ttgaattgtt 12664
 aattcacaga atagcacaata ctacaattaa aactaagcac aaagccattc taagtcatgt 12724
 gggaaacggg gtgaacttca ggtggatgag gagacagaat agagtgatag gaagcgtctg 12784
 gcagatactc cttttgocac tgctgtgtga ttagacaggc ccagtggagc gcggggcaca 12844
 tgctggccgc tctcctccta gaaaaaggca gtggcctaaa tcttttttaa atgacttggc 12904
 tcgatgctgt gggggactgg ctgggtgct gcaggccgtg tgtctgtcag cccaaccttc 12964
 acatctgtca cgttctccac acgggggaga gacgcagtcc gccaggtcc ccgctttctt 13024
 tggagccagc agctcccgca gggctgaagt ttggcgttaag atgatggatt ttgattggcc 13084
 tctcctctgt catagagctg caggggtgat tgttacagct tcgctggaaa cctctggagg 13144
 tcatctcggc tgttctctgag aaataaaaag cctgtcattt caaacactgc tgtggacctt 13204
 actgggtttt taaaatattg tcagtttttc atcgtcgtcc ctgacctgcc aacagccatc 13264
 tgcccagaca gccgcagtga ggatgagcgt cctggcagag acgcagtgtg ctctggggcg 13324
 ttgccagagc cagcaacccc agacctgttt gtatcatccg ggctccttcc gggcagaaac 13384
 aactgaaaat gcaacttcaga cccacttatt tatgccacat ctgagtcggc ctgagataga 13444
 cttttccctc taaactggga gaatatcaca gtggtttttg ttagcagaaa atgcactcca 13504
 gcctctgtac tcatctaaagc tgcttatttt tgaattttgt gtcagtctgt aaattggatac 13564
 ttacttttaa taactgttgc ttagtaattg gctttgtaga gaagctggaa aaaaatgggt 13624
 ttgtcttcaa ctcttttgca tgccaggcgg tgatgtggat ctgggttct gtgagcctgt 13684
 gctgtgggca gggctgagct ggagccgccc ctctcagccc gcctgccacg gcctttcctt 13744
 aaaggccatc cttaaaacca gacctcatg gctgccagca cctgaaagct tctctgacat 13804
 ctgttaataa agccgtaggc ccttgtctaa gcgcaaccgc ctgactttc tttcagatac 13864
 atgtccacat gtccattttt cagggttctc aagttggagt ggagtcggg aagggttgtg 13924
 aatgaggctt ctgggctatg ggtgaggttc caatggcagg ttagagcccc tcgggccaac 13984
 tgccatcctg gaaagtagag acagcagtgc ccgctgccc gaagagacca gcaagccaaa 14044
 ctggagcccc cattgcaggc tgcgcgcatg tggaaagagt aactcacaat tgccaataaa 14104
 gtctcatgtg gttttatcta cttttttttt ctttttctt ttttttgaga caaggccttg 14164
 ccctcccagg ctggagtga gtggaatgac cacagctcac cgcaacctca aattcttgcg 14224
 ttcaagtga cctcccactt tagcctccca agtagctggg actacaggcg cagcccatca 14284
 caccoggcta attgaaaaat tttttttttt gtttagatg aatctcactt tgttgccag 14344
 gctgggtctca aactcctggg ctcaagtgat catcctgctt cagcgtccga cttgttggt 14404
 ttataggcgt gagccactgg gcctgacct gctaccattt tttaatgcag aaatgaagac 14464
 ttgtagaaat gaaataactt gtccaggata gtcgaataag taacttttag agctgggatt 14524
 tgaacccagg caatctggct ccagagctgg gccctcactg ctgaaggaca ctgtcagctt 14584
 gggaggggtg ctatggtcgg ctgtctgatt ctagggagtg agggctgtct ttaaagcacc 14644
 ccattccatt ttcagacagc tttgtcagaa aggctgtcat atggagctga cacctgcctc 14704
 cccaaggctt ccatagatcc tctctgtaca ttgtaacctt ttattttgaa atgaaaattc 14764
 acaggaagtt gtaaggctag tacaggggat cc 14796

<210> 11

<211> 18

<212> DNA
 <213> Artificial Sequence

 <220>
 <223> Antisense Oligonucleotide

 <400> 11
 cgacggcagc ggagggtg 18

 <210> 12
 <211> 18
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Antisense Oligonucleotide

 <400> 12
 aagagccacc tgaaccgc 18

 <210> 13
 <211> 18
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Antisense Oligonucleotide

 <400> 13
 cgcagagggt gaaggag 18

 <210> 14
 <211> 18
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Antisense Oligonucleotide

 <400> 14
 gttgccacc tcggagcc 18

 <210> 15
 <211> 18
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Antisense Oligonucleotide

 <400> 15
 acactgcctg agagttgc 18

 <210> 16
 <211> 18
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Antisense Oligonucleotide

 <400> 16
 gtgtctggta ttggttct 18

 <210> 17

<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 17
atcaccacct cacacctc 18

<210> 18
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 18
tgtcccgtga gcacaatc 18

<210> 19
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 19
gaggtcggca ttgtgtcc 18

<210> 20
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 20
tgcaggaagg agaggctg 18

<210> 21
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 21
gcggagggtg ggcaatgg 18

<210> 22
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 22
cgtggctgga gttggtgt 18

<210> 23
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 23
cctgacagaa tctcggtg 18

<210> 24
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 24
gggtccctcac gatgtccc 18

<210> 25
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 25
cactatctca gcatctcg 18

<210> 26
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 26
ccattgtcct tcaccact 18

<210> 27
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 27
aggaccccag catcgccc 18

<210> 28
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 28
tcaatgtctg gcagtctt 18

<210> 29
 <211> 18
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Antisense Oligonucleotide

 <400> 29
 gcacagatgg tcttggtc 18

 <210> 30
 <211> 18
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Antisense Oligonucleotide

 <400> 30
 ccattacact gaggagca 18

 <210> 31
 <211> 18
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Antisense Oligonucleotide

 <400> 31
 catggcagca ctggttgg 18

 <210> 32
 <211> 18
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Antisense Oligonucleotide

 <400> 32
 caggcaaagc agtctgtg 18

 <210> 33
 <211> 18
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Antisense Oligonucleotide

 <400> 33
 tgtagacaag aggctgtg 18

 <210> 34
 <211> 18
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Antisense Oligonucleotide

 <400> 34
 acaaactcct ccatactg 18

<210> 35
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 35
ctgacacagg atgtttga 18

<210> 36
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 36
acatcttgag cccatttt 18

<210> 37
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 37
ccagagcctg ttccctca 18

<210> 38
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 38
ttcacaaatc catcaatg 18

<210> 39
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 39
gactggatgt tcaggtaa 18

<210> 40
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 40

cggttgtaga ggcttctg 18

<210> 41
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 41
tcggaagccc agagatgt 18

<210> 42
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 42
agagtgggtgg tagcagag 18

<210> 43
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 43
aagcaccttg gtccagtt 18

<210> 44
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 44
ggacaagcac tgaccagg 18

<210> 45
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 45
tggcaggaga agcattcg 18

<210> 46
<211> 18
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 46

acaagtatca gagcccgga

18

<210> 47

<211> 18

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 47

gggcacattg agcacaag

18

<210> 48

<211> 18

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 48

tgtcctaaac agtcttga

18

<210> 49

<211> 18

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 49

tgtcagatgg gttttgcc

18

<210> 50

<211> 18

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 50

cctgctatca ctgtcaaa

18

<210> 51

<211> 18

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 51

aatcactacc aatcctgc

18

<210> 52

<211> 18

<212> DNA

<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 52
ccagtagaga aaagtgcc 18

<210> 53
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 53
cctcatagcc cttttatt 18

<210> 54
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 54
ccccgttcca agtatcgc 18

<210> 55
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 55
tatgctctca ccccgttc 18

<210> 56
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 56
gactttgtta gccttctc 18

<210> 57
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 57
agacacccga gccaaagca 18

<210> 58
<211> 18
<212> DNA

<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 58
ttgattgatt caccctca 18

<210> 59
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 59
ccactcttgt cctcaatg 18

<210> 60
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 60
aaaactctgc cgtccact 18

<210> 61
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 61
tagtcccagc agccttac 18

<210> 62
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 62
gagaacccag aggcaaat 18

<210> 63
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 63
ctccccagtt gagcagca 18

<210> 64
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 64
cgggcagcca ggtttcta 18

<210> 65
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 65
cacctgaacc tgactggg 18

<210> 66
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 66
caccaaaatc tgccacct 18

<210> 67
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 67
atcatcagga ggcagcag 18

<210> 68
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 68
cccaaagtgg atactctc 18

<210> 69
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 69

caactcccaa actgtcac 18

<210> 70
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 70
cccgaaggt catcaact 18

<210> 71
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 71
ggtacttcag ccaatcgt 18

<210> 72
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 72
atcaatcatc caacactt 18

<210> 73
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 73
gggcgaatgt tctcatca 18

<210> 74
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 74
cttcttgttt gtcagacc 18

<210> 75
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 75
gtgttccaac tggtaggc 18

<210> 76
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 76
gtggcattgg gtgtagag 18

<210> 77
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 77
acattgacac tttctcct 18

<210> 78
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 78
ccgttgacat cctcttcc 18

<210> 79
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 79
gacagaactg agaccac 18

<210> 80
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 80
attcatactc ctcatctt 18

<210> 81
<211> 18
<212> DNA

<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 81
tcttcatctg gagttgtg 18

<210> 82
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 82
ttcataccct tgctcaga 18

<210> 83
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 83
tcagggttat caaaggca 18

<210> 84
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 84
tacgttctct gggcatta 18

<210> 85
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 85
agcctccaaa gattgaat 18

<210> 86
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 86
ggaatgggac tgggaaag 18

<210> 87
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 87
acaaaggcac acataaga 18

<210> 88
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 88
ccctttcctc ttcttgac 18

<210> 89
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 89
tcctaacctc tttcttca 18

<210> 90
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 90
gtaggtgaag tttagtat 18

<210> 91
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 91
aggatgataa aggactaa 18

<210> 92
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 92

tggtctcaaa ctccttgc

18

<210> 93

<211> 18

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 93

gggtcttact atgttggc

18

<210> 94

<211> 18

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 94

caaagtgctg agattaca

18

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US01/22751

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : Please See Extra Sheet.

US CL : 435/6, 91.1, 455, 366, 375; 514/44; 536/23.1, 24.5, 25.3

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/6, 91.1, 455, 366, 375; 514/44; 536/23.1, 24.5, 25.3

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

WEST, Dialog, Sequence search

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	YOO et al. Changes in heregulin bteal signaling after inhibition of ErbB2 expression in a human breast cancer cell line. Molecular and Cellular Endocrinology. 1998. Vol. 138, pages 163-171, see especially abstract; second paragraph on the right on page 164; figure 1 on page 166; figure 4 on page 167.	1,2,4-11
Y	EP 0444961 A1 (BRISTOL-MYERS SQUIBB COMPANY) 04 September 1991 (04-09-91), figure 1 and page 4, lines 34-39.	1,2,4-11
Y	US 5,801,154 A (BARACCHINI et al) 01 September 1998 (9/1/98) See especially columns 6-9.	4-11



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:		"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A"	document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E"	earlier document published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"G"	document member of the same patent family
"O"	document referring to an oral disclosure, use, exhibition or other means		
"P"	document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

10 SEPTEMBER 2001

Date of mailing of the international search report

30 OCT 2001

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

JANE ZARA

Telephone No. (703) 308-1235

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US01/22751

A. CLASSIFICATION OF SUBJECT MATTER:

IPC (7):

C12N 15/63, 5/08, 5/00; C12P 19/34; C12Q 1/68; C07H 21/00, 21/02, 21/04